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ABSTRACT 
 
Increasing levels of morbidity and mortality due to malaria are being reported, fuelled by 
the development of drug-resistant strains of Plasmodium falciparum. This indicates that 
new compounds and drug targets are needed to strengthen the drug arsenal. Concentrating 
on the discovery of novel drug targets, two P. falciparum genes were selected for study, 
due to their putative importance in major protein-protein interaction pathways facilitating 
growth and survival within the erythrocytic stage of the parasite. PFB0150c codes for a 
putative protein kinase (PK). Biopanning a phage display library had previously shown 
that the PK interacted with protein 4.1 and spectrin of the host erythrocyte membrane. 
The catalytic domain of PFB0150c was subcloned with a GST-tag and the recombinant 
protein was expressed in E. coli. A kinase assay using [γ-32P] ATP showed that the 
recombinant PK phosphorylated exogenous casein. This enzyme is hypothesised to 
phosphorylate host RBC membrane proteins and facilitate RBC invasion by merozoites. 
It may also play a role in intraerythrocytic growth and exit of the parasite. The PK may 
be multifunctional since the catalytic kinase domain makes up only a small portion of the 
protein. The additional domains could be good drug targets since they have very low 
sequence homology to human proteins. PFE1400c codes for a putative adaptor protein 
complex-1 β1 subunit presumed to be involved in protein trafficking, which is essential 
to the survival of malaria parasites. The N-terminal adaptin and C-terminal clathrin 
adaptor appendage domains were subcloned with a histidine- and a GST-tag, 
respectively, and were expressed in E. coli. The N-terminal adaptin domain was highly 
conserved, but the smaller C-terminal domain had low homology with the orthologous 
human protein and has potential as a drug target. Targeting P. falciparum invasion 
proteins is difficult because they are highly redundant. By inhibiting the protein 
trafficking complex, transport of invasion proteins to the micronemes and rhoptries 
would be blocked and they would be unable to reach their final destination and carry out 
their function. Thus invasion of host RBC by these defective merozoites would be 
prevented. The current study forms the foundation for future work in characterising the 
structure and function of these P. falciparum proteins. 
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CHAPTER 1 
INTRODUCTION 
 
1.1) Malaria: Approaching resistance 
 
On an annual basis, over 300 million individuals experience an acute infection of malaria, 
caused by Plasmodium falciparum of the phylum Apicomplexa, and more than a million 
of them perish. The majority of these mortalities occur in sub-Saharan Africa and affect 
children under the age of five years (World Health Organisation, 2007). 
 
The life cycle of the Plasmodium parasite is divided into an asexual and a sexual phase 
(Figure 1). The former phase is initiated when a female Anopheles mosquito carrying the 
parasite partakes in a human blood meal, thus injecting her anticoagulating saliva into the 
host along with the infective sporozoites. The parasite enters the bloodstream and 
subsequently migrates to the liver, where it invades the hepatocytes (Roberts & Janovy, 
1996). Once safely enveloped in the liver cell, the sporozoite transforms into a feeding 
trophozoite that ingests the host cell cytoplasm via pinocytosis. Upon maturation, the 
trophozoite undergoes schizogony to form a schizont which contains multiple daughter 
nuclei. Further maturation results in the emergence of merozoites which are released from 
the hepatocytes. This signals the end of the pre-erythrocytic stage and newly liberated 
merozoites initiate the erythrocytic leg of development by penetrating host red blood cells 
(RBCs) and invading them (Roberts & Janovy, 1996). During the process of invasion, the 
parasite produces a parasitophorous vacuole membrane (PVM) which surrounds the 
merozoite. The compartment formed within the membrane is known as the 
parasitophorous vacuole (PV). The merozoite again metamorphoses into a feeding 
trophozoite and proceeds to ingest the host cytoplasm and haemoglobin. The parasite 
flattens, giving rise to the characteristic signet-ring stage (Haynes, 1993). Another round 
of schizogony occurs and the resultant schizont develops into multiple merozoites. Once 
mature, merozoites secrete proteases that disrupt cell plasma membranes, causing the 
parasitised erythrocytes to burst, propelling the parasites into the blood stream to infect a 
fresh set of RBCs (Glushakova et al, 2005). 
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Figure 1. The malaria life cycle (Roberts & Janovy, 1996) 
The life cycle of P. falciparum consists of a sexual cycle that occurs in the mosquito and 
an asexual cycle that occurs in the human host. 
 
The asexual cycle repeats itself a number of times. A few merozoites develop into the 
sexual cycle gametocytes, namely the macro- and microgametocytes. When ingested by a 
suitable mosquito, the gametocytes slough off the erythrocyte membrane and develop 
into mature gametes within the insect’s gut. The microgamete penetrates and fertilises the 
macrogamete. A motile ookinete develops and enters the lining of the mosquito’s gut. 
Transformation occurs and an oocyst is formed, maturing to produce multiple 
sporoblasts. Thousands of sporozoites created from the repeatedly dividing sporoblasts 
rupture the oocyst and migrate to the salivary glands. Within the channels of the 
invertebrate glands, Plasmodium is in a prime position to infect a new human host when 
next the insect feeds (Roberts & Janovy, 1996). 
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The latest approximation of the worldwide toll that malaria is taking indicates that the 
situation is worsening, with increasing levels of morbidity and mortality being reported 
(World Health Organisation, 2007). One of the main reasons for this deterioration is the 
development of drug-resistant strains of P. falciparum against which most conventional 
drugs – such as amodiaquine, chloroquine and sulfadoxine-pyrimethamine – are 
ineffective. One group of anti-malarials remains effective against the parasite, namely the 
artemisinin-derived drugs – dihydroartemisinin, artesunate and artemether (World Health 
Organisation, 2007). These compounds have an endoperoxide function, interacting with 
haem to generate toxic carbon-centred free radicals. These free radicals disable a number 
of proposed parasite proteins, one being the enzyme PfATPase6, the only SERCA-type 
(Sarco-endoplasmic reticulum calcium ATPase-type) Ca2+-ATPase in the P. falciparum 
genome, leading to the death of the parasite (Eckstein-Ludwig et al, 2003). No clinical 
cases of resistance to the artemisinin compounds have occurred to date, but in vitro 
resistance in field isolates has been shown by several research groups (Afonso et al, 2006; 
Jambou et al, 2005), indicating that new compounds and drug targets are needed to 
strengthen the drug arsenal in the event that in vivo resistance does emerge.  
 
The elucidation of the entire P. falciparum genome by Gardner et al (2002) has facilitated 
the discovery of potential drug targets in the form of genes that are either specific to the 
parasite, or have low sequence similarity to human homologues (Hoffman et al, 2002). 
Using bioinformatics and functional genomics, the P. falciparum proteins predicted from 
the genome can be analysed to determine probable molecular function, cellular 
localisation and expression levels at each of the life cycle stages. These genes or their 
protein products can then be exclusively targeted, without disrupting or damaging host 
functions (Hoffman et al, 2002). 
 
1.2) Heterologous expression of P. falciparum proteins 
 
A total of 5 268 predicted proteins are encoded by the parasite genome (Gardner et al, 
2002) and 65 percent of these have no homology to known proteins and therefore 
represent a goldmine of potential drug targets (Florens et al, 2002). Unfortunately, the 
expression and purification of these parasite proteins using an E. coli expression system 
is no easy task, since the recombinant proteins are often insoluble (Mehlin et al, 2006). 
18 
 
This resistance to heterologous expression of soluble proteins stems from the following 
factors, in decreasing order of significance: the isoelectric point (pI) of the protein; the 
hypothetical status of the protein and the percentage AT content of the gene. 
 
Mehlin et al (2006) observed that the insolubility of expressed proteins increased with 
increasing pI. Expressed proteins that were most soluble had a pI between 3.45 and 6.8, 
while those that were least soluble had a pI range of 9.6-12.1. At very low pI values (less 
than 3.45) proteins had deficient expression; however, the small amount that was 
expressed had a high level of solubility. It was also noted that if the protein was annotated 
on PlasmoDB (the P. falciparum genome database) as hypothetical – meaning that the 
protein had no known function – the insolubility was significantly higher compared to 
characterised proteins. The group found no significant correlation between the size of the 
gene – and subsequently expressed protein – and solubility. The P. falciparum genome 
has approximately 80 percent AT content, resulting in a different codon preference to E. 
coli genes, and this was found to be a significant factor contributing to insolubility when 
analysed independently. However, multivariate analysis showed that pI was the most 
important factor for expression of soluble parasite protein, while the percentage AT 
content had the least effect.  
 
These aforementioned factors may contribute to the expression of P. falciparum target 
proteins as insoluble inclusion bodies (Mehlin et al, 2006). Inclusion bodies are 
aggregations of misfolded proteins that have a low solubility and are therefore not easily 
extracted (Kiefhaber et al, 1991). The formation of these bodies occurs most often when 
the genes from an evolutionarily superior organism are expressed in a lower organism, as 
is the case when eukaryotic P. falciparum genes are expressed in prokaryotic E. coli cells. 
The microenvironment into which the recombinant protein emerges is foreign in terms of 
pH and osmolarity; mechanisms and chaperones for folding the eukaryotic protein are 
also absent in the prokaryotic microenvironment, and these factors may contribute to the 
production of an insoluble, inactive inclusion body (Baca and Hol, 2000; Ling Goh et al, 
2003). However, a number of recombinant P. falciparum proteins have been successfully 
expressed in soluble form. 
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By optimising the time, pH and temperature of induction, as well as eliminating bacterial 
proteases and using E. coli cells that express rare tRNAs, the probability of expressing 
soluble recombinant proteins is increased (Sorensen & Mortensen, 2005). Inclusion 
bodies can also be treated with high molar concentrations of urea to solubilise the 
recombinant protein, followed by dialysis to allow renaturation and refolding of the 
protein which usually – but not always – restores functionality (Yeo et al, 1997). 
 
1.3) Malaria parasite-host protein-protein interactions 
 
Protein-protein interactions (PPIs) are of interest when applying molecular methods to 
combat P. falciparum infection, due to the fact that these connections are utilised by the 
malaria parasite during vital periods of its life cycle. It has been predicted that 516 PPIs 
occur between Homo sapiens and P. falciparum (Dyer et al, 2007). If some of these 
fundamental interactions could be disrupted, the parasite would not be able to complete 
specific stages of development and would perish, thereby alleviating malaria infections in 
the human population. PPIs within the erythrocytic stage of the P. falciparum life cycle 
are vital, as all the pathogenesis associated with malaria occurs during this time. The 
invasion of and growth within host red blood cells is therefore an important factor in the 
disease which, if disrupted, could prevent infection. 
 
1.3.1) PPIs during invasion 
 
The erythrocytic stage is initiated when merozoites come into contact with the red blood 
cell membrane and specialised secretory organelles – micronemes and rhoptries – release 
parasitic proteins that facilitate invasion of the host cells. These two types of organelles 
are located in the apical end of invasive merozoites (Figure 2). 
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Figure 2. Structure of a P. falciparum merozoite (Bannister et al, 2000) 
(a) Electron micrograph: A merozoite from the asexual cycle of P. falciparum showing 
the apical prominence (ap) with a rhoptry (r), dense granules (d), and an indented 
nucleus (n). Scale bar =0.5 µm. 
(b) 3D structure: The merozoite pellicle is partly cut away to show the internal structure. 
The micronemes, dense granules and rhoptries are located at the apical end of the 
merozoite. Inset: relative sizes of merozoites and the RBC being invaded. 
 
Rhoptry-associated and micronemal proteins interact with host proteins on the 
erythrocyte membrane. The membrane consists of two main components: a lipid bilayer 
and a skeletal protein network (Figure 3). The lipid bilayer is embedded with 
glycophorins and the anion exchanger, band 3. These transmembrane proteins have sialic 
acid moieties that extend into the vascular space (Gallagher, 2006). The skeletal protein 
network consists primarily of spectrin tetramers. Spectrin is a fibrous polypeptide that 
exists in two isoforms, alpha and beta, which are loosely coiled around one another to 
form a relaxed helix. Tetramers are formed via the association of two alpha-beta helices 
which are joined by protein 4.1 to form a protein meshwork. Protein 4.1 stabilises the 
interaction of spectrin with actin to provide mechanical stability (Gallagher, 2006). 
Phosphorylation of protein 4.1 by protein kinases destabilises the erythrocyte plasma 
membrane (Chishti et al, 1994). This protein is vital to survival of the malaria parasite, as 
normal development of P. falciparum does not occur in red blood cells that lack protein 
4.1 (Chishti et al, 1994). Band 3 is anchored to the main component of the protein 
network, namely spectrin, via the 215kD protein, ankyrin. The spectrin network is further 
stabilised by interactions with the proteins actin, adducin, tropomyosin and tropomodulin 
(Gallagher, 2006).  
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Merozoite attachment to the host red blood cell membrane is mediated by a parasite-host 
PPI between the microneme-derived EBAs and the red cell membrane glycophorins and 
band 3 (Mayer et al, 2002). EBA is part of the Duffy binding-like family of parasitic 
ligands, which are the primary facilitators of merozoite binding. Plasmodium strains that 
utilise the sialic acid residues of glycophorins as invasion receptors are termed sialic acid-
dependent; those that exploit other host receptors are termed sialic acid-independent. 
 
 
Figure 3. Structure of human erythrocyte membrane (Luna & Hitt, 1992) 
The RBC plasma membrane consists of a lipid bilayer, containing polar head groups and 
non-polar fatty acid tails, and a protein skeletal network of spectrin tetramers joined 
together by several other proteins. Various accessory proteins link the two layers and 
stabilise the membrane.  
 
Sialic acid-dependent strains have two main erythrocyte-binding ligands: EBA140, also 
known as BAEBL, and EBA175. EBA140 recognises glycophorin C, while EBA175 
recognises glycophorin A (Mayer et al, 2002). By inhibiting the binding of EBA140 to 
glycophorin C, merozoites were prevented from penetrating host red blood cells (Maier et 
al, 2003). This discovery seemed to point to the possibility of manufacturing a vaccine 
against this EBA140 strain, but experimentation by Mayer et al (2002) indicated that 
multiple polymorphic forms of EBA140 exist, not all of which specifically bind 
glycophorin C. Because different parasite strains express different EBA isoforms, each 
with an affinity for different host ligands, the disruption of this PPI to thwart parasite 
invasion will not be successful as a global intervention (Mayer et al, 2002). However, the 
disruption of transport of these proteins to the micronemes and rhoptries would 
circumvent this redundancy, as the transport mechanisms in P. falciparum are likely to be 
general and not specific for each EBA (see Section 1.4: What makes a good drug 
target?).
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During invasion, various proteins are secreted from the micronemes and rhoptries and 
interact with host RBC membrane proteins. RhopH3 is one such protein that is found in 
association with membrane-bound fractions (Topolska et al, 2003). This protein interacts 
with host membrane phospholipids and it has been postulated that RhopH3 causes 
changes to the inner leaflet of the erythrocyte membrane that facilitate invagination and 
the formation of the parasitophorous vacuole. Monoclonal antibodies against this protein 
have inhibited the growth of the parasite and attempts to disrupt the RhopH3 gene have 
been unsuccessful (Topolska et al, 2003). These reports suggest that RhopH3 has a key 
role to play in the parasite life cycle (Topolska et al, 2004). Invasion proteins secreted by 
the rhoptries include Rhoptry Associated Proteins (RAP) 1 and 2, and gp76 rhoptry 
protein. Antibodies to both the RAP proteins prevented invasion of erythrocytes in vitro. 
Furthermore, monkeys immunised with RAP1 had partial immunity against infection 
(Topolska et al, 2003). The gp76 rhoptry protein degraded glycophorin A and band 3, 
major structural components of the host RBC membrane. This membrane destabilisation 
by the parasitic serine protease promotes speedy invasion by the merozoite. Proteins 
involved in the invasion of human erythrocytes that are secreted by the micronemes 
include P. falciparum apical membrane antigen 1 (PfAMA1), which facilitates 
reorientation of the merozoite such that its apical end is in contact with the erythrocyte 
cell membrane, along with the erythrocyte binding antigens (EBAs). PfAMA1 performs 
an essential role in the invasion of erythrocytes, evident from experiments that show 
inhibition of merozoite invasion in the presence of both monoclonal and polyclonal 
antibodies directed against PfAMA1 (Healer et al, 2002). 
 
1.3.2) Parasite-host PPIs during intraerythrocytic development 
 
Once established within a red blood cell, the parasite secretes various proteins that are 
transported to the erythrocyte plasma membrane surface (Marti et al, 2004; Hiller et al, 
2004). These proteins form protrusions on the host cell membrane and are termed 
‘knobs’. These parasitic knobs consist primarily of P. falciparum erythrocyte membrane 
protein 1 (PfEMP1) (Maier et al, 2007). The various PPIs that PfEMP1 takes part in are 
responsible for much of the acute pathology of malaria (Chen et al, 1998; Flick & Chen, 
2004).  
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Parasitised red blood cells (pRBC) are removed from the host circulation by the binding 
of PfEMP1 to specific host endothelial cell surface receptors, for example: intercellular 
adhesion molecule-1 (ICAM-1), a cell surface ligand with a role in leukocyte adhesion 
and inflammation; CD36, a glycoprotein expressed on leukocytes, platelets and 
endothelium; and thrombospondin, an extracellular adhesive protein that plays a role in 
platelet aggregation and angiogenesis. This adhesion to host vasculature prevents the 
circulation of pRBCs in the blood stream and the subsequent sequestration by the spleen. 
The CD36 cell surface receptor is also present on dendritic cells – phagocytic cells of the 
host immune system – and PfEMP1 binding to these cells may initiate apoptosis of the 
cell and thereby prevent antigen presentation by the class II MHC to T-helper cells (Flick 
and Chen, 2004), contributing to the ineffective host immune response to malaria 
parasites. 
 
1.4) What makes a good drug target? 
 
A previous approach in identifying malaria proteins suitable for vaccine development and 
drug targeting concentrated on the EBA invasion proteins after release from micronemes 
but due to the redundancy of receptor binding specificities, these proteins make poor 
targets (Mayer et al, 2002). PfEMP1 is a protein important for the survival of the parasite, 
but it does not represent a good drug target as a multigene family of 59 var genes encodes 
this highly variable protein. Of the 59 genes, only one will be expressed by a single 
parasite at a time, making population-wide targeting impossible. Malaria proteins that are 
exposed to the host immune system are therefore not good drug targets, as this confers 
increased antigenic variation to the proteins so that detection by immune cells is 
thwarted. By concentrating on malaria proteins that function within the confines of the 
pRBC – for example, protein kinases (PKs) and trafficking proteins – an effective target 
for molecular intervention may be elucidated.  
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PKs have been targeted in various diseases and their inhibition often provides therapeutic 
benefits. In the case of chronic myeloid leukaemia (CML), the leukaemogenic oncogene 
Bcr-Abl is the causative molecular abnormality of the disease. The product of this 
oncogene is a constitutively activated tyrosine kinase which functions in numerous 
signalling pathways, deregulating them to cause the uncontrolled proliferation of myeloid 
blasts in the blood. The development of Imatinib, an inhibitor of Bcr-Abl tyrosine kinase, 
has proved effective in killing or inhibiting the proliferation of all Bcr-Abl-expressing 
cells (Druker, 2002). A number of P. falciparum PKs have been targeted by inhibitors 
with varying degrees of success. Syin et al (2001) carried out a study on the catalytic 
subunit gene of P. falciparum cAMP-dependent protein kinase (Pfpka-c). This gene is 
expressed at high levels during the asexual stage of parasite growth, mainly in schizonts. 
The group determined that the treatment of pRBC in culture with the PKA-C inhibitor 
H89 halted the growth and development of the parasite. However, due to the high 
sequence similarity between the human erythrocytic and parasite PKA-C enzymes, it is 
possible that the RBC PKA-C was being inhibited. Therefore, the growth of the 
intraerythrocytic parasite could be dependent on the erythrocyte PKA-C, and not the 
parasitic PKA-C as initially assumed. Another group ascertained that a cGMP-dependent 
protein kinase (PKG) inhibitor that had antiparasitic activity toward a Toxoplasma gondii 
PKG was also effective in blocking motility and invasion by malaria parasites (Diaz et al, 
2006). The PKG inhibitor, a trisubstituted pyrrole pyridine known as Compound 1, was 
active against the P. falciparum PKG. It inhibited the growth of chloroquine-resistant and 
chloroquine-sensitive strains during erythrocytic growth in vitro. Compound 1 also delays 
the onset of parasitemia in P. berghei mouse models of infection, although it does not 
cure the infection (Diaz et al, 2006). It should be noted, however, that a large number of 
PK inhibitors have a rather poor specificity and tend to inhibit other PKs more potently 
than their presumed targets, rendering some cell-based experiments inaccurate (Davies et 
al, 2000; Bain et al, 2003; Bain et al, 2007). 
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Trafficking proteins have not been exploited as much as PKs when it comes to drug 
targeting. Ramya et al (2007) determined that the mechanism of action of a known 
antimalarial, 15-Deoxyspergualin (DSG), involved the disruption of protein trafficking. 
At submicromolar concentrations, DSG kills P. falciparum by preventing the transport of 
nucleus-encoded proteins to the apicoplast during the first asexual cycle, which leads to 
missegregation and subsequent loss of the apicoplast in the second asexual cycle (Ramya 
et al, 2007). The apicoplast is an organelle specific to some apicomplexan parasites. It is 
a non-photosynthetic plastid, assumed to be a relic of a photosynthetic organism that was 
phagocytosed by the host, but not digested. DSG induces delayed death – during the 
second asexual cycle – by starving the apicoplast of proteins that are indispensable to 
various metabolic processes in the parasite. This effect was observed in the late 
trophozoite and schizont stages, where fatty acid biosynthesis was inhibited, killing the 
malaria parasite. This indicates that the targeting of trafficking proteins within the trans-
Golgi network of the parasite could also lead to its demise. 
 
1.5) Protein kinases 
 
PKs are enzymes that catalyse the phosphorylation of proteins within eukaryotic cells. 
This regulates protein function – activating, modulating or deactivating the molecules – 
and thereby controls cell behaviour. Of the proteins expressed in an average eukaryotic 
cell, almost 33 percent contain covalently bound phosphate molecules (Hubbard & 
Cohen, 1993). Approximately 3 percent of all eukaryotic genes code for PKs and these 
are classified according to structural similarity, as well as parallel substrate specificity 
and mode of regulation (Hanks & Hunter, 1995).  
 
The reaction catalysed by PKs is: 
 
                            PK 
Protein + ATP                  phosphoprotein + ADP 
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Eukaryotic PKs are divided into seven established groups, with the two main sub-
divisions being the protein-serine/threonine kinases and the protein-tyrosine kinases 
(Hanks & Hunter, 1995). The entire complement of PKs encoded in a genome is termed 
the kinome.  
 
1.5.1) P. falciparum protein kinases 
 
Phosphorylation and dephosphorylation processes play an important role in the life cycle 
of the malaria parasite (Suetterlin et al, 1991). This is especially true for the 
intraerythrocytic stage which is accompanied by a distorted phosphorylation pattern of 
the host RBC membrane (Chishti et al, 1994). This vital stage of the parasite lifecycle is 
prevented by PK inhibitors (Ward et al, 2004; Anamika et al, 2005).  
 
According to Ward et al (2004) – who identified 65 malaria PK sequences – and 
Anamika et al (2005), who identified 99 PKs in the P. falciparum genome using various 
amino acid sequence profile matching algorithms, several of the parasite sequences did 
not cluster within any of the known eukaryotic PK groups. Furthermore, the highest 
number of malarial sequences were those involved in the control of cell proliferation, 
namely the cyclin-dependent- (CDK), mitogen-activated- (MAPK), glycogen-synthase- 
(GSK) and CDK-like kinases, along with a kinase family that includes PKs A, G and C 
(AGC). Interestingly, no malarial PK clustered with the tyrosine kinase group; 
homologues of MEK (MAPK kinase), MEKK (MAPK kinase kinase) and PKC-like 
kinases were also lacking in the P. falciparum genome. A splinter group of 20 PK-related 
sequences formed a novel family called FIKK, which seems to be restricted to the 
Apicomplexa (Ward et al, 2004). According to Schneider & Mercereau-Puijalon (2005), 
even though kinase activity has not been demonstrated in this group, the presence of most 
of the amino acids necessary for phosphotransfer indicates an enzymatic role. Nunes et al 
(2007) provide experimental evidence of kinase activity and transport of some FIKKs to 
the erythrocyte. 
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The large divergence in the kinome of P. falciparum compared to that of humans 
suggests that exclusive targeting of parasite enzymes is possible. This is promising as 
PKs play crucial roles in most cellular processes and thus their targeted inhibition could 
incapacitate the parasite and prevent disease progression.  
 
1.5.2) PFB0150c: A putative PK 
 
In previous research in Professor T.L. Coetzer’s Plasmodium Molecular Research Unit, a 
P. falciparum phage display library was created and bio-panned against a host protein of 
the erythrocyte plasma membrane, namely protein 4.1 (Figure 3).  
A host-parasite PPI was found to exist between protein 4.1 and a putative PK encoded by 
the PFB0150c gene (Lauterbach et al, 2003). Research by Chishti et al (1994) has shown 
that phosphorylation of protein 4.1 decreases its interaction with the skeletal network, 
thereby destabilising the erythrocyte plasma membrane. This increased flexibility of the 
erythrocyte membrane has been postulated to facilitate parasite growth and survival 
(Chishti et al, 1994). The group determined that the enzyme that phosphorylated protein 
4.1 in parasitised erythrocytes was a casein kinase of parasite origin, by showing that 
phosphorylation of the RBC membrane protein was prevented by casein kinase I and II 
inhibitors. This casein kinase enzyme could be the product of PFB0150c, the gene of 
interest.  
 
PFB0150c is a P. falciparum gene found on chromosome 2. The gene has Crick-
orientation, meaning that the coding sequence is found on the antisense (3’ to 5’) strand 
of the chromosomal DNA (Figure 4). The gene consists of a single exon and is 7 448bp 
in length. The PK domain, found at the C-terminal of the protein, contains the catalytic 
core of the enzyme. (www.plasmodb.org, version 5.4, 2008). 
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Figure 4. Genomic context of PFB0150c (PlasmoDB 5.4, 2008; www.plasmodb.org) 
Crick-orientation genes are represented in red, while Watson-orientation genes are 
coloured blue. Updates of the gene model for PFB0150c as of February 1, 2008 can be 
seen in the green area of the diagram.  
 
PFB0150c is described as a hypothetical phosphotransferase of the serine- or threonine-
specific kinase subfamily (Letunic et al, 2006). The role of this protein as a kinase was 
inferred from its homology to other eukaryotic PKs (www.genedb.org) but its function 
has not been proved. According to The Gene Ontology Consortium (2007) 
(http://www.genedb.org/amigo/perl) there are no data available indicating the cellular 
location of the PFB0150c gene product within the parasite but, as no transmembrane 
domains or signal peptides are found within the protein, it is unlikely that it is positioned 
on the parasite plasma membrane. According to the same group, the biological processes 
that this putative PK is involved in include pathogenesis, protein phosphorylation and 
proteolysis. The probable molecular function of this enzyme is described as ATP binding, 
metal-ion binding, metallo-endopeptidase activity, PK activity and protein 
serine/threonine kinase activity.  
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1.6) Protein trafficking in eukaryotes 
 
In eukaryotic cells, normal functionality is dependent on the transfer of newly created 
polypeptides to their correct cellular locations. These sites may occur within the cell’s 
cytoplasm, on the plasma membrane or external to the cell. Protein trafficking in 
eukaryotes occurs via the classical vesicle-mediated secretory pathway. A hydrophobic 
sequence at the N-terminal of the proteins acts as a polypeptide signal, directing them 
into the secretory pathway (von Heijne, 1985). Eukaryotic proteins are synthesised by 
ribosomes and then directed into the endoplasmic reticulum (ER) (Rodnina et al, 2006). 
ER chaperones ensure that the newly-formed proteins are correctly folded and 
membrane-bound vesicles shuttle the properly-folded polypeptides to the Golgi 
apparatus. Proteins are released at the cell surface by exocytosis. COP II coat protein 
functions in the transport of vesicles to the Golgi in what is termed anti-retrograde 
transport, while COP I returns the vesicles to the ER. These coat proteins are essential for 
the selection of suitable cargo proteins, as well as the deformation of the plasma 
membrane to form vesicles for transport (Duden, 2003).  
 
Key molecules in trafficking are the adaptor protein (AP) complexes. AP-1 and AP-2 
have been well characterised in mammals, where they are involved in protein sorting and 
transport to different organelles in the cell (Ohno, 2006). AP complexes are 
heterotetramers composed of two large adaptin subunits (γ and β), a medium subunit (μ) 
and a small subunit (σ) (Heldwein et al, 2004). Of the four subunits making up the 
adaptor protein, the µ-subunit is involved in cargo binding via the recognition of 
particular sequence motifs, while the β-subunit induces the assembly of clathrin 
triskelions to form a latticed coat (Brodsky et al, 2001). Mammalian AP-1 and -2 
complexes are responsible for the formation of clathrin-coated pits and vesicles which are 
created during endocytosis (Brodsky et al, 2001); the former initiates formation of these 
vesicles at the ER in the trans-Golgi network while the latter is found in plasma 
membrane clathrin-coated pits. These clathrin-coated vesicles (CCVs) then referee the 
trafficking of various membrane-bound proteins (Brodsky et al, 2001). 
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CCVs are made up of three distinct layers. The inner layer contains the transmembrane 
cargo, which is usually protein in nature. The middle layer consists of AP complexes and 
links the inner layer to the outer protein layer, which is composed of a stabilising clathrin 
coat of interlinking triskelia (Owen et al, 2000; Wang et al, 1995). Homologues of AP-1 
and AP-2 have been found in other organisms (Brodsky et al, 2001) including T. gondii 
and P. falciparum.  
 
1.6.1) Protein trafficking in P. falciparum 
 
Trafficking of proteins by the malaria parasite involves transport of two main types, 
namely transport of proteins inside the parasite, and export of proteins into the RBC and 
onto the host RBC membrane. Protein trafficking in P. falciparum seems to follow the 
classical vesicle-mediated secretory pathway described in section 1.6 (Cooke et al, 2004; 
Figure 5). The exact design of the secretory pathway has not been fully elucidated; some 
groups postulate that it consists of a tubovesicular membrane network that is directly 
connected to the parasitophorous vacuole and includes a rudimentary Golgi apparatus and 
ER (Behari & Haldar, 1994).  
Templeton and Deitsch (2005) maintain that the pathway exists as a conglomeration of 
Maurer’s clefts. In any case, the use of Brefeldin A, a drug that inhibits vesicle-mediated 
trafficking, has been demonstrated to prevent secretion of most exported malarial proteins 
(Cooke et al, 2004). 
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Figure 5. Putative trafficking pathways in P. falciparum-infected erythrocytes. 
(Adapted from Cooke et al, 2004)  
The classical vesicle-mediated secretory pathway traffics proteins to a number of 
organelles and cellular domains. PfEMP1 (red), MAHRP and KAHRP (purple) are 
targeted to the erythrocyte membrane via the PEXEL/VTS motif. For the current study, 
the pathway of interest is highlighted in blue. It involves AP-1, which facilitates the 
formation of protein-containing vesicles at the Golgi-like complex for trafficking to 
storage organelles like the rhoptries and micronemes. COPI and COPII are involved in 
the transport of proteins between the ER and Golgi-like complex. COP - coat protein; 
DMV - double membrane-bound vesicle; ER - endoplasmic reticulum; KAHRP - knob-
associated histidine-rich protein; MAHRP - membrane-associated histidine-rich protein; 
MC - Maurer’s clefts; PfEMP1 - P. falciparum erythrocyte membrane protein 1; PM - 
plasma membrane; PPM - parasite PM; PV - parasitophorous vacuole; PVM - PV 
membrane; RBC - red blood cell; TVN - tubovesicular network. 
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As can be seen in figure 5, trafficking in the parasite involves the transport of proteins 
between the ER and Golgi-like complex – mediated by COPI and COPII – and from the 
trans-Golgi network to other organelles, which is mediated by AP complexes. Various 
parasite proteins are also exported to the plasma membrane of the host RBC. The 
exported parasite membrane proteins, knob-associated histidine-rich protein (KAHRP) 
and PfEMP1 (Figure 5), are exposed on the surface of the pRBC. Both soluble and 
integral membrane proteins are translocated into the ER via an N-terminal signal 
sequence and are then delivered into the parasitophorous vacuole by way of the Golgi-
like complex (Figure 5). A second motif, known as the Plasmodium export element 
(PEXEL) or vacuolar transport signal (VTS), targets export proteins for onward transport 
to the erythrocyte ((Marti et al, 2004; Hiller et al, 2004)). Once there, they are exported 
to the membrane, forming knobby protrusions that are involved in the cytoadherence of 
pRBC to the host vasculature (Foley and Tilley, 1998).  
 
In the apicomplexans AP-1 is involved in sorting of proteins to the micronemes and 
rhoptries (Ngô et al, 2003) as indicated by the blue pathway in figure 5. These organelles 
secrete numerous proteins involved in the parasitic invasion of host cells (see Section 
1.3.1: PPIs during invasion). Rhoptry Associated Membrane Antigen (RAMA) is a 
protein with the dual roles of RBC invasion and rhoptry creation. RAMA is synthesised 
in the early trophozoite stage before the rhoptries exist, and is stored within lipid-rich 
areas of the Golgi-like complex. As maturation progresses, the portions of the Golgi 
containing RAMA bud to form vesicles that are trafficked to the apical prominence and 
mature into rhoptries (Topolska et al, 2003). 
 
The putative function of AP-1 in malaria transport pathways is outlined in figure 6. AP-1 
recruits clathrin molecules to a membrane segment of a post-Golgi endocytic 
compartment and a clathrin-coated vesicle is formed. The vesicle then surrounds the 
membrane-bound protein that is to be transported and buds from the endocytic 
compartment which causes the coat to fall off. The uncoated vesicle is then able to fuse 
with the rhoptries and micronemes and deliver its contents to these apical organelles (Ngô 
et al, 2003).  
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Figure 6. Classical clathrin-mediated vesicular transport (Adapted from Malaria 
Parasite Metabolic Pathways, http://sites.huji.ac.il/malaria) 
1. Activation at the TGN: At the trans-Golgi network (TGN), coat assembly is instigated 
by adaptor protein-1 (AP-1) which engages a receptor at the plasma membrane.  
2. Cargo capture: One end of AP-1 binds to protein cargo. 
3. Coat assembly: The other end of AP1 binds the coat component, clathrin. Clathrin 
triskelion assembly results in the formation of hexagonal and pentagonal cages that 
cause membrane distortion.  
4. Scission: The resulting exvagination is pinched off via the action of dynamin. 
5. Uncoating: As the vesicle buds off from the TGN compartment, uncoating occurs via 
the action of heat shock cognate 70 (Hsc70) and auxillin with the concomitant hydrolysis 
of ATP. The vesicle is then transported to its destination and fuses with its destination 
compartment’s plasma membrane, releasing the protein contents. 
 
By targeting proteins like AP-1 involved in vesicle-formation within the trafficking 
pathway, proteins involved in attachment to and invasion of RBCs could be prevented 
from reaching the secretory organelles, and the erythrocyte invasion process could thus 
be prevented.  
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1.6.2) PFE1400c: a putative AP-1 β subunit 
 
The second gene that will be investigated, namely PFE1400c, found on chromosome 5, is 
3 714bp in length and contains seven exons (Figure 7). 
 
 
 
Figure 7. Genomic context of PFE1400c (PlasmoDB 5.3, 2007; www.plasmodb.org) 
Crick-orientation genes are represented in red, while Watson-orientation genes are 
coloured blue. 
 
The gene has Crick-orientation, meaning that the coding sequence is found on the 
antisense strand. This gene codes for the putative adaptor protein complex-1 (AP-1) β1 
subunit. This subunit is potentially involved in the formation of clathrin-coated vesicles 
for protein trafficking within the parasite, ensuring that proteins reach their final cellular 
destinations (Cooke et al, 2004).  
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1.7) Aims of the project 
 
The aim of this project is to express, extract and purify recombinant P. falciparum 
proteins that participate in vital protein-protein interactions within the parasite and with 
the host erythrocyte membrane. Two proteins have been chosen: a PK, the product of 
PFB0150c, and an AP-1 β1 subunit, the product of PFE1400c, that will be expressed as 
two domains – the clathrin adaptor appendage domain and the adaptin N-terminal 
domain. The specific objectives of the project are as follows:  
• culture the 3D7 strain of P. falciparum 
• design primers and amplify the genes of interest using PCR 
• subclone the genes into expression vectors 
• express the recombinant proteins in competent E. coli cells 
• purify the recombinant proteins using affinity separation 
• analyse the structural and biochemical characteristics of the expressed proteins  
This project will form the groundwork for further studies involving the inhibition of these 
proteins by gene knockout or knockdown to determine whether they are feasible drug 
targets. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
All solutions were made using ultrapure laboratory grade water filtered using the Milli-
QTM Water System (Millipore Corporation, USA). Sterile methods were employed for all 
culturing techniques, and solutions were sterilised by autoclaving or filtration. The 
methods for preparing the solutions in each section appear in the Appendix.  
 
2.1) Malaria culturing techniques 
  
The P. falciparum 3D7 strain was cultured in a sterile hood using an amended method of 
Trager and Jensen (1976), the amendment being the exclusion of the candle jar procedure 
to obtain the correct gas mixture for culturing. The parasitised red blood cells (pRBC) 
were decanted into sterile culture flasks (Nunc, Germany) and maintained in complete 
medium at 37°C in a gas mixture of 5.5% CO2, 2.75% O2 and 91.25% N2 (Afrox, South 
Africa). The life cycle stage, percentage parasitaemia and health of the parasites were 
determined on a daily basis via preparation of smears and examination under a 
microscope (Zeiss Axiostar, Germany). Complete medium was aspirated and replaced on 
a daily basis. Cultures were maintained at approximately 5% parasitaemia and when this 
level exceeded 10%, cultures were divided or excess cells were aspirated. Fresh washed 
erythrocytes were added to maintain the haematocrit at 5%. 
  
2.1.1) Preparation of culture from frozen stock 
 
The preparation of cultures from frozen stock was carried out according to the 
method of Haeggström and Schlichtherle (2004). Tubes of cryo-frozen P. 
falciparum-infected erythrocytes were removed from liquid nitrogen. The tubes 
were placed into a 37°C water bath for 5 minutes or until thawed. The stock was 
transferred to 15ml Nunc tubes and 100µl 12% NaCl was added in a drop-wise 
fashion for each millilitre of stock. The tube was gently swirled and left to stand 
at room temperature for 5 minutes. Nine volumes of 1.6% NaCl were added and 
gently mixed.  
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The tube was centrifuged using an Eppendorf centrifuge 5702R (Eppendorf, 
Germany) at 250x g at 4°C for 5 minutes and the supernatant was aspirated. The 
pellet was resuspended in 9 volumes of 0.9% NaCl/0.2% glucose solution and 
centrifuged at 250x g for 5 minutes. The supernatant was aspirated and the 
remaining pellet was made up to 250µl with freshly washed erythrocytes. This 
solution was transferred to a 50ml culture flask and made up to 5ml using 
complete medium with 20% plasma. This plasma-enriched medium was used for 
the first week to initiate culture growth; thereafter medium with 10% plasma was 
used. The flask was gassed with 5.5% CO2, 2.75% O2 and 91.25% N2 for 
30 seconds and sealed tightly. The flask was incubated at 37°C for 48hrs. 
 
2.1.2) Heat inactivation of plasma 
 
 Aliquots of frozen AB plasma (SANBS, South Africa) were thawed at room 
temperature, followed by heat-inactivation for 2 hours at 56°C. The inactivated 
plasma was transferred to sterile 50ml Nunc tubes. The tubes of plasma were 
centrifuged (Centrifuge 5702R; Eppendorf, Germany) at 750x g at 20°C for 10 
minutes. 10ml or 45ml of the plasma was aliquotted into 15ml or 50ml Nunc 
tubes respectively and stored at –70°C. 
 
 2.1.3) Washing erythrocytes 
 
 Fresh blood from volunteers was collected in 6ml acid citrate dextrose tubes 
(Becton Dickinson Biosciences, USA) ((Ethics number M03-11-06; University of 
the Witwatersrand; Committee for Research on Human Subjects (medical)) and 
centrifuged (MSE Coolspin centrifuge; Fisons Scientific, UK) at 400x g for 
10 minutes at 4°C. The plasma and buffy coat were aspirated in a sterile hood. 
Two volumes of PBS were added to the remaining erythrocytes and the solution 
was mixed and centrifuged as before. This process was repeated twice, after 
which the erythrocytes were resuspended in 1 volume of incomplete medium. 
Washed erythrocytes were stored in sterile 15ml tubes at 4°C for 5 days after 
which the unused cells were discarded and a fresh batch was prepared. 
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 2.1.4) Preparation of smears 
 
The culture flask was gently tilted so that the medium was displaced and the 
pRBC were concentrated on the bottom of the flask. A pipette was used to 
aspirate 10µl of the erythrocytes and this was transferred onto a glass microscope 
slide. The drop of erythrocytes was thinly smeared across the slide and allowed to 
air dry. The smear was then stained using the Rapindiff staining kit (Global 
Diagnostics, South Africa). The slide was air dried and viewed at 1000x 
magnification under oil immersion using a microscope (Zeiss Axiostar, Germany). 
  
 2.1.5) Calculating parasitaemia 
 
The infected erythrocytes and uninfected erythrocytes were counted in at least 5 
different fields containing more than 100 erythrocytes per field. 
The percentage parasitaemia for each field was calculated using the following 
formula: 
 
 
                                                    # Infected erythrocytes 
% Parasitaemia =  __________________________________________ X 100 
                              # Infected erythrocytes + # uninfected erythrocytes 
 
 An average percentage parasitaemia was calculated. 
 
2.1.6) Feeding the culture  
 
The flask was tilted gently to collect the medium in a corner. Using a Pasteur 
pipette and pump, the stale medium was aspirated. Fresh complete medium, 
warmed up to 37°C, was added to the flask. The volume of complete medium 
added was 5ml for small 50ml-volume flasks, 15ml for medium 80ml-volume 
flasks and 30ml for large 175ml-volume flasks. The flask was gassed with 5.5% 
CO2, 2.75% O2 and 91.25% N2 for 30 seconds and sealed tightly. The flask was 
incubated at 37°C in an incubator. The medium was changed once a day, at 
approximately the same time each day. 
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2.1.7) Dividing the culture 
 
A culture was divided when the parasitaemia was greater than 10% or when a 
culture needed to be continued when using the majority for DNA/RNA extraction. 
5ml of complete medium was decanted into the small flask and washed 
erythrocytes were added to a final haematocrit of 5%. A 1ml aliquot of pRBC was 
taken from the culture flask and added to the new flask to give an approximate 
parasitaemia of 2%. Flasks were gassed and incubated at 37°C in an incubator. 
 
2.1.8) Synchronisation of the culture – Sorbitol treatment 
 
Synchronisation of P. falciparum erythrocytic stages in culture was achieved 
using the method determined by Lambros and Vanderberg (1979). This method 
involves the lysis of pRBCs containing trophozoites and schizonts, due to the 
increased permeability of the RBC membrane to sorbitol during these later stages. 
The influx of sorbitol causes a concomitant influx of water and the osmotically 
fragile pRBCs burst. The only pRBCs that will remain are those containing the 
early ring-stages of the parasite.  
A 5% D-Sorbitol solution was prepared and sterilised by filtration using a Millex 
GP 0.22µm syringe-driven filter unit (Millipore, Ireland) and stored at 4°C. A 
smear was prepared to verify that parasites were mainly in the early ring stage 
with a parasitaemia greater than 10%. The culture was transferred to a 50ml Nunc 
tube and centrifuged (Centrifuge 5702R; Eppendorf, Germany) at 250x g for 5 
minutes at 20°C. The supernatant was aspirated and 10 volumes of D-sorbitol 
were added to the pRBC pellet. The pellet was resuspended and left to stand at 
room temperature for 30 minutes. The solution was centrifuged as before and the 
supernatant was removed. The pellet was resuspended in complete medium and 
washed erythrocytes were added to a haematocrit of 5%. The flask was gassed 
with 5.5% CO2, 2.75% O2 and 91.25% N2 for 30 seconds and sealed tightly. The 
flask was incubated at 37°C. 
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2.1.9) Freezing of cultures 
 
Cultures were frozen when parasites were mainly in the ring stage and 
parasitaemia was 10% or more. The culture was centrifuged (Centrifuge 5702R; 
Eppendorf, Germany) at 250x g for 5 minutes at 20°C and the supernatant was 
removed. The packed cells were resuspended in a 1:1 ratio with 60% glycerol 
solution. The suspension was transferred to sterile cryotubes in 1ml aliquots and 
left to settle for 5 minutes. The tubes were then placed in liquid nitrogen. 
 
2.2) DNA experiments 
 
2.2.1) DNA extraction from P. falciparum 
 
DNA extraction was carried out on parasites in the late stages of the life cycle 
(trophozoites and/or schizonts) from cultures with 10-15% parasitaemia according 
to the methods of Schlichtherle and Wahlgren (2004). The culture was transferred 
from 175ml-volume large culture flasks, containing 30ml of culture, to sterile 
50ml Nunc tubes and centrifuged (Centrifuge 5702R; Eppendorf, Germany) at 
750x g for 5 minutes at 4°C. The supernatant was removed and the pellet was 
washed in PBS followed by centrifugation at 750x g for 5 minutes at 4°C. The 
supernatant was removed and the pRBC pellet was resuspended in 1ml PBS in a 
15ml Nunc tube. 10µl of a 5% saponin (USB Corporation, USA) solution was 
added for every millilitre of pRBC. The suspension was left at room temperature 
for 3-5 minutes to allow the erythrocytes to lyse. This was followed by 
centrifugation at 750x g for 5 minutes at 4°C. The supernatant was decanted. PBS 
was added to a volume twice that of the pellet volume to resuspended the pellet. 
This mixture was centrifuged at 750x g for 5 minutes at 4°C and the pellet was 
washed three times with brief vortexing. 1mg of PCR-grade recombinant 
proteinase K (Roche Applied Science, Germany) was added to 1ml of lysis buffer. 
250µl lysis buffer/proteinase K solution was diluted with 750µl water and added 
to the parasite pellet, which was resuspended by gentle aspiration.  
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Proteinase K is an endopeptidase that cleaves peptide bonds, thus promoting cell 
lysis and inactivating endogenous nucleases.  
The sample was incubated for 3 hours at 37°C, with mixing every hour using a 
pipette to promote parasite lysis. After 3 hours, the solution was aspirated with a 
syringe and 21 gauge needle to ensure that parasites were completely lysed. DNA 
was extracted from the crude cell lysate using the phenol extraction and ethanol 
precipitation method (Moore & Dowhan, 2002). An equal volume of 1:1 
phenol/chloroform mixture was added. The phenol (Sigma-Aldrich Inc, USA) used 
had a pH of 8.2 and was saturated with 10mM Tris HCl (pH 8.0) and 1mM 
EDTA. The solution was mixed well by inverting the tube several times. The 
sample was then centrifuged (Centrifuge 5415R; Eppendorf, Germany) at 18 000x 
g for 5minutes at 4°C. 80-90% of the aqueous phase was collected and transferred 
to a new Eppendorf tube. 500µl TE buffer was added to the remaining organic 
phase. This mixture was centrifuged at 18 000x g for 5 minutes at 4°C. The 
aqueous phase was collected and added to the previously collected aqueous phase. 
An equal volume of chloroform was added, followed by centrifugation at 
18 000x g for 5 minutes at 4°C. The aqueous phase was collected. 10µl of 
RNase A (Fermentas, Europe), supplied in 50mM Tris-HCl (pH 7.4) and 50% 
glycerol, was added per ml of aqueous phase (final concentration = 100ug/ml) 
followed by incubation at 37°C for 30 minutes. The phenol/chloroform extraction 
was repeated. DNA from the aqueous phase was precipitated by adding 0.1 
volumes of 3M sodium acetate (pH 5.2) and 2.5 volumes 100% ice-cold ethanol. 
This solution was placed at -70°C for 30 minutes and then centrifuged at 
18 000x g for 30 minutes at 4°C. The supernatant was removed and 70% ice-cold 
ethanol was added to the pellet. This was followed by centrifugation at 18 000x g 
for 5 minutes at 4°C. The supernatant was removed and the pellet was air-dried 
for 15 minutes to ensure that the ethanol had evaporated. The pellet was 
resuspended in 20µl nuclease-free water (Promega, USA) and stored at 4°C 
overnight and at -70°C thereafter. 
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2.2.2) Determination of DNA concentration and purity  
 
DNA concentration was determined using a Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies Inc, USA) according to the following 
equation: 
 
 [DNA] in µg/µl = A260 x 50 x DF x 0.001 
  
Where: DF = dilution factor 
   50 = extinction coefficient of 1µg/ml dsDNA 
   0.001 = conversion factor for ml to µl 
 
The DNA purity was determined using the A260/A280 value. A value of 1.8 
indicates a pure sample. If the A260/A280 reading is less than 1.8, contamination 
with proteins, salt, ethanol or aromatic substances like phenol may be present. An 
A260/A280 reading greater than 2 indicates the presence of RNA in the sample. 
Samples with an A260/A280 reading between 1.5 and 1.9 were considered pure 
enough for further use. Integrity and purity of the DNA samples were determined 
via electrophoresis on a 0.8% mini agarose gel (10x8cm). The agarose used was 
D-1 LE agarose (Hispanagar, Spain). The gel was cast into a horizontal mini-gel 
kit model # MGU-200T (CBS Scientific, USA). The gel was electrophoresed for 
1 hour at 65V (Electrophoresis power supply EPS 301; Amersham pharmacia 
biotech, Sweden) in 1x TAE buffer. 2.5µl of 10µg/µl ethidium bromide was added 
to the anode chamber of the gel system. Ethidium bromide binds to nucleic acids 
and fluoresces orange under UV light. DNA was visualised under UV light and 
photographed using GeneSnap version 6.05 image acquisition software (Syngene, 
UK). 
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2.3) RNA experiments 
 
 2.3.1) RNA extraction from P. falciparum 
 
 Parasitised erythrocytes were harvested from a large culture flask with 10-15% 
parasitaemia in the late stages of development. The cultures were centrifuged 
using an Eppendorf centrifuge 5702R (Eppendorf, Germany) at 750x g for 
4 minutes at 4°C. RNA was extracted according to the Tri-Reagent (Sigma-
Aldrich Inc, USA) manufacturer’s protocol. The supernatant was removed and 
5ml of Tri-Reagent was added for every 0.5 ml erythrocytes. The solution was 
shaken and incubated at 37°C for 5 minutes. Chloroform was added to a volume 
0.2 times that of the original Tri-Reagent volume. The solution was vigorously 
vortexed for 15 seconds and placed at room temperature for 3 minutes. 
Centrifugation at 1 600x g at 4°C for 35 minutes was then carried out. The upper 
aqueous phase was carefully transferred into 2ml Eppendorf tubes. Cold 
isopropanol to 0.5 times the original Tri-Reagent volume was added to precipitate 
the RNA. The solution was mixed by inversion and placed on ice for 2 hours. The 
solution was centrifuged (Centrifuge 5415R; Eppendorf, Germany) at 18 000x g 
for 30 minutes at 4°C. The supernatant was removed and 800µl of cold 70% 
ethanol was added to the RNA pellet. Centrifugation at 18 000x g for 5 minutes at 
4°C followed. The ethanol was removed and the pellet was air dried for 15 
minutes at room temperature. 20µl of nuclease-free water (Promega, USA) was 
added and the RNA was stored at -70°C. 
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2.3.2) Determination of RNA concentration and integrity 
 
RNA concentration was determined using a Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies Inc, USA) according to the following 
equation: 
 
 [RNA] in µg/µl = A260 x 40 x DF x 0.001 
  
Where: DF = dilution factor 
   40 = average extinction coefficient of 1µg/ml ribonucleic acids 
   0.001 = conversion factor for ml to µl 
 
 RNA purity was ascertained according to the A260/A280 value obtained. A value 
equal to 2 indicates a pure sample of RNA. If the ratio is less than 2 then protein 
contamination may be present. Samples with A260/A280 values between 1.7 and 2 
were considered pure enough for RT-PCR. RNA integrity was determined via 
electrophoresis on a 1% agarose gel in TAE buffer. The gel was cast, 
electrophoresed and visualised as described in section 2.2.2.  
 
2.3.3) Reverse transcription  
 
RNA was reverse transcribed using the SuperScript TM III RNase H Reverse 
Transcriptase kit (Invitrogen Life Technologies, UK) to produce cDNA. The 
manufacturer’s protocol was followed. The following components were added to 
a nuclease-free PCR tube: 1µl oligo (dT)12-18, 1µg total RNA, 4µl 2.5mM dNTP, 
nuclease-free water to 13µl. The mixture was heated to 65°C for 5 minutes - to 
ensure that any RNA secondary structures were resolved - and then incubated on 
ice for 1 minute. The following reagents were added: 4µl 5X first strand buffer, 
1µl 0.1M DTT, 1µl RNaseOUT and 1µl SuperScript TM III. The solution was 
gently mixed and incubated at 55°C for 60 minutes. The enzyme was inactivated 
by heating to 70°C for 15 minutes. The cDNA was then amplified to produce the 
PFE1400c clathrin adaptor appendage domain insert. 
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2.4) PCR 
 
 2.4.1) Primer design 
 
Primers were designed based on DNA sequences obtained from the Plasmodium 
genome database, PlasmoDB version 5.3 (2007). Using Integrated DNA 
Technologies SciTools Oligo Analyzer 3.0 (www.idtdna.com) the primers were 
analysed to ensure that minimal hairpins and primer-dimers would be formed. 
Recognition sites for the restriction endonucleases BamHI, XhoI and NdeI were 
included to facilitate ligation into either the pGEX-4T-2 (Amersham Biosciences, 
UK) or pET-15b (Novagen, USA) vector (Vector maps, Appendix section 5.8). 
Primers were synthesised by Inqaba Biotec (South Africa) and provided in 
lyophilised form. The lyophilised primers were reconstituted in TE buffer to a 
final concentration of 100µM and stored at -20°C. 
 
The following primers were used, with the bases in red indicating the restriction 
endonuclease recognition site; the bases in bold indicate the extra bases added to 
facilitate enzyme binding and activity at the site, and the arrows show the exact 
site of cleavage:  
 
PFB0150c PK domain: 
 
Forward primer (with BamHI recognition site) 
5’- CGC G↓GA TCC GAT GAA AAG GAT GGA TAT G -3’ 
 
Reverse primer (with XhoI recognition site) 
5’- CCG C↓TC GAG TCA TTT CTG GGA TTG TTC AGT -3’ 
 
The restriction endonuclease recognition sites (red) are included to facilitate 
insertion into the pGEX-4T-2 vector. The PCR product produced using these 
primers was 1 515bp in size. 
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PFE1400c adaptin N-terminal domain: 
 
Forward primer (with NdeI recognition site) 
5’- CGG TTT CCA↓ TAT GAT GTC TGA TTT ACG CTA CTT -3’ 
 
Reverse primer (with BamHI recognition site) 
5’- CGC G↓GA TCC ATG ATC ATT ATT ATT ATC AGA A -3’ 
 
The restriction endonuclease recognition sites (red) are included to facilitate 
insertion into the pET-15b vector. The PCR product produced using these primers 
was 1 800bp in size. 
  
PFE1400c clathrin adaptor appendage domain: 
 
Forward primer (with BamHI recognition site) 
5’- CGC G↓GA TCC TCT TCG GAT GAA TTC AAT AA -3’ 
 
Reverse primer (with XhoI recognition site) 
5’- CCG C↓TC GAG TCA CTG AGT TAC ACT TAA GGA AAA -3’ 
 
The restriction endonuclease recognition sites (red) are included to facilitate 
insertion into the pGEX-4T-2 vector. The PCR product produced using these 
primers was 723bp in size.  
 
 2.4.2) PCR protocol 
 
The PCR was carried out using the Expand High Fidelity PLUS PCR system (Roche 
Applied Science, Germany). The high-fidelity DNA polymerase ensures that the 
DNA sequence is amplified with high specificity and accuracy, and is six-fold 
more accurate than Taq DNA polymerase alone. The reaction mixture was 
prepared as indicated in Table 1. 
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TABLE 1: Reaction mixture for PCR using the Expand High Fidelity PLUS PCR   
                   system 
 
REAGENT VOLUME  
(µl) 
FINAL 
CONCENTRATION 
PCR grade water Add to 50  
Expand HiFi PLUS reaction buffer 
5X ; Vial 2 
10 1.5mM MgCl2 
dNTP (10mM) 1 200µM 
Forward primer (20µM) 1 0.4µM 
Reverse primer (20µM) 1 0.4µM 
Expand HiFi PLUS enzyme blend; 
Vial 1 
0.5 2.5U 
Genomic DNA 0.8 125ng 
 
The SuperScript TM manufacturer’s protocol recommended 2µl of cDNA be added 
to the reaction mixture for PCR. The reaction tubes were placed in a Mastercycler 
gradient thermocycler (Eppendorf, Germany). Two successive annealing 
temperatures were used for each amplicon. Annealing temperatures were 
calculated to be 3°C lower than the melting temperatures, which were supplied by 
the manufacturer (Inqaba Biotec, South Africa). A range of temperatures (within 
6°C of the calculated melting temperature) were tested to optimise the reaction 
conditions for each DNA sequence to be amplified. The first annealing 
temperature was calculated for the P. falciparum sequence primer without the 
added bases making up the restriction site. The second annealing temperature took 
into account the extra bases. The following programs produced the best results 
and were used for subsequent PCRs: 
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PFB0150c PK domain: 
 
Initial denaturation: 94°C for 2 minutes 
Denaturation: 94°C for 1 minute 
Primer annealing: 52.2°C for 1 minute, 5 cycles; 59.2°C for 1 minute, 29 cycles 
Extension: 72°C for 1 minute 
Final extension: 72°C for 5 minutes 
 
PFE1400c adaptin N-terminal domain: 
 
Initial denaturation: 94°C for 2 minutes 
Denaturation: 94°C for 1 minute 
Primer annealing: 48.5°C for 1 minute, 5 cycles; 56.9°C for 1 minute, 29 cycles 
Extension: 72°C for 1 minute 
Final extension: 72°C for 5 minutes 
 
PFE1400c clathrin adaptor appendage domain: 
 
Initial denaturation: 94°C for 2 minutes 
Denaturation: 94°C for 1 minute 
Primer annealing: 46.1°C for 1 minute, 5 cycles; 52°C for 1 minute, 29 cycles 
Extension: 72°C for 1 minute 
Final extension: 72°C for 5 minutes 
 
The PCR products were purified using the phenol extraction and ethanol 
precipitation method as previously described (section 2.2.1) to change the PCR 
buffer. For every 50µl of PCR product, 50µl of nuclease-free water was added. 
Following the extraction, the dried pellet was resuspended in 40µl of nuclease-
free water. Aliquots of the purified PCR products were resolved on a 1% agarose 
gel and the concentration of the samples was determined on a Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies Inc, USA) as described for DNA 
(section 2.2.2). 
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2.4.3) Restriction digestion of PCR products 
 
Double digests on the purified PCR products were carried out using Fermentas 
(Europe) restriction endonucleases. The reaction mixtures were prepared - to a 
final volume of 20µl - as recommended by the Fermentas DoubleDigestTM engine 
(www.fermentas.com/ doubledigest), outlined in Table 2. Briefly, double digestion 
with BamHI and XhoI was carried out in 2X Tango™ buffer at 37°C for 18 hours. 
Incubation times of 2, 6 and 18 hours were tested, with the latter resulting in 
optimum digestion. Under these conditions BamHI has an activity of 50-100% 
and star activity is ameliorated; XhoI has 100% activity under these conditions. 
Star activity is the non-specific cleavage of DNA by restriction enzymes when 
reaction conditions are not optimised. Double digestion with BamHI and NdeI 
was carried out in 2X Tango™ buffer at 37°C for 18 hours. These reaction 
conditions result in enzyme activity of 50-100% for both BamHI and NdeI. 
 
TABLE 2: Reaction mixture for PCR product restriction digests using Fermentas  
                   restriction endonucleases 
 
PCR 
PRODUCT 
RESTRICTION 
ENZYME 1 
RESTRICTION 
ENZYME 2 
2X  
BUFFER 
MILLI-Q 
WATER 
PFB0150c 
Kinase 
(1µg) 
BamHI - 2µl 
(20U) 
XhoI - 1µl 
(10U) 
10X TangoTM 
buffer - 4µl 
Make up 
to 20µl 
PFE1400c 
Clathrin 
(1µg) 
BamHI - 2µl 
(20U) 
XhoI - 1µl 
(10U) 
10X TangoTM 
buffer - 4µl 
Make up 
to 20µl 
PFE1400c 
Adaptin 
(1µg) 
BamHI - 2µl 
(20U) 
NdeI - 2µl 
(20U) 
10X TangoTM 
buffer - 4µl 
Make up 
to 20µl 
 
 Aliquots of the samples were resolved on a 1% agarose gel as previously 
described (section 2.2.2) to check the size of the DNA inserts (in case of star 
activity). After restriction digestion, DNA inserts were purified using phenol 
extraction and ethanol precipitation as previously described (section 2.2.1). The 
concentrations of DNA inserts were determined using a Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies Inc, USA).
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2.5) Plasmid preparation 
 
 2.5.1) Extraction of plasmid DNA from DH5α cells 
 
Plasmids, namely pGEX-4T-2 (Amersham Biosciences, UK) and pET-15b 
(Novagen, USA) were extracted from Subcloning EfficiencyTM DH5αTM 
chemically competent cells (Invitrogen, USA) using the GenElute Plasmid 
Miniprep Kit (Sigma-Aldrich Inc, USA) according to the manufacturer’s protocol 
and using kit reagents. The method relies on an SDS-based lysis of E. coli cells, 
followed by the adsorption of plasmid DNA onto silica in the presence of high 
salt concentrations. A spin-wash step removes any contaminants and the bound 
DNA is eluted.  
 
DH5α cells from glycerol stock were inoculated into sterile 100ml Erlenmeyer 
flasks containing 10ml Luria broth, which contains nutrients and a buffer to 
provide optimum growth conditions for the cells. The cell cultures were grown 
overnight, incubated in an orbital shaker at 37°C. The cells were harvested by 
centrifuging (Beckman model J2-21 centrifuge; Beckman Coulter, USA) at 
3 500x g for 10 minutes at room temperature. The supernatant was discarded and 
cells were resuspended in 200µl Resuspension solution. 200µl of alkaline Lysis 
solution was added to the cells and the tubes were inverted gently to mix. The 
solution was allowed to clear for 5 minutes and then 350µl of Neutralisation 
solution was added. The solution was gently mixed and transferred to 2ml 
Eppendorf tubes. The debris was pelleted by centrifuging (Centrifuge 5415R; 
Eppendorf, Germany) at 18 000x g for 10 minutes. Binding columns were 
prepared by adding 500µl Column Preparation Solution and centrifuging at 
18 000x g for 1 minute. The flow-through was discarded and the cleared lysate 
was transferred into the Eppendorf tube containing the binding column. 
Centrifugation at 18 000x g for 1 minute followed and the flow-through was 
discarded. 750µl of Wash Solution was added to the column, followed by 
centrifugation at 18 000x g for 1 minute. The flow-through was discarded and the 
binding column was centrifuged again to remove any excess ethanol.  
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The binding column was transferred to a new collection tube and 100µl of Elution 
solution was added. The collection tube was centrifuged at 18 000x g for 1 minute 
and the plasmid DNA was eluted. The concentration of plasmid DNA was 
determined using a Nanodrop ND-1000 spectrophotometer (Nanodrop 
Technologies Inc, USA). Aliquots of the samples were resolved on a 1% agarose 
gel as previously described (section 2.2.2) to check the size and integrity of the 
plasmids. Samples were stored at -20°C until required. 
 
2.5.2) Restriction enzyme digestion of plasmids 
 
Plasmids were subjected to double restriction digests, using Fermentas (Europe) 
restriction endonucleases, to prepare them for ligation with P. falciparum DNA 
inserts. The reaction mixtures were prepared as outlined in Table 3, and 
previously described (section 2.4.3). 
 
TABLE 3: Reaction mixture for plasmid restriction digests using Fermentas  
                   restriction endonucleases 
 
PLASMID RESTRICTION 
ENZYME 1 
RESTRICTION 
ENZYME 2 
2X  
BUFFER 
MILLI-Q 
WATER 
pGEX-4T-2 
(1µg) 
BamHI - 2µl 
(20U) 
XhoI - 1µl 
(10U) 
10X 
TangoTM 
buffer - 
4µl 
Make up 
to 20µl 
pET-15b 
(1µg) 
BamHI - 2µl 
(20U) 
NdeI - 2µl 
(20U) 
10X 
TangoTM 
buffer - 
4µl 
Make up 
to 20µl 
 
The solutions were incubated at 37°C for 18 hours. After restriction digestion, 
plasmids were purified using the phenol-chloroform extraction and ethanol 
precipitation method as previously described (section 2.2.1). The concentration of 
plasmid DNA was determined using a Nanodrop ND-1000 spectrophotometer 
(Nanodrop Technologies Inc, USA) and aliquots were resolved on a 1% agarose 
gel as before (section 2.2.2) to check that the plasmids had been linearised.  
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Fermentas FastDigestTM restriction endonucleases were also utilised, which only 
required a 1 hour incubation time. The reaction mixtures were prepared as follows 
in Table 4. 
 
TABLE 4: Reaction mixture for plasmid restriction digests using Fermentas  
                   FastDigestTM restriction endonucleases 
 
PLASMID RESTRICTION 
ENZYME 1 
RESTRICTION 
ENZYME 2 
1X  
BUFFER 
MILLI-Q 
WATER 
pGEX-4T-2 
(1µg) 
FastDigestTM 
BamHI - 1µl 
(0.25U) 
FastDigestTM 
XhoI - 1µl 
(0.5U) 
10X 
TangoTM 
buffer - 2µl 
Make up 
to 20µl 
pET-15b 
(1µg) 
FastDigestTM 
BamHI - 1µl 
(0.25U) 
FastDigestTM 
NdeI - 1µl 
(0.5U) 
10X 
TangoTM 
buffer - 2µl 
Make up 
to 20µl 
  
2.5.3) Alkaline phosphatase treatment of linearised plasmids 
 
After purification the restriction digested plasmids were treated with calf 
intestinal phosphatase (CIP) (Roche Applied Science, Germany) to prevent self-
ligation. For every 20µl of insert, 1µl of CIP and 2µl of 10X CIP buffer was 
added. The solution was incubated at 37°C for 1 hour. The purification process 
was then repeated. The concentration of plasmid DNA was determined using a 
Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies Inc, USA) 
(section 2.2.2). 
 
2.6) Subcloning 
 
 2.6.1) Ligation of DNA insert and plasmid 
 
 Ligations were carried out using the DNA Ligation Kit (Roche Applied Science, 
Germany). A 1:3 molar ratio of plasmid to DNA insert, with the total amount of 
DNA not exceeding 200ng, was added to 2µl 5X DNA dilution buffer and made 
up to 10µl with nuclease-free water.  
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Next, 10µl of T4 DNA Ligation buffer was added to this solution and mixed. 
Lastly, 1µl of T4 DNA Ligase was added and the solution was incubated at 16°C 
for 30 minutes. Thereafter, 5µl of ligated DNA solution was used for 
transformation, while the remainder was stored at -20°C. 
 
 2.6.2) Transformation of DH5α cells 
 
 50µl aliquots of Subcloning EfficiencyTM DH5αTM chemically competent cells 
(Invitrogen, USA) were thawed on ice. The plasmid-DNA insert solution was 
incubated at 70°C for 10 minutes to heat-inactivate the T4 DNA Ligase enzyme. 
5µl of the ligated plasmid-DNA insert solution was added to the DH5α cells and 
incubated on ice for 30 minutes. A control reaction contained the plasmid with no 
insert. The suspension was incubated at 37°C for 20 seconds to heat shock the 
cells. The cells were placed on ice for 2 minutes. 500µl of Luria broth was added 
and the solution was placed in an orbital shaker at 37°C for 1 hour. Aliquots of 
50µl, 100µl and 350µl were spread in a sterile manner onto agar plates. The agar 
plates were made by autoclaving 1L of Luria broth with 15g of Biolab 
bacteriological agar (Merck, Germany), cooling the solution and adding 1ml of 
100mg/ml ampicillin (Roche Applied Science, Germany). This solution was 
poured into 85mm culture plates (Costar, USA). The plates were left to set 
overnight. Once the transformed DH5α cells had been spread onto the plates, they 
were inverted and placed in an incubator overnight at 37°C. The plasmid contains 
an ampicillin resistance gene; therefore the addition of the antibiotic to the agar 
plate ensures that only plasmid-bearing, ampicillin-resistant bacterial colonies will 
proliferate. 
 The next morning, colonies were compared to the control plate to check for any 
self-ligated vectors. Five single colonies were removed from the plate using a 
pipette and placed in 10µl Milli-Q water. 5µl of this solution was used in a PCR 
reaction. Primers specific for the P. falciparum insert were used. The bacteria 
were first lysed by heating at 94°C for 5 minutes in a thermocycler and PCR 
reagents were added as outlined in Table 1 (section 2.4.2). The PCR products 
were resolved on a 1% agarose gel (section 2.2.2) to check that the inserts were 
present.
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The remaining 5µl of the positive colonies was added to BD Falcon™ round 
bottom tubes (Becton Dickinson Biosciences, USA) containing 2ml Luria broth 
with 20µl of 100mg/ml ampicillin and placed in a 37°C orbital shaker overnight. 
The next day, stock solutions were made by adding 500µl of the transformed 
DH5α cells to 500µl of 60% sterile glycerol. The stocks were stored at -70°C. The 
plasmids were extracted from the remaining cells using the GenElute Plasmid 
Miniprep Kit (Sigma-Aldrich Inc, USA) as described in section 2.5.1. 50µl of the 
plasmid was digested for two hours with the relevant restriction endonucleases 
(section 2.5.2). Whole plasmids and digested plasmids were resolved on a 1% 
agarose gel (section 2.2.2) to verify the presence of the insert. 
 
2.6.3) Transformation of Rosetta 2 (DE3) cells  
 
 Rosetta 2 (DE3) cells (Novagen, USA) supply tRNAS for seven rare codons that 
are not usually present in E. coli cells, which enhances the expression of 
eukaryotic proteins.  20µl aliquots of Rosetta 2 (DE3) cells in were thawed on ice. 
1µl of the recombinant plasmid was added to the competent cells and gently 
mixed by inversion. The cells were incubated on ice for 30 minutes, followed by a 
heat shock at 37°C for 30 seconds. The solution was immediately placed on ice 
for 2 minutes. 500µl of Luria broth was added, which was placed in an orbital 
shaker at 37°C for 1 hour. 50µl and 450µl aliquots were sterily spread onto agar 
plates treated with ampicillin (100mg/ml) and chloramphenicol (50mg/ml) and 
placed in an incubator at 37°C overnight. The addition of the two antibiotics 
selects for the recombinant ampicillin-resistant plasmids that have been taken up 
by Rosetta 2 (DE3) cells which contain chloramphenicol-resistant plasmids. The 
next morning, colonies were compared to the control plate to check for any self-
ligated vector. Ten single colonies were removed using a pipette and placed into 
10µl Milli-Q water. 5µl of this solution was used in a PCR reaction as described 
in section 2.4.2. The PCR products were resolved on a 1% agarose gel (section 
2.2.2) to check that the inserts were present. Stock solutions were prepared and 
stored as in section 2.6.2. The plasmids were extracted from the remaining cells 
using the manual plasmid preparation method (section 2.6.4). 
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Half of the plasmid solution was digested for two hours with the relevant 
restriction endonucleases (section 2.5.2). Whole plasmids and digested plasmids 
were resolved on a 1% agarose gel (section 2.2.2) to verify the presence of the 
insert. 
 
2.6.4) Extraction of plasmid DNA from Rosetta 2 (DE3) cells 
 
The extraction of plasmid DNA from Rosetta 2 (DE3) cells was performed by 
utilising the alkaline lysis method as described by Bimboim & Doly (1979) with 
modern enhancements by Ehrt & Schnappinger (2003). This manual method 
resulted in better yields of plasmid than the kit. The method is based on the 
disparity between the denaturation of chromosomal and plasmid DNA, which 
allows the separation of the two. Both the high molecular weight chromosomal 
DNA and the plasmid denature on addition of an SDS/ NaOH solution, but the 
latter remains double-stranded. The solution is neutralised by the addition of 
KCH3COO, which causes the chromosomal DNA to form an insoluble mass while 
the plasmid remains soluble. The precipitated chromosomal DNA forms a 
complex with the SDS and potassium, and is removed via centrifugation along 
with the cellular proteins. The plasmid DNA is retrieved by ethanol precipitation.  
Rosetta 2 (DE3) cells were grown overnight in 2ml Luria broth, 20µl 100mg/ml 
ampicillin and 20µl 50mg/ml chloramphenicol. The overnight growths were 
transferred into 2ml Eppendorf tubes and centrifuged (Centrifuge 5415R; 
Eppendorf, Germany) at 18 000x g for 1 minute at 4°C. The supernatant was 
discarded and 100µl ice cold lysis buffer was added to resuspend the cell pellet. 
The samples were incubated at room temperature for 5 minutes. 200µl of fresh 
0.2M NaOH/1% SDS solution was added to each sample and mixed by inversion. 
150µl ice-cold, fresh KCH3COO (pH 4.8) was added to each sample, followed by 
incubation on ice for 5 minutes. Samples were centrifuged at 18 000x g for 
10 minutes at room temperature. The supernatants were removed to Eppendorf 
tubes and 500µl of a 1:1 phenol/chloroform solution was added. Samples were 
centrifuged at 18 000x g for 5 minutes at 4°C. The upper aqueous phase was 
collected and 2.5 volumes of 100% ice cold ethanol was added, followed by 
incubation at room temperature for 5 minutes. 
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Samples were centrifuged at 18 000x g for 10 minutes at 4°C. The supernatants 
were discarded and the pellets were air dried for 20 minutes.  
Once the pellets were transparent and dry, 100µl TE buffer and 1µl RNase A 
(Fermentas, Europe) were added to each pellet and incubated at 37°C for 30 
minutes. 40µl fresh KCH3COO (pH 4.8) was added, followed by 260µl of 
nuclease-free water. 500µl of a 1:1 phenol/chloroform solution was added and 
mixed. Samples were centrifuged at 18 000x g for 5 minutes at 4°C.The aqueous 
phase was collected and 250µl chloroform was added and mixed by inversion. 
Samples were then centrifuged at 18 000x g for 5 minutes at 4°C. The aqueous 
phase was collected and 1ml of 100% ice cold ethanol was added. The samples 
were incubated at -70°C for 15 minutes. Samples were centrifuged at 20 000x g 
for 15 minutes at 4°C. The 100% ethanol was discarded and the pellet was 
washed with 1ml 70% ethanol. The pellets were air dried at room temperature for 
20 minutes, resuspended in 40µl nuclease-free water and stored at 4°C. Vector 
constructs were sequenced by Inqaba Biotech using pGEX sequencing primers 
(Amersham Biosciences, UK) for recombinant GST-tagged proteins and T7 
sequencing primers for recombinant His-tagged protein. The 5’ pGEX 
Sequencing Primer binds nucleotides 869-891 while the 3’ pGEX Sequencing 
Primer binds nucleotides 1 019-997. The T7 promoter sequencing primer has the 
following sequence: 5’-TAA TAC GAC TCA CTA TAG GG-3’. The T7 
terminator sequencing primer has the following sequence: 5’-GCT AGT TAT 
TGC TCA GCG G-3’   
 
2.7) Recombinant protein experiments 
 
 2.7.1) Recombinant protein induction and expression  
 
Expression of recombinant proteins was induced using the Overnight ExpressTM 
Autoinduction System (Novagen, USA). 10µl of glycerol stock containing 
transformed Rosetta 2 (DE3) cells was transferred into 1ml of Luria broth with 
10µl ampicillin (100mg/ml) and 10µl chloramphenicol (50mg/ml). The samples 
were placed in an orbital shaker at 37°C and incubated overnight.  
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The next day the optical density (OD) was checked at a wavelength of 600nm 
using a Du® -65 Spectrophotometer (Beckman, UK). The OD indicates the amount 
of bacterial cells present in the broth and therefore the approximate phase of 
growth that has been reached. If the OD was less than 0.4, the samples were 
incubated for a longer period of time to allow the bacterial cells to proliferate 
further and reach log phase. If the OD was between 0.4 and 0.6 the samples were 
used for expression. 200µl of the overnight grow was added to 20ml Overnight 
ExpressTM instant TB medium along with 20µl ampicillin (100mg/ml) and 20µl 
chloramphenicol (50mg/ml) in a 250ml Erlenmeyer flask. The flask was placed on 
a shaking platform for 18 hours at room temperature. After 18 hours the OD was 
checked at a wavelength of 600nm. If the OD was between 1.3 and 1.5, the 
bacterial cells were estimated to have reached the stationary phase and protein 
extraction was carried out. 
 
2.7.2) Recombinant protein extraction 
 
Protein extraction was carried out using BugBusterTM Protein Extraction Reagent 
(Novagen, USA), which utilises a mixture of non-ionic detergents to disrupt the 
cell wall of E. coli without denaturing soluble proteins. The cell culture was 
transferred to 50ml Beckman tubes and centrifuged (Beckman model J2-21 
centrifuge; Beckman Coulter, USA) at 3 500x g for 10 minutes. The supernatant 
was removed and the remaining pellet was placed in a -70°C freezer for 20 
minutes. 1ml of BugBusterTM Protein Extraction Reagent and 1µl of Protease 
Inhibitor Cocktail Set III (Novagen, USA) were added to resuspend each frozen 
pellet. The cell suspension was transferred to an Eppendorf tube and placed on a 
shaking platform at room temperature for half an hour. The insoluble fraction was 
removed by centrifugation (Centrifuge 5415; Eppendorf, Germany) at 18 000x g 
for 20 minutes. The supernatant was transferred to a fresh Eppendorf tube and 
stored at 4°C. 150µl aliquots were taken at specific stages of the extraction to 
evaluate protein expression.  
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An aliquot of overnight express culture was taken to analyse total cell protein 
content; an aliquot of supernatant after BugBusterTM protein extraction was taken 
to analyse the soluble protein fraction; the pellet after BugBusterTM protein 
extraction was resuspended in 1ml TE buffer and a 150µl aliquot was used to 
analyse the insoluble protein fraction (table 5). Each 150µl sample was added to 
40µl 5x suspension solution, 4µl β-mercaptoethanol and 5µl bromophenol blue 
solution. The samples were boiled for 2 minutes and stored at -20°C prior to 
electrophoresis (section 2.7.7). 
 
2.7.3) Recombinant protein purification 
 
 The purification of glutathione S-transferase (GST) fusion proteins was carried 
out using the MagneGSTTM Protein Purification System (Promega, USA). The 
system utilises paramagnetic particles which have glutathione immobilised on 
their surface. The GST enzyme specifically binds to its substrate, glutathione, in a 
lock-and-key manner. On addition of the particles to a soluble protein fraction 
containing GST fusion proteins, the fusion proteins bind to the immobilised 
glutathione. Using a magnetic particle separator, the particles are rinsed to remove 
unbound proteins. The bound fusion proteins are eluted with a buffer containing a 
high concentration of glutathione, which competes with the glutathione-coated 
particles for binding of the GST fusion proteins.  
 
150µl aliquots of sample from various steps of the purification were taken to be 
analysed via SDS PAGE (table 5). The manufacturer’s protocol was followed; for 
every 20ml of original culture, 20µl of MagneGSTTM particles were resuspended 
and transferred to a 2ml Eppendorf tube. 20µl of particles have a binding capacity 
of 50µg fusion protein. The tube was placed in a magnetic particle separator 
(Roche Applied Science, Germany) and the particles were captured by the magnet. 
The supernatant was carefully removed and 100µl of MagneGSTTM binding/wash 
buffer was added to the particles. The particles were resuspended by pipetting and 
the tube was placed in the magnetic stand. The supernatant was removed and the 
wash step was repeated twice. After the final wash the particles were gently 
resuspended in 100µl MagneGSTTM binding/wash buffer. 
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The soluble protein fraction (section 2.7.2) was added to the particles along with 
1µl Protease Inhibitor Cocktail Set III (Novagen, USA). The suspension was 
incubated at 4°C overnight with gentle mixing on an Intelli-mixer RM 2M Skyline 
(ELMI Ltd, Latvia) to prevent the beads from settling. The manufacturer’s 
protocol recommended incubation at 4°C for 30 minutes to facilitate binding of 
the tagged recombinant protein to the beads, but incubation overnight resulted in 
better yields of eluted protein. 
 
The next day the tube was placed in the magnetic particle separator. The 
supernatant was removed and stored to be used for rebinding if the recombinant 
protein yield was low. 1ml of MagneGSTTM binding/wash buffer was added to the 
particles and incubated at room temperature for 5 minutes with occasional mixing. 
The tube was placed in the magnetic particle separator and the supernatant was 
removed. The washing step was repeated a total of three times. After the final 
wash, 50µl of elution buffer was added to the sample and incubated at room 
temperature on the Intelli-mixer for 15 minutes. The tube was placed in the 
magnetic particle separator and the eluted protein was removed to a clean tube. A 
second elution was carried out and the beads were then stripped of protein by 
adding 50µl of 1% SDS in binding/wash buffer. To each 50µl elution volume, 
13µl 5x suspension solution, 1.5µl β-mercaptoethanol and 1.7µl bromophenol 
blue solution was added. The samples were boiled for 2 minutes and stored at -
20°C prior to electrophoresis (section 2.7.7). 
 
The purification of histidine (His)-tagged proteins was carried out using HIS-
SelectTM Magnetic Agarose Beads (Sigma-Aldrich Inc, USA). The beads consist of 
nickel bound to a chelate, which is covalently attached to magnetic 6% beaded 
agarose via a linker. The system exploits the high metal affinity of histidine. On 
addition of the particles to a soluble protein fraction containing His-tagged 
proteins, binding of the amino acid tag to the immobilised nickel occurs. Using a 
magnetic particle separator, the particles are rinsed and the bound fusion protein is 
eluted with a buffer containing a high concentration of imidazole – a histidine 
analog – which competes with the nickel-coated particles for binding of the 
histidine fusion proteins. 
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The manufacturer’s protocol was followed. The magnetic bead suspension was 
mixed until uniformly suspended. 20µl aliquots were then transferred into 
Eppendorf tubes. 20µl of particles have a binding capacity of 150µg fusion 
protein. The beads were equilibrated in 250µl Equilibration/Wash buffer by 
washing three times. The supernatant containing the soluble protein fraction 
(section 2.7.2) was added to the beads along with 1µl Protease Inhibitor Cocktail 
Set III (Novagen, USA). The solution was incubated at 4°C overnight with gentle 
mixing on the Intelli-mixer. The manufacturer’s protocol recommended 
incubation at 4°C for 30 minutes to facilitate binding of the tagged recombinant 
protein to the beads, but incubation overnight resulted in better yields of eluted 
protein. 
 
The next day the tubes were placed in the magnetic separator and the same elution 
protocol for the GST-tagged proteins was followed, using buffers specific for the 
HIS-SelectTM system. Table 5 illustrates the complete set of protein samples 
gathered at each stage of extraction and purification. 
 
TABLE 5: Protein samples collected during extraction and purification  
 
PROTEIN SAMPLE TOTAL VOLUME 
(ml) 
ALIQUOT VOLUME & 
SOURCE 
Total protein, induced 20 (E. coli culture) 150µl of cell culture from 
Overnight ExpressTM 
Autoinduction System 
overnight grow 
Total protein, 
uninduced 
20 (E. coli culture) 150µl of cell culture from LB 
overnight grow 
Total insoluble protein 1 150µl protein pellet 
resuspended in TE buffer 
after BugBusterTM treatment  
Total soluble protein 1 150µl of protein after 
BugBusterTM treatment 
Unbound fraction 1 150µl of supernatant after 
overnight binding 
1st Elution 0.05 50µl of eluted protein 
2nd Elution 0.05 50µl of eluted protein 
Stripped beads 0.05 50µl of bound protein 
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2.7.4) Inclusion body purification 
 
In the event that the expressed protein was insoluble, inclusion body purification 
was carried out using BugBusterTM Protein Extraction Reagent (Novagen, USA). 
Washing the insoluble pellet containing the inclusion bodies with a 1:10 diluted 
solution of BugBusterTM, which contains non-ionic detergents, effectively purifies 
the pellet and removes any contaminating proteins.  
 
The manufacturer’s protocol was followed. Protein was extracted as described in 
section 2.7.2. The insoluble cell debris – containing inclusion bodies – was 
pelleted by centrifugation (Centrifuge 5415; Eppendorf, Germany) at 18 000x g 
for 20 minutes. The pellet was washed in 1ml of BugBusterTM. The mixture was 
pipetted and vortexed to obtain an even suspension. Thorough resuspension is 
crucial to obtaining a high purity inclusion body preparation, free of 
contaminating proteins. A final concentration of 1KU/ml rLysozymeTM (Novagen, 
USA) was added from a stock of 130KU/µl (i.e 7.7µl of rLysozymeTM stock was 
added to 1ml of the BugBusterTM suspension.) The solution was mixed by gentle 
vortexing and incubated at room temperature for 5 minutes. 6 volumes of a 1:10 
diluted BugBusterTM reagent was added to the suspension and mixed by vortexing 
for 1 minute. The suspension was centrifuged at 18 000x g for 20 minutes at 4°C 
to collect the inclusion bodies. The supernatant was removed and the inclusion 
bodies were resuspended in half the original culture volume (i.e. for 20ml grow, 
resuspend in 10ml) of 1:10 diluted BugBusterTM reagent. The mixture was 
vortexed and centrifuged (Beckman model J2-21 centrifuge; Beckman Coulter, 
USA) at 3 500x g for 20 minutes at 4°C. This step was repeated twice. The 
supernatant was removed and the pellet of purified inclusion bodies was stored at 
-70°C. 
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2.7.5) Inclusion body solubilisation 
 
High molar concentrations of guanidine hydrochloride were used to denature the 
inclusion bodies, thus solubilising the recombinant protein. The purified inclusion 
bodies from a 20ml culture were defrosted, resuspended in 2ml 6M guanidine 
hydrochloride buffer and incubated on a shaker at 4°C overnight. Once fully 
dissolved, the solution was transferred to an Eppendorf tube and centrifuged 
(Centrifuge 5415R; Eppendorf, Germany) at 30 000x g for 20 minutes. The 
supernatant containing the denatured recombinant protein was carefully 
transferred to a fresh Eppendorf tube. A280nm values were obtained from analysis 
of the supernatant using a Du® -65 Spectrophotometer (Beckman, UK). Samples 
were calibrated against an aliquot of 6M guanidine hydrochloride buffer. Protein 
concentration was estimated using the following equation (Simonian & Smith, 
2003): 
 
 
  
 
 
 
 
 
A280nm = ecl 
 
Therefore c = A280nm x dilution factor 
                                    el 
Where e = protein extinction coefficient (M-1.cm-1) 
                      c = concentration (mol/L) 
                      l = light path length (cm-1) 
 The protein extinction coefficient was obtained using the Recombinant Protein 
Solubility Prediction tool (University of Oklahoma, School of Chemical 
Engineering and Materials Science, http://www.biotech.ou.edu/). The 
recombinant protein was stored in 100µl aliquots at -20°C. 
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2.7.6) Recombinant protein refolding 
 
Following denaturation, recombinant proteins were dialysed against a native 
buffer to remove the guanidine hydrochloride and allow renaturation and 
refolding of the protein, thus restoring functionality. A 100µl aliquot of denatured 
protein was thawed and an equal volume of 10mM DTT was added, reducing the 
guanidine hydrochloride buffer concentration to 3M. The solution was incubated 
on a shaker at 4°C for 1 hour to ensure that all disulphide bonds were reduced. 
20µl aliquots of 1x refolding buffer were added to the sample on ice every 12 
minutes over the period of an hour. This decreased the guanidine hydrochloride 
buffer concentration to 2M. 100µl of protein sample was pipetted into a Slide-A-
Lyzer® mini dialysis unit (Pierce, USA) and placed inside an Eppendorf tube 
filled with 1ml of refolding buffer. The sample was dialysed at room temperature 
for 5 minutes. This process was repeated 10 times, which was the maximum 
amount of dialysis before recombinant adaptin precipitated. The guanidine 
hydrochloride was completely removed from the recombinant protein solution by 
this time. The recombinant protein was purified from the solution using HIS-
SelectTM Magnetic Agarose Beads (Sigma-Aldrich Inc, USA) as described in 
section 2.7.3. 
 
2.7.7) Laemmli SDS-PAGE 
 
Protein samples were resolved using the Laemmli SDS-PAGE method (Laemmli, 
1970). A 12% polyacrylamide SDS separating gel was prepared and overlaid with 
a 4% stacking gel in a Mighty Small II SE250 gel cassette (Hoefer Scientific 
Instruments, USA) that was 8x10cm in size. Volumes of protein sample loaded 
were as follows: total cell extract and insoluble fraction - 10µl; soluble fraction 
and eluted protein fraction - 20µl; unbound fraction - 20µl. 5µl of red blood cell 
membrane proteins (4-8µg) was used as a marker to estimate the relative size of 
proteins. The marker was prepared from human red blood cells by Kubendran 
Naidoo, Plasmodium Molecular Research Unit, Wits Medical School.  
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The protein samples underwent separation at 15mA per gel for 1 hour, followed 
by 20mA per gel for a further hour, using a Mighty SlimTM SX250 power supply 
(Hoefer Scientific Instruments, USA). During electrophoresis, gels were cooled to 
4°C using a Labcon CPE 50 circulator (Labcon, South Africa). Gels were stained 
in 0.05% Coomassie blue stain overnight and destained in 10% acetic acid/10% 
methanol solution for 2 hours. The gels were destained further in 10% acetic acid 
overnight. 
 
2.7.8) Western blotting 
  
Following electrophoresis, two pieces of blotting paper and a piece of  
HybondTM-c extra supported nitrocellulose membranes (Amersham Biosciences, 
UK) were soaked in transblot buffer along with the polyacrylamide gels. The 
blotting cassettes (Hoefer Scientific Instruments, USA) were assembled with the 
gel on the cathode side and the nitrocellulose membrane on the side of the anode. 
The cassette was placed in the Western blotting chamber (TE Series Transphor 
electrophoresis unit; Hoefer Scientific Instruments, USA) which was filled with 
1.5L of transblot buffer. The proteins were transferred at 35V, 90mA (Model 
200/2.0 power supply; Biorad, USA) at 4°C overnight on a magnetic stirrer. 
 
2.7.9) Immunoblotting 
 
The nitrocellulose membranes were washed in TBS for 5 minutes and the gels 
were placed in Coomassie blue stain to ascertain transfer efficiency. The blots 
were drained and coated for 1 minute in 1ml Ponceau S (Sigma-Aldrich Inc, USA) 
to detect protein transfer. The blots were placed in Milli-Q water to rinse off 
excess dye. The banding of the RBC membrane marker was recorded on the 
membrane, which was returned to the water for 30 minutes to completely remove 
the Ponceau S stain.  
For genes that were subcloned into the pGEX-4T-2 vector the recombinant 
protein contained a GST tag and the following Amersham Biosciences (UK) 
protocol was followed to detect the recombinant protein:  
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Once the membrane was sufficiently rinsed it was placed in a 3% BSA/TBS 
solution on a shaking platform for 1 hour to block the areas of the nitrocellulose 
membrane that did not contain transferred protein. This would prevent the 
antibodies from binding to the membrane due to its positive charge. The blot was 
washed five times in 0.5% Tween-TBS solution for 5 minutes each to remove any 
unbound protein, followed by a rinse in TBS for 5 minutes. The membrane was 
incubated in a 1:100 000 dilution of anti-GST horse radish peroxidise (HRP)-
conjugated primary antibody (Amersham Biosciences, UK) for 1 hour at room 
temperature. The membrane was washed five times in 0.5% Tween-TBS solution 
for 5 minutes each to remove any unbound antibody. This was followed by a rinse 
in TBS for 5 minutes. 
 
For the gene that was subcloned into the pET-15b vector the recombinant protein 
contained a histidine tag and the following Qiagen (UK) protocol was followed:  
Once the membrane was sufficiently rinsed it was placed in anti-His HRP-
conjugated blocking buffer (Qiagen, UK) on a shaking platform for 1 hour to 
block the areas of the nitrocellulose membrane that did not contain transferred 
protein. The blot was washed twice in 0.5% Tween-TBS solution for 10 minutes 
each to remove any unbound protein, followed by a rinse in TBS for 10 minutes. 
The membrane was incubated in a 1: 2 000 dilution of QIAexpress anti-His HRP-
conjugated antibody (Qiagen, UK) for 1 hour at room temperature. The membrane 
was washed twice in 0.5% Tween-TBS solution for 10 minutes each to remove 
any unbound antibody. This was followed by a rinse in TBS for 10 minutes. 
 
2.7.10) Chemiluminescence 
 
GST- and His-tagged proteins immobilised on the nitrocellulose membrane and 
complexed with HRP-conjugated antibodies were visualised using luminescent 
substrates (Sasse & Gallagher, 2003) in the SuperSignal® West Pico 
chemiluminescent substrate kit (Pierce, USA). On addition of the peroxide 
substrate and luminol, the HRP enzyme catalyses the oxidation of the latter, 
thereby releasing energy in the form of light. Exposing x-ray film to the 
membrane records the luminescent band. 
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The manufacturer’s protocol was followed. Operating in a darkroom, the working 
solution was prepared by adding equal parts of stable peroxide solution and 
luminol/enhancer solution provided in the kit. The membrane was incubated in 
working solution for 5 minutes. The excess solution was drained off the 
membrane, which was covered with clear plastic. The blot was placed in an x-ray 
film cassette with the protein side facing upward. A piece of CP-G plus medical 
x-ray film (Agfa, Germany) was placed over the blot and exposed for 60 seconds. 
Subsequent pieces of film were exposed for 5 minutes and 10 minutes, 
respectively. The film was developed using manual x-ray developer diluted 1:4 
with water (Axim, South Africa). It was rinsed in water and finally fixed in Perfix 
high speed x-ray fixer (Champion photochemistry, South Africa) diluted 1:4 with 
water, followed by drying at room temperature for 30 minutes. The nitrocellulose 
membrane was placed in amido black stain (AppliChem, Germany) to detect the 
proteins on the membrane. To remove background dye, the membrane was 
destained in amido black destain. 
 
2.8) PK assay  
 
2.8.1) Determination of recombinant PK concentration 
 
The Coomassie Plus – The Better BradfordTM Assay Kit (Pierce, USA) was used 
to determine the recombinant kinase concentration. The kit consists of Coomassie 
Plus Reagent and bovine serum albumin (BSA) standard ampoules containing 1ml 
each of 2mg/ml BSA stock solution. The method is based on the 
spectrophotometric shift from 465nm to 595nm that occurs when Coomassie blue 
dye adsorbs to arginine, histidine and the aromatic amino acids making up the 
protein. The absorbance data can be plotted against the known BSA 
concentrations to construct a standard curve from which unknown sample 
concentrations can be extrapolated. 
The manufacturer’s procedure was followed. Diluted BSA standards were 
prepared as follows in Table 6. 
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TABLE 6: Preparation of diluted BSA standards 
 
SAMPLE VOL. OF 
MagneGSTTM 
ELUTION 
BUFFER (µl) 
VOLUME OF BSA 
(µl)  
AMOUNT OF BSA 
(µg) 
Blank 10 0 0 
Standard 1 10 1 2 
Standard 2 10 2 4 
Standard 3 10 4 8 
Standard 4 10 6 12 
Standard 5 10 8 16 
  
10µl of recombinant PK was transferred to an Eppendorf tube. The Coomassie 
Plus reagent was mixed by inversion immediately before use. The amount needed 
was transferred to a test tube and equilibrated to room temperature. 1.5ml of 
Coomassie Plus reagent was added to each sample and the solution was mixed 
well. The samples were incubated at room temperature for 10 minutes. The Du® -
65 Spectrophotometer (Beckman, UK) was set to 595nm and calibrated against an 
aliquot of MagneGSTTM elution buffer. The A595 of all samples was measured. A 
standard plot of A595 to standard protein amount (µg) was constructed. The 
amount of recombinant PK in the unknown sample was extrapolated from the 
graph. 
 
2.8.2) Kinase assay 
 
Recombinant PK was tested for activity using a standard kinase assay (Sefton & 
Shenolikar, 1996; Wang & Roach, 1993). The method is based on the principle of 
assaying the PK by the transfer of radiolabel from 2.5µCi [γ-32P] ATP 
(PerkinElmer, USA), with a specific activity of 3 000Ci/mmol, to the following 
exogenous substrates: 10µg histone protein 1 (Merck, Germany), 5µg myelin 
basic protein (Sigma-Aldrich Inc, USA) and 2µg bovine casein (Merck, Germany). 
Sodium fluoride and β-glycerophosphate (Calbiochem, Germany) were added to 
inhibit phosphatases. Sodium fluoride inhibits serine/threonine phosphatases, 
while β-glycerophosphate inhibits tyrosine phosphatases (Schaefer et al, 1996). 
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The assay was carried out in a reaction volume of 30µl, consisting of 0.5 - 3µg 
recombinant protein in a kinase reaction mix. The Eppendorf containing the 
reaction solutions was incubated at 30°C for 45 minutes and the reaction was 
terminated by addition of 8µl 5x suspension solution, 0.8µl β-mercaptoethanol 
and 1µl bromophenol blue solution. The solution was boiled for 5 minutes. The 
samples were loaded onto a 12% SDS polyacrylamide gel and electrophoresed, 
followed by staining in Coomassie blue overnight (section 2.7.7). The gel was 
destained and soaked in gel drying solution for 2 hours. The gel was dried in a 
Model 224 Gel Slab Dryer (Biorad, USA) for 2 hours at 80°C, which was attached 
to a Vacuum Pump XF54 230 50 (Millipore Corporation, USA) with a maximum 
vacuum of 84KPa. The dried gel was transferred to an x-ray cassette with 
intensifying screens and exposed to CP-G plus medical x-ray film (Agfa, 
Germany) for 12 hours at -70°C. The film was developed as for chemilumi-
nescence (section 2.7.10). 
 
2.8.3) Densitometric analysis 
 
Densitometric analysis was performed on Coomassie-stained SDS-PAGE gels 
using a GS300 transmittance/reflectance scanning densitometer (Hoefer, USA). 
The data were integrated using the Hoefer Electrophoresis data reduction software 
and presented as recombinant protein peak areas.  
 
2.9) Bioinformatics 
 
The solubility of recombinant proteins was determined using a recombinant protein 
solubility prediction tool designed by the University of Oklahoma, School of Chemical 
Engineering and Materials Science (www.biotech.ou.edu). The ExPasy ProtParam tool 
was used to obtain the molecular weight and pI of recombinant proteins 
(http://au.expasy.org). Sequence alignments were carried out using the EMBOSS 
Pairwise Alignment Algorithm tool of the European Bioinformatics Institute 
(www.ebi.ac.uk). The protein secondary structure was determined using the Jnet 
secondary structure prediction algorithm (Cuff and Barton, 2000).  
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Using the Swiss Model Template Library (http://swissmodel.expasy.org), three 
dimensional models of the P. falciparum protein domains, without the recombinant tags, 
were predicted (Arnold et al, 2006; Kopp & Schwede, 2004; Schwede et al, 2003; Guex 
and Peitsch, 1997). This comparative homology modeling server reliably generates a 3D 
model of the target from its amino acid sequence, provided that a template sharing 
sequence identities of more than 40 percent with the target is present in the library. If 
target-template pairs have less than 40 percent identity, errors in sequence alignment 
algorithms may occur. Homology of P. falciparum proteins with other Plasmodium 
species proteins was achieved using the Basic Local Alignment Search Tool (BLAST) on 
PlasmoDB (www.plasmoDB. org). T gondii proteins with homology were found using the 
BLAST on ToxoDB (www.toxoDB.org). Homologous H. sapiens proteins were 
discovered using the Ensembl Multi-BLAST View tool (www.ensembl.org) 
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CHAPTER 3 
RESULTS 
 
3.1) DNA extraction 
 
The P. falciparum DNA samples were electrophoresed and the integrity was good with a 
single high molecular weight band. However, some RNA coprecipitated with the DNA 
(Figure 8), resulting in A260/A280 values greater than 2. Pure DNA has an A260/A280 value 
between 1.8 and 2. If this ratio is less than 1.8, the preparation is contaminated with 
proteins and aromatic substances (Hoffmann-Rohrer & Kruchen, 2006). 
 
                           1                   2                     3 
 
 
1 – DNA 1  
2 – DNA 2  
3 – MassRulerTM DNA ladder mix 
 
 
     
Figure 8. Agarose gel electrophoresis of P. falciparum DNA 
 
To remedy the RNA contamination, DNA was treated with RNase A. This resulted in 
improved A260/A280 values (Table 7). To confirm that the RNA had been removed and the 
DNA had retained structural integrity, electrophoresis was repeated (Figure 9). 
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                                      1                  2                  3 
 
 
1 – DNA 1  
2 – DNA 2 
3 – MassRulerTM DNA ladder mix  
 
 
Figure 9. Agarose gel of P. falciparum DNA treated with RNase A 
 
Of the two DNA samples obtained after RNase A treatment, DNA 1 (Table 7) had the 
best purity, but a low concentration. The low recovery of DNA was probably due to the 
short duration (5 minutes) of centrifugation during precipitation (Zeugin & Hartley, 
1985). The second sample, DNA2, was centrifuged for 30 minutes at the precipitation 
stage, which dramatically improved the yield (Zeugin & Hartley, 1985). DNA 2 was 
slightly less pure, but was used for all PCR experiments due to the higher concentration. 
 
TABLE 7: Spectrophotometric data for P. falciparum genomic DNA 
  
SAMPLE CONCENTRATION 
(ng/µl) 
A260/A280 
DNA 1 201.29 2.14 
DNA 2 199.13 2.06 
DNA 1 (RNase A-treated) 42.8 1.81 
DNA 2 (RNase A-treated)  161.56 1.74 
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3.2) RNA extraction 
 
RNA integrity was determined using agarose gel electrophoresis and spectrophotometric 
data. Intact P. falciparum ribosomal RNA resolves as three distinct bands of 28s, 18s and 
5.8s, with sizes of 4 104 bases, 2 149 bases and 121 bases, respectively (www.plasmo-
DB.org, 2008; Daily et al, 2004), as seen in figure 10. RNA was considered to be 
degraded if the expected bands appeared as a smear within the gel.  
 
                                               1 
 
 1 – RNA 1  
 
Figure 10. Agarose gel electrophoresis of P. falciparum RNA  
The RNA showed good integrity with minimal smearing. No RNA marker was 
available and sizes are presumptive based on information from Daily et al (2004). 
28s RNA has a size of 4 104 bases. 18s RNA is 2 149 bases and 5.8s RNA is 121 
bases in length. 
 
An A260/A280 value greater than or equal to 2 for RNA indicates a pure sample, while a 
value less than 2 indicates carry over of protein or phenol (Hoffmann-Rohrer & Kruchen, 
2006). Sample RNA 1 (Table 8) was used for RT-PCR experiments. 
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TABLE 8: Spectrophotometric data for P. falciparum RNA 
 
SAMPLE CONCENTRATION 
(ng/µl) 
A260/A280 
RNA 1 323.57 2.14 
 
3.3) PCR 
 
 3.3.1) Primer design 
 3.3.1.1) PFB0150c 
 
 Primers were designed for three domains from the two P. falciparum genes 
coding for putative proteins. In the case of PFB0150c – the putative PK – the 
entire gene was too large to amplify and express, so only the PK domain was 
chosen for subcloning. This functional region of the enzyme containing the 
catalytic core is 1 515bp in length and spans nucleotides 149 527 to 151 042 
(Figure 11).  
  
 
 
 
 
 
 
 
Figure 11. PFB0150c diagramatic representation of primer positions 
P. falciparum chromosome 2 is represented by the yellow bar. The PFB0150c 
gene is represented in red and has Crick orientation. It consists of a single exon 
7 448bp in length. The gene codes for a 352.8kD protein with a pI of 7.21. The 
forward primer is green, while the reverse primer is blue. Base pair positions on 
chromosome 2 are as follows: 1 - 149 524; 2 - 156 971; A - 149 527; B - 151 042  
 
The DNA sequence of the insert chosen for amplification is represented in figure 
12. The PK domain is central to the amplicon.  
1
5’ 
5’ 
3’ 
3’ 
                                                                                                        1   2  
Pf Chromosome 2 
PFB0150c 
A B 
5’
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GATGAAAAGGATGGATATGAAGAAATGAATGGGGGAGATAAGAATGAAGAAATGAATGGGGGAGATAAGAATGAAGA
AATGAATGTGGGAGATAAAAATGGAGGAATAAATGAGGAACATAAAAATGAAGGAATAAATGAGGAACATAAGGATG
AACTAATAAATAAGGAACATAAAAACGAGCGAATAAATGAGGAACATAAAAACGAACGAATAAATGAGGAACATAAA
AATGAAGGAATAAATGAGGAACATAAAAATGAAGGAATAAATGAGGAACATAAAAACGAACGAATAAATGAGGAACA
TAAAAATGAAGGAATAAATAAACTGACCTATCATAATATGAATAAAAATAATATTTCAAATGAAAATAATTATAATG
ATGACGATTCTTATGATGAAGATAATTTGGTATCCCTGAAGATAATAAACTTAAAATATTTAAGTAAAAAGAATAGT
TTAAAAAACATTTTGAGAGAAGTAAATTTTTTAAAAATGTGTGAACATCCAAATGTAGTAAAATATTTCGAATCTTT
TTTTTGGCCTCCTTGTTATTTAGTTATTGTGTGTGAATATTTATCAGGAGGAACATTATATGATTTATATAAAAATT
ATGGTAGAATATCAGAAGATCTTTTAGTATATATCTTAGATGATGTATTAAATGGTTTAAATTATTTACATAATGAA
TGTAGTTCACCACTTATACATAGAGATATAAAACCAACAAATATCGTTCTTTCCAAAGATGGTATAGCTAAGATAAT
TGATTTTGGTTCTTGTGAAGAATTGAAAAATAGTGATCAGTCTAAAGAATTAGTGGGTACTATATATTATATATCAC
CTGAAATATTGATGAGAACTAATTATGATTGTTCATCTGATATATGGTCATTGGGTATTACAATATATGAAATTGTT
TTATGTACCTTACCATGGAAAAGAAATCAATCATTTGAAAATTATATAAAAACCATAATTAATTCATCACCAAAAAT
TAACATAACAGAAGGATATAGTAAACACTTATGTTATTTTGTTGAGAAGTGTTTACAAAAGAAACCTGAGAACAGAG
GAAATGTGAAAGATTTATTAAATCATAAATTTTTGATTAAAAAGAGGTATATTAAAAAGAAACCTAGTTCTATATAT
GAAATAAGAGATATATTAAAAATATATAATGGTAAAGGTAAAACAAATATCTTCCGAAATTTTTTTAAGAACCTTTT
TTTCTTCAATGATAAGAATAAAAAAAAAAAACCAAATAAAATGATCAGTTCCAAATCCTGTGATGCAGAAATGTTCT
TTGAACAGTTAAAAAGGGAAAATTTTGATTTTTTTGAAATTAAATTAAAAGATGATGAAAATAGTAGATCCTTGAAT
ACGTTTAATATAAATATATCTAAAGAAAGAGACGACATATCATATTCTTCTTTAAATTTGGAAAAAATCAAAGAACA
GTCTCAATATGGTAGCATCTGTTGTCGGGACTGAACAATCCCAGAAACA  
 
Figure 12. DNA sequence of PFB0150c insert (PlasmoDB 5.3, 2007) 
Primer positions are indicated in blue and start at base pair position 149 527 of 
chromosome 2, ending at base pair 151 042; the red, underlined segment denotes 
the PK domain.  
 
The protein sequence was predicted to be most soluble with a GST tag, as 
opposed to a His tag, and was annotated rGST PK (Figure 13). A 63.2 percent 
chance of insolubility was predicted for this recombinant protein, along with a 
molecular weight of 84.8kD. The calculated pI of the rGST PK insert is 5.88.  
 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYIAD
KHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFM
LYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDEKDGYEEMNGG
DKNEEMNGGDKNEEMNVGDKNGGINEEHKNEGINEEHKDELINKEHKNERINEEHKNERINEEHKNEGINEEHKNEG
INEEHKNERINEEHKNEGINKLTYHNMNKNNISNENNYNDDDSYDEDNLVSLKIINLKYLSKKNSLKNILREVNFLK
MCEHPNVVKYFESFFWPPCYLVIVCEYLSGGTLYDLYKNYGRISEDLLVYILDDVLNGLNYLHNECSSPLIHRDIKP
TNIVLSKDGIAKIIDFGSCEELKNSDQSKELVGTIYYISPEILMRTNYDCSSDIWSLGITIYEIVLCTLPWKRNQSF
ENYIKTIINSSPKINITEGYSKHLCYFVEKCLQKKPENRGNVKDLLNHKFLIKKRYIKKKPSSIYEIRDILKIYNGK
GKTNIFRNFFKNLFFFNDKNKKKKPNKMISSKSCDAEMFFEQLKRENFDFFEIKLKDDENSRSLNTFNINISKERDD
ISYSSLNLEKIKEHSLNMVASVVGTEQSQK 
 
Figure 13. Protein sequence of rGST PK  
The entire PK protein is 2 485 amino acids in length. The rGST PK insert is 723 
amino acids in length. It consists of the GST tag, (green) which has 220 amino 
acids, and the P. falciparum protein which has 503 amino acids including the PK 
domain (red) which spans amino acids 97-372. The amino acid composition of the 
P. falciparum sequence is: Alanine (A) 1.8%; Arginine (R) 3.3%; Asparagine (N) 
9.4%; Aspartic Acid (D) 6.5%; Cysteine (C) 1.9%; Glutamine (Q) 1.5%; 
Glutamic Acid (E) 10.1%; Glycine (G) 5.4%; Histidine (H) 2.9%; Isoleucine (I) 
8.3%; Leucine (L) 9.3%; Lysine (K) 11.2%; Methionine (M) 2.5%; Phenylalanine 
(F) 4.0%; Proline (P) 3.3%; Serine (S) 6.2%; Threonine (T) 2.5%; Tryptophan 
(W) 1%; Tyrosine (Y) 5.3%; Valine (V) 3.6%.  
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3.3.1.2) PFE1400c 
Primers were designed for the two domains of interest on the PFE1400c gene, 
namely the clathrin adaptor appendage domain and the adaptin N-terminal 
domain. The clathrin adaptor appendage domain primers delineated an amplicon 
723bp in length (Figure 14, A and B), spanning nucleotides 1 157 840 to 
1 159 584. As the sequence included six introns, the primers were designed within 
exons one and seven and the insert was amplified from reverse transcribed RNA. 
The PFE1400c N-terminal adaptin domain primers defined an amplicon spanning 
nucleotides 1 159 748 to 1 161 547, resulting in a 1 800bp-sized product (Figure 
14, C and D). The insert was amplified directly from DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. PFE1400c diagramatic representation of primer positions 
P. falciparum chromosome 5 is represented by the yellow bar. The PFE1400c 
gene is represented in red and has Crick orientation. It consists of seven exons. 
The gene is 2 778bp in size, including introns, and codes for a 105.6kD protein 
with a pI of 5.83. The forward primers are green, while the reverse primers are 
blue. 
 
 
5’ 3’ 
3’ 5’ 
1 2 3 4 5 6 7 
A B C D
1  2     3     4        5         6  7    8    9 10 11  12    13      14                                               
Base pair positions on chromosome 5: 
1 – 1 157 834   10 – 1 159 065 
2 – 1 157 893   11 – 1 159 195 
3 – 1 158 038   12 – 1 159 276 
4 – 1 158 226   13 – 1 159 393 
5 – 1 158 334   14 – 1 161 547 
6 – 1 158 608    A – 1 157 840 
7 – 1 158 744    B – 1 159 584 
8 – 1 158 814    C – 1 159 748 
9 – 1 159 004    D – 1 161 547 
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The DNA sequence of the clathrin adaptor appendage domain chosen for 
amplification is represented in figure 15. 
 
TCTTCGGATGAATTCAATAATGATATCGATGATGCAGATGATAGTAAAAAATCTATGGACTTGATAGGATTAAATGA
TGATGAAAGCAAACCCCAAAAAACAATTCCACCGGTCAAAATGGTTCAGGTATTATCATCAGAGGATGCTGGTTTGA
AGGGACAGACGGGTCTCTCCATTTTTGCCTCAATAAATCGTATTGACAGAAAAATTCAACTCAAAATATCAGTAACA
AATCAAACCCAGAACGAAATCGTAGTATCAGGAGTTCAAATAAATAAAAATTCATTTGGATTATCGTCACCGAACAA
TTTGGATGTACAGAATATTGGCTTTGGAGAAACAAAAGAAATGCTCATATATTTAATTCCAAATACGTTAAATTCGA
ATACACCTCCAGCAACCCCCTTATTTTTACAAGTTGCCATAAGAACAAATTTAGATATATTTTATTTCAATGTACCG
TACGACATTTTTGTCGTTTTTGTCGAAAATTTTCATATGGAAAAAGACATATTTAAAAAGAAATGGCAAATTATAGA
AGAAGCAAAAGAGGAATTATATTATTTTGCTTGTATAACCACAAACAATCTAGTAATATTAAGTGAAGTCACAATTC
AACCTGAGAAAAAGAACGTGAAATTGTGCATTCGTACAGATTCCTCATCTGTGATACCACTTTATAAGCTTTTATTT
TAAGGCATTTTCCTTAAGTGTAACTCAGGT  
 
Figure 15. DNA sequence of PFE1400c clathrin adaptor appendage domain, 
excluding introns (PlasmoDB 5.3, 2007) 
A 723bp DNA sequence was amplified from cDNA. Primer positions are indicated 
in blue, with the forward primer starting at base pair number 1 157 840 on 
chromosome 5, and the reverse primer ending at base pair 1 159 584. 
 
The protein sequence translated from this amplicon was predicted as most soluble 
with a GST tag, and was annotated rGST AP1 C-terminal (Figure 16). rGST AP1 
C-terminal has a predicted insolubility of 56.9 percent and the molecular weight is 
53.2kD. The calculated pI is 5.4. 
 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYIAD
KHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFM
LYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDNNSSDEFNNDI
DDADDSKKSMDLIGLNDDESKPQKTIPPVKMVQVLSSEDAGLKGQTGLSIFASINRIDRKIQLKISVTNQTQNEIVV
SGVQINKNSFGLSSPNNLDVQNIGFGETKEMLIYLIPNTLNSNTPPATPLFLQVAIRTNLDIFYFNVPYDIFVVFVE
NFHMEKDIFKKKWQIIEEAKEELYYFACITTNNLVILSEVTIQPEKKNVKLCIRTDSSSVIPLYKLLFVKAFSLSVT
QT 
 
Figure 16. Protein sequence of rGST AP1 C-terminal  
The entire AP-1 β complex is 925 amino acids in length. The AP1 C-terminal 
protein sequence is 464 amino acids in length. It consists of the 220 amino acid 
GST tag (green) and the parasite AP1 C-terminal of 244 amino acids. The amino 
acid composition of the P. falciparum sequence is: Alanine (A) 3.9%; Arginine 
(R) 2.8%; Asparagine (N) 5.6%; Aspartic acid (D) 7.3%; Cysteine (C) 1.3%; 
Glutamine (Q) 3.7%; Glutamic acid (E) 6.5%; Glycine (G) 4.7%; Histidine (H) 
1.5%; Isoleucine (I) 8.0%; Leucine (L) 10.6%; Lysine (K) 8.8%; Methionine (M) 
2.8%; Phenylalanine (F) 5.0%; Proline (P) 5.2%; Serine (S) 6.5%; Threonine (T) 
4.5%; Tryptophan (W) 1%; Tyrosine (Y) 4.3%; Valine (V) 6.0%. 
 
77 
 
The DNA sequence of the adaptin N-terminal domain chosen for amplification is 
represented in figure 17. 
 
ATGTCTGATTTACGCTACTTTCAAACGACTAAAAAAGGAGAAATCCATGAGCTTAAAGAA 
GAATTACATTCTTCTCATAAGGAAAAAAAAAAGGAAGCTATTAAAAAGATTATTGCTGCT 
ATGACTGTTGGGAAAGATGTCTCGACATTATTTTCTGATGTTGTGAATTGCATGCAAACA 
TCGAATATAGAATTAAAGAAGCTTGTTTATTTATACGTTATAAATTATGCTAAGGTACAA 
CCTGAACTAGCTATTTTAGCTGTTAATACATTTCGAAAAGATTCCTCAGACCCAAATCCC 
CTTATAAGAGCTTTAGCTATTCGAACAATGGGATGTATACGACTAGAACAAATAACAGAA 
TATTTAATCGAACCATTGAGGAGATGTTTAAAAGATGAAGATCCATACGTAAGAAAAACA 
GCTGTTATATGTATAGCCAAATTATATGATATATCACCGAAATTAGTAGAAGAAGAAGGT 
TTTATAGATACGCTTTTAGATATATTAGATGATAATAATGCCATGGTTGTTGCTAATGCT 
GTTATATCGTTAACGGATATTTGTGAGAATTCAAACAAGAGCATATTAAAAGATGTTATA 
AACAAAGATGAAAATAATGTGAATAAACTTTTAAATGCTATTAATGAATGTGTAGAATGG 
GGACAAGTTTTTATTTTAGATGCATTAGTTTTATATGAACCTAAAACTAGTAAAGATGCT 
GAACGTGTTTTAGAAAGAATATTACCAAGATTATCACATGCTAATTCAGCAGTAGTTCTA 
TCATCTATTAAAGTTATCTTATGCTTATTAGATAAAATCAATGATAAAGAATTTATTAAA 
AATGTACATAAGAAATTAAGCCCATCTTTAGTCACACTTTTATCTGCGGAACCAGAAATT 
CAATATATTGCATTAAGAAATATTAATTTAATAACACAGAAATTACCCAACATGCTCTCT 
GATAAAATCAATATGTTTTTCTGTAAATATAATGAACCTGCTTATGTAAAAATGGAAAAA 
CTTGATATTATTATAAGACTTGTATCAGATAAAAATGTAGACCTTGTTCTATATGAATTA 
AAAGAATATTCTACAGAAGTAGATGTCGAATTTGTTAAAAAAAGTGTAAGAGCTATAGGT 
AGCTGTGCAATAAAATTACCACAATCAAGTGAAAAATGTATTAATATATTATTAGATTTA 
ATAGATACCAAAATTAATTATGTTATACAAGAATGTATAGTTGTAATTAAAGATATTTTT 
AGAAAATATCCAAATAAATATGAAAGTATAATAACCATTCTATGTGAAAATCTAGAATCT 
TTAGATGAATCAAATGCAAAAGCATCCTTAATATGGATAATAGGAGAATATGTAGAACGT 
ATTGATAATGCTGATGAATTAATAGATTCCTTTTTAGAAAATTTTAGTGATGAACCATAT 
AATGTTCAATTACAAATTCTAACGGCTAGCGTCAAATTATTTTTAAAATGTTCAAAAAAC 
ACAAAAGATATTATAACCAAAGTCTTAAAATTATCCACAGAAGAAAGTGATAATCCTGAT 
TTAAGAGATAGGGCTTATATTTATTGGAGATTGTTATCTAAAAATATTGATGTTGCCAAA 
AAAATTGTACTTGCCGATAAACCCCCAATACAAGAAGAGAATAAAATTACTGATACCAAA 
GTATTAAATAAATTAATTAAAAATATATCCATGTTATCATCTGTATATCATAAATTACCA 
GAAACTTTTATATCAAAAAAAAATTCCTATTCCTTAAATTCTGATAATAATAATGATCAT 
 
Figure 17. DNA sequence of PFE1400c N-terminal adaptin domain  
A 1 800bp DNA sequence was obtained from PlasmoDB version 5.3, 2007. 
Primer positions are indicated in blue, with the forward primer starting at 
position 1 159 748 on chromosome 5 and the reverse primer ending at base pair 
number 1 161 547. 
 
The polypeptide derived from this amplicon was predicted to be most soluble with 
a histidine tag, and was annotated rHis AP1 N-terminal (Figure 18). rHis AP1 N-
terminal has a predicted insolubility of 50.4 percent. The calculated molecular 
weight of the recombinant protein is 72.2kD and the pI is 6.3. 
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HHHHHHSSGLVPRGSMSDLRYFQTTKKGEIHELKEELHSSHKEKKKEAIKKIIAAMTVGKDVSTLFSDVVNCMQT 
SNIELKKLVYLYVINYAKVQPELAILAVNTFRKDSSDPNPLIRALAIRTMGCIRLEQITEYLIEPLRRCLKDEDP 
YVRKTAVICIAKLYDISPKLVEEEGFIDTLLDILDDNNAMVVANAVISLTDICENSNKSILKDVINKDENNVNKL 
LNAINECVEWGQVFILDALVLYEPKTSKDAERVLERILPRLSHANSAVVLSSIKVILCLLDKINDKEFIKNVHKK 
LSPSLVTLLSAEPEIQYIALRNINLITQKLPNMLSDKINMFFCKYNEPAYVKMEKLDIIIRLVSDKNVDLVLYEL 
KEYSTEVDVEFVKKSVRAIGSCAIKLPQSSEKCINILLDLIDTKINYVIQECIVVIKDIFRKYPNKYESIITILC 
ENLESLDESNAKASLIWIIGEYVERIDNADELIDSFLENFSDEPYNVQLQILTASVKLFLKCSKNTKDIITKVLK 
LSTEESDNPDLRDRAYIYWRLLSKNIDVAKKIVLADKPPIQEENKITDTKVLNKLIKNISMLSSVYHKLPETFIS 
KKNSYSLNSDNNNDHMQDDHYDDDDYDKDNHVL 
 
            Figure 18. Protein sequence of rHis AP1 N-terminal 
The protein sequence is 633 amino acids in length. It consists of the His tag 
(green) which is 6 amino acids in length, the vector sequence (orange) which is 9 
amino acids in length and the parasite AP1 N-terminal of 618 amino acids. The 
amino acid composition of the P. falciparum sequence is: Alanine (A) 6.0%; 
Arginine (R) 3.3%; Asparagine (N) 7.1%; Aspartic acid (D) 6.5%; Cysteine (C) 
2.1%; Glutamine (Q) 2.1%; Glutamic acid (E) 7.9%; Glycine (G) 1.4%; Histidine 
(H) 2.1%; Isoleucine (I) 10.1%; Leucine (L) 11.7%; Lysine (K) 10.3%; 
Methionine (M) 1.4%; Phenylalanine (F) 2.2%; Proline (P) 3.2%; Serine (S) 
7.6%; Threonine (T) 3.9%; Tryptophan (W) 0.5%; Tyrosine (Y) 3.5%; Valine (V) 
7.1%.  
 
3.3.2) Digestion of PCR products  
 
PCR products were digested with their respective endonucleases to ensure that the 
correct ‘sticky ends’ were generated for ligation into the vectors. The amplicon 
sizes were estimated against a DNA ladder after restriction digestion, as observed 
in figure 19. The adaptin and protein kinase inserts migrated to their estimated 
correct positions in line with the DNA ladder markers. The clathrin insert, 
however, did not align as expected. Though the annotated size of clathrin is 
723bp, it consistently moved to a position between the 800bp and 900bp markers. 
This occurred with all clathrin inserts and indicated that the sequence was longer 
than expected. 
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                            1           2           3           4         
 
 1 – MassRulerTM DNA ladder mix  
2 – Clathrin  
3 – Adaptin  
4 – PK  
 
 
 
Figure 19. Digested P. falciparum PCR products resolved on 1% agarose gel  
PCR products were digested with BamHI, and either XhoI or NdeI restriction 
endonucleases and purified, followed by electrophoresis. The sizes of the PCR 
products are as follows: clathrin – 723bp; PK – 1 515bp; adaptin – 1 800bp. 
 
The concentration and purity of digested amplicons are shown in table 9. The low 
purity of the PK amplicon sample may have been due to contamination with 
proteins, salt, ethanol or phenol. 
 
TABLE 9: Spectrophotometric data for digested amplicons 
 
AMPLICON CONCENTRATION 
(ng/µl) 
A260/A280 
Adaptin  100 1.82 
Clathrin 62 1.74 
PK 98 1.52 
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3.4) Plasmid preparation 
 
 3.4.1) Extraction of plasmid DNA 
 
Plasmids were extracted from DH5α E. coli cells and 10µl aliquots of the samples 
were electrophoresed on agarose gel to determine their integrity. Native plasmids 
resolve into three major bands representing the various conformations of the 
circular DNA. This was the case when extracted samples were electrophoresed 
(Figure 20), indicating that the plasmids were not degraded. 
                                 
                                  1          2            3           4 
   
 
1 – MassRulerTM DNA ladder mix  
2 – pGEX-4T-2 (0.6µg) 
3 – pET-15b (1.5µg) 
4 – pET-15b (2.7µg) 
 
 
 
Figure 20. Plasmid stocks resolved on 1% agarose gel  
Plasmids extracted from DH5α cells were intact and resolved into three main 
bands representing the native plasmid conformations. 
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3.4.2) Digestion of plasmids  
 
Plasmids were digested with their respective endonucleases to linearise their 
structure in preparation for ligation with the digested PCR amplicons. The pGEX-
4T-2 plasmid, which encodes a 5’ GST tag, was digested with BamHI and XhoI. 
The pET-15b plasmid, which encodes a 5’ hexahistidine tag, was digested with 
BamHI and NdeI. A single band of the correct size was observed for both the 
pGEX-4T-2 and pET-15b digested samples (Figure 21). The yield and 
concentration for pGEX-4T-2 were consistently greater than for pET-15b. This 
can be observed in figure 21, where the band for pGEX-4T-2 is much broader and 
darker than that for pET-15b, indicating a higher concentration of the former.  
                              
                                             1               2            3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 – MassRulerTM DNA ladder mix  
2 – pGEX-4T-2  
3 – pET-15b  
 
 
Figure 21. Digested plasmids resolved on 1% agarose gel  
Plasmids were digested and purified, followed by treatment with calf intestinal 
phosphatase (CIP) to prevent self-ligation of the linearised vectors. 10µl of each 
sample was loaded. The plasmids had the following sizes: pET-15b – 5 708bp; 
pGEX-4T-2 – 4 900bp. 
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Spectrophotometric data confirmed that the concentration of the pGEX-4T-2 
sample was much higher than that of the pET-15b sample (Table 10). Both 
samples were of high purity, as seen by the A260/A280 ratios. These samples were 
used for subsequent ligation reactions. 
TABLE 10: Spectrophotometric data for digested, CIP-treated plasmids 
 
SAMPLE CONCENTRATION 
(ng/µl) 
A260/A280 
pET-15b  201 2 
pGEX-4T-2  1 246 1.94 
 
3.5) Results for P. falciparum PK 
 
3.5.1) Verification of PK vector construct 
 
After vector-insert ligation and transformation of E. coli DH5α cells, restriction 
digests and PCR were carried out on plasmids extracted from the transformed 
colonies to ensure that the correct inserts were present. Colonies 1 to 5 contained 
the PK insert, as can be seen in lanes 2 to 5 of figure 22. Linear pGEX-4T-2 
resolves at 4 900bp while the PK insert migrates to 1 515bp.  
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                              1          2          3         4          5         
 
 
1 – MassRulerTM DNA ladder mix  
2 - 5 – Digested vector constructs from colonies 1-4  
 
Figure 22. Digested PK vector constructs from DH5α cells 
The PK insert was excised by digestion with the same restriction endonucleases 
used for the plasmid preparation (section 3.4.2) and was resolved on a 1% 
agarose gel. 
 
The presence of the insert was also verified by PCR of plasmids extracted from 
transformed colonies using insert-specific primers. Three positive colonies are 
shown in figure 23, lanes 3, 4 and 5. Amplified PK from genomic P. falciparum 
DNA was used as a control to verify the size of the inserts at 1 515bp. 
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                                1             2            3            4            5 
 
 1 – MassRuler
TM DNA ladder mix  
2 – Amplified P. falciparum DNA (control) 
3 – Amplified vector construct from colony 2 
4 – Amplified vector construct from colony 5  
5 – Amplified vector construct from colony 10  
 
 
 
Figure 23. Amplified PK vector constructs from DH5α cells 
The presence of the PK insert was verified in plasmids extracted from DH5α 
colonies 2, 5 and 10 which were resolved on 1% agarose gel. The insert size was 
estimated against the DNA ladder as 1 515bp, which was the expected size. 
 
3.5.2) PK vector construct sequence data  
 
The chromatogram for the 5’ section of the PK DNA sequence (Figure 24) was 
well resolved with definite, high amplitude peaks and low baseline noise, 
indicating a high quality sequence at the 5’ end. Towards the 3’ end of the 
sequence the peaks overlapped and were lower in amplitude. This is a normal 
occurrence as the sequencing gel loses resolution and is difficult to read. The 
insert was therefore also sequenced from the 3’ end to obtain reliable sequence 
data for the entire insert. 
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Figure 24. Section of PK vector construct chromatogram  
A vector construct from colony 10 was sequenced with a 5’ pGEX 4T-2 primer. 
The P. falciparum sequence starts at base pair 64, highlighted in blue, with the 
forward primer 5’-GAT GAA AAG GAT GGA TAT G -3’.  
 
To confirm that the subcloned sequence was identical to the original sequence 
obtained from the PlasmoDB website, the two sequences were aligned (Figure 
25).            
          
 
  7450 GATGAAAAGGATGGATATGAAGAAATGAATGGGGGAGATAAGAATGAAGA   7499 
              |||||||||||||||||||||||||||||||||||||||||||||||||| 
            1 GATGAAAAGGATGGATATGAAGAAATGAATGGGGGAGATAAGAATGAAGA     50 
 
         7500 AATGAATGGGGGAGATAAGAATGAAGAAATGAATGTGGGAGATAAAAATG   7549 
              |||||||||||||||||||||||||||||||||||||||||||||||||| 
           51 AATGAATGGGGGAGATAAGAATGAAGAAATGAATGTGGGAGATAAAAATG    100 
 
         7550 GAGGAATAAATGAGGAACATAAAAATGAAGGAATAAATGAGGAACATAAG   7599 
              |||||||||||||||||||||||||||||||||||||||||||||||||| 
          101 GAGGAATAAATGAGGAACATAAAAATGAAGGAATAAATGAGGAACATAAG    150 
 
         7600 GATGAACTAATAAATAAGGAACATAAAAACGAGCGAATAAATGAGGAACA   7649 
              |||||||||||||||||||||||||||||||||||||||||||||||||| 
          151 GATGAACTAATAAATAAGGAACATAAAAACGAGCGAATAAATGAGGAACA    200 
 
         7650 TAAAAACGAACGAATAAATGAGGAACATAAAAATGAAGGAATAAATGAGG   7699 
              |||||||||||||||||||||||||||||||||||||||||||||||||| 
          201 TAAAAACGAACGAATAAATGAGGAACATAAAAATGAAGGAATAAATGAGG    250 
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         7700 AACATAAAAATGAAGGAATAAATGAGGAACATAAAAACGAACGAATAAAT   7749 
              |||||||||||||||||||||||||||||||||||||||||||||||||| 
          251 AACATAAAAATGAAGGAATAAATGAGGAACATAAAAACGAACGAATAAAT    300 
 
         7750 GAGGAACATAAAAATGAAGGAATAAATAAACTGACCTATCATAATATGAA   7799 
              |||||||||||||||||||||||||||||||||||||||||||||||||| 
          301 GAGGAACATAAAAATGAAGGAATAAATAAACTGACCTATCATAATATGAA    350 
 
         7800 TAAAAATAATATTTCAAATGAAAATAATTATAATGATGACGATTCTTATG   7849 
              |||||||||||||||||||||||||||||||||||||||||||||||||| 
          351 TAAAAATAATATTTCAAATGAAAATAATTATAATGATGACGATTCTTATG    400 
 
         7850 ATGAAGATAATTTGGTATCCCTGAAGATAATAAACTTAAAATATTTAAGT   7899 
              |||||||||||||||||||||||||||||||||||||||||||||||||| 
          401 ATGAAGATAATTTGGTATCCCTGAAGATAATAAACTTAAAATATTTAAGT    450 
 
         7900 AAAAAGAATAGTTTAAAAAACATTTTGAGAGAAGTAAATTTTTTAAAAAT   7949 
              |||||||||||||||||||||||||||||||||||||||||||||||||| 
          451 AAAAAGAATAGTTTAAAAAACATTTTGAGAGAAGTAAATTTTTTAAAAAT    500 
 
         7950 GTGTGAACATCCAAATGTAGTAAAATATTTCGAA-TCTTTTTTTT-GGCC   7997 
              |||||||||||||||||||||||||||||||.|| |||||||||| |||| 
          501 GTGTGAACATCCAAATGTAGTAAAATATTTCCAAWTCTTTTTTTTRGGCC    550 
 
         7998 TCCTTGTTATTTAGTTATTGTGTGTGAATATTTATCAGGAGGAACATTAT   8047 
              ||||||||||||||||||||.||||||||| ||||||||||||||||||| 
          551 TCCTTGTTATTTAGTTATTGRGTGTGAATA-TTATCAGGAGGAACATTAT    599 
 
         8048 AT-GATTTATATAAAAATTATGGTAGAATATCAGAA-GATCTTTTAGTAT   8095 
              || ||||||||||||||||||||.|.||||...||| .|||.|||||. . 
          600 ATKGATTTATATAAAAATTATGGGARAATAWYMGAARRATCYTTTAGW-W    648 
 
         8096 ATATCTTAGATGATGTATTAAATGGTTTAAATTATTTACATAATGAATGT   8145 
              .||||.||.||||||||||||||||.|||||||||||.|.|||||||.|. 
          649 WTATCYTARATGATGTATTAAATGGGTTAAATTATTTWCMTAATGAAWGK    698 
 
          
Figure 25. Alignment of PK DNA sequences from 5’ sequencing 
The sequence obtained from subcloning (red) was aligned with the original 
sequence obtained from the PlasmoDB database (blue). The underlined sections 
indicate the forward primer position 5’-GAT GAA AAG GAT GGA TAT G -3’. 
Key to ambiguous bases: W = T and A overlap in sequence; M = multiple overlap 
of peaks in sequence; R = A and G overlap; Y = C and T overlap. A dot between 
base pairs indicates a non-alignment, while a dash indicates a missing base. 
 
Discrepancies towards the 3’ end were resolved by sequencing the reverse strand 
(Appendix, section 5.8) which completes the entire 1 515bp sequence correctly, 
indicating that there is 100 percent sequence identity between the subcloned 
sequence and the original DNA sequence from PlasmoDB. 
87 
 
3.5.3) Verification of PK vector construct in Rosetta 2 cells  
 
Rosetta 2 (DE3) cells were transformed with the PK vector constructs and 
transformation was verified by digestion of plasmids extracted from the cells (not 
shown) and by PCR with P. falciparum gene specific primers (Figure 26). The 
presence of PCR products with a length of 1 515bp indicated that the recombinant 
insert was present and that the transformation had been successful. This can be 
seen in lanes 2 - 6 of figure 26.  
 
                                  1          2          3           4          5          6          7 
 
   
 
 
Figure 26. Amplified Rosetta vector constructs resolved on 1% agarose gel 
1 – Mass- RulerTM DNA ladder mix 
2-6 – Amplified vector constructs, colonies 1-5  
7 – Amplified P. falciparum DNA (control) 
All Rosetta 2 (DE3) colonies were positive for the PK insert (lanes 2-6). Lane 7 
contained amplified PK from genomic P. falciparum DNA as a control.    
 
3.5.4) Laemmli SDS-PAGE of rGST PK  
 
E. coli cells were induced to express recombinant proteins that were analysed by 
SDS PAGE and immunoblotting. The rGST PK protein has a predicted molecular 
weight of 84.8kD. Soluble protein of the approximate molecular weight was 
detected in the eluted fractions as seen in lanes 4-6 of figure 27. PK 1st elution and 
PK 2nd elution contained GST-tagged protein sequestered from the beads during 
affinity purification. 
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The PK stripped fraction consisted of any proteins that remained attached to the 
beads after elution. The control containing only the GST tag resolved below the 
29kD mark, as expected, with a molecular weight of 25.5kD. 
              
                         1        2         3       4        5          6         7         8  
 
 1 – RBC membrane marker                 6 – PK stripped beads        
2 – PK total induced fraction               7 – PK unbound fraction 
3 – PK insoluble fraction                      8 – GST control   
4 – PK 1st elution  
5 – PK 2nd elution                               
 
 
 
Figure 27. Purification of rGST PK protein  
The protein fractions obtained during extraction and purification of rGST PK 
from Rosetta cells were resolved on a 12% SDS polyacrylamide gel. The purity of 
rGST PK in the first elution (lane 4) is 53.2 percent (section 3.5.7). Lane 8 
contained GST protein expressed from E. coli cells containing non-recombinant 
pGEX 4T-2 plasmids. The 3 bands indicated in the RBC membrane marker (lane 
1) are: Band 3 – 93kD; Protein 4.1 – 78kD; Stomatin/tropomyosin – 29kD. 
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3.5.5) Western blot of rGST PK  
 
Figure 28 illustrates a nitrocellulose membrane stained after the transfer of 
proteins from the SDS acrylamide gel (Figure 27) and immunoblotting with an 
anti-GST primary antibody.                              
                                                    
                                                     1          2            3            4               5           6           7            8 
 
1 – GST control                                  6 – PK insoluble fraction 
2 – PK stripped beads                        7 – PK total induced 
3 – PK 2nd elution                               8 – PK unbound fraction 
4 – PK 1st elution  
5 – RBC membrane marker
 
 
 
 
 Figure 28. rGST PK Western blot  
The Western blot was stained in amido black to visualise proteins. Faint bands of 
approximately 84.8kD were obtained in the 1st elution and stripped fractions 
(lanes 2 and 4), indicating recombinant target protein in soluble form. Lane 8 
contained GST protein expressed from E. coli cells containing non-recombinant 
pGEX 4T-2 plasmids. The RBC membrane marker (lane 5) consists of: Band 3 – 
93kD; Protein 4.1 – 78kD; Stomatin/tropomyosin – 29kD. An anti-GST primary 
antibody was used for immunoblotting. 
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3.5.6) Immunoblot of rGST PK 
 
An autoradiograph was obtained from the chemiluminescent immunoblot probed 
with an HRP-linked anti-GST primary antibody. This confirmed the presence of 
soluble protein in the correct molecular weight range for rGST PK in the stripped 
and 1st elution fractions as seen in lanes 2 and 4 (Figure 29). The presence of 
rGST PK in the stripped fraction indicated that the elutions were not completely 
effective and target protein was retained on the beads. 
 
 
  
1 – GST control   4 – PK 1st elution  
2 – PK stripped beads             5 – RBC membrane marker 
3 – PK 2nd elution                                   
Autoradiograph 
              1        2       3       4     5 
Western overlaid with autoradiograph 
                1       2        3      4     5 
 
 
Figure 29. Immunoblot of rGST PK  
X-ray film was exposed to chemiluminescent immunoblots for 60 seconds to 
obtain autoradiographs. Lane 8 contained GST protein expressed from E. coli 
cells containing non-recombinant pGEX 4T-2 plasmids. The RBC membrane 
marker (lane 5) consists of: Band 3 – 93kD; Protein 4.1 – 78kD; 
Stomatin/tropomyosin – 29kD. 
 
The molecular weight of rGST PK bands on the autoradiograph was determined 
via retardation factor (Rf) values of proteins making up the RBC membrane 
marker (Table 11). 
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TABLE 11: Data used to determine molecular weight of rGST PK  
 
PROTEIN Mr 
(kD) 
Log Mr 
 
MIGRATION 
DISTANCE (mm) 
Rf 
VALUE
Band 3 93 1.9685 14 0.280 
Protein 4.1 78 1.8921 17 0.340 
Protein 4.2 72 1.8573 19 0.380 
Actin 43 1.6335 28 0.560 
G3PD 35 1.5441 33 0.660 
Stomatin/tropomyosin 29 1.4624 37 0.740 
GST 25.5 1.4065 39 0.780 
PK (on autoradiograph) 82.97 1.9189 16 0.320 
Dye front   50  
 
The molecular weight of rGST PK that was extrapolated from Graph 1 is 
82.97kD. This is very close to the predicted value of 84.4kD. The difference 
between the two values could be due to the anomalous size migration of 
P. falciparum proteins on SDS polyacrylamide gels due to non-uniform binding of 
SDS, which has been reported previously. This occurs in low complexity regions 
of the parasite proteins which are highly charged (Cooke, 2001). The predicted 
molecular weight of 3D7 strain parasite proteins can also vary between different 
strains and isolates (http://www.expasy.org/tools/pi_tool.html). The R2 value 
indicates that there is 99.8 percent correlation, signifying that the standard points 
accurately predict molecular weight under conditions of normal protein size 
migration.  
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Graph  1: rGST PK - Plot of log Mr vs Rf values
y = -1.1178x + 2.2766
R2 = 0.998
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3.5.7) Purity of rGST PK 
 
The first elution fraction was scanned (Figure 30) from the SDS-PAGE gel of 
recombinant PK (Figure 27). There was no visible band of recombinant protein in 
the second elution fraction. The target protein is represented by peak 4. 
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Figure 30. Densitometric scan of first elution of rGST PK 
Peak 4 shows the amount of target protein; the other peaks consist of 
contaminating proteins. 
 
The seven peak areas are represented by numbers 2, 4, 6, 8, 11, 13 and 15 (Table 
12). Taking these peaks into account, the rGST PK fraction had an approximate 
purity of 53.2 percent.  
 
TABLE 12: Densitometric data for first elution of rGST PK 
 
PEAK AREA PERCENTAGE AREA 
2 319 8.2 
4 2 066 53.2 
6 60 1.5 
8 201 5.2 
11 262 6.7 
13 912 23.4 
15 69 1.8 
TOTAL 3 889 100 
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3.5.8) Concentration of rGST PK 
 
The Coomassie Assay Kit was used to determine the concentration of rGST PK. 
The BSA standard curve data obtained are shown in table 24 (Appendix, section 
5.6) and graph 2. The R2 value indicates that there is 99.8 percent correlation, 
which means that the standards closely predict the amount of protein present in 
the samples. 
 
 
Graph 2: BSA standard curve
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The extrapolated protein concentrations for rGST PK from three separate 
experiments is shown in table 13. The protein concentration of the first elution 
ranged from 0.35µg/µl to 0.4µg/µl in 30µl of elution buffer. With a purity of 
53.2 percent, these amounts revert to 0.18µg/µl and 0.21µg/µl. The amount of 
pure rGST PK recovered from a 30ml culture volume, in 30µl of total elution 
buffer, is thus approximately 5.4µg to 6.3µg. This equates to 180-210µg of pure 
recombinant protein per litre of culture. 
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TABLE 13: Extrapolated protein concentration of rGST PK 
 
rGST PK 
SAMPLE 
VOLUME 
(µl) 
A595 PROTEIN 
(µg) 
PROTEIN 
CONCENTRATION 
(µg/µl) 
1 - 1st elution 10 0.080 3.5 0.35 
2 - 1st elution 10 0.093 4.0 0.40 
3 - 1st elution 10 0.085 3.7 0.37 
 
3.5.9) Kinase assay 
 
A standard kinase assay was carried out using 6µl of recombinant PK (Table 13, 
sample 1), resulting in approximately 1µg of pure recombinant enzyme in the first 
elution fraction (Figure 31). Lanes 2 to 7 contained radioactive assay mix along 
with the indicated PK samples, while lane 1 contained only bovine casein. It was 
inferred from research by Chishti et al (1994) that the PK would most probably 
function as a casein kinase, hence this exogenous protein was electrophoresed 
individually. Bovine casein consists of 3 protein subunits of varying molecular 
weights, namely: α casein 1 at 25kD; α casein 2 at 22kD and κ casein subunit at 
19kD. The other two substrates, myelin basic protein and histone protein 1, have 
molecular weights of 18.4kD and 21.5kD, respectively. 
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                                    1         2         3       4        5        6        7 
 
1 – Bovine casein               5 – PK stripped beads   
2 – PK total uninduced     6 – GST control   
3 – PK 2nd elution             7 – PK total induced     
4 – PK 1st elution                        
 
 
 
Figure 31. Dried SDS acrylamide gel of kinase assay 
40µg of bovine casein was loaded into lane 1. Lanes 2-7contained the radioactive 
kinase assay mix and recombinant enzyme, including 2µg bovine casein, 10µg 
histone protein 1 and 5µg myelin basic protein which were not visible on the gel 
due to their low concentration. rGST PK was soluble in the 1st and 2nd elution 
fractions in lanes 3 and 4.   
 
An autoradiograph of the kinase assay gel showed that radioactivity was detected 
in lane 4, indicating that the purified recombinant enzyme was active (Figure 32). 
From the overlay, it was determined that the substrate that was phosphorylated 
was bovine casein, specifically the α subunits of the protein. The radioactive band 
on the autoradiograph seems to be a double band, with the upper section being 
fainter than the lower. This indicates that the α casein 1 subunit was 
phosphorylated to a lesser extent than the α casein 2 subunit. These results signify 
that the parasite PK functions as a casein kinase. 
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          1          2           3          4          5         6        7       
1 – Bovine casein              5 – PK stripped beads    
2 – PK total uninduced    6 – GST control   
3 – PK 2nd elution            7 – PK total induced      
4 – PK 1st elution                         
 
 
 
Figure 32. Autoradiograph of kinase assay gel 
The autoradiograph was obtained from overnight exposure to the dried 
radioactive kinase gel. The bands obtained in lane 4 lined up with the α1 and α2 
subunits of bovine casein, indicating that this protein was the target of rGST PK 
phosphorylation. 
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3.5.10) Bioinformatic data for P. falciparum PK 
3.5.10.1) Structure of P. falciparum PK 
 
 The Swiss Model Template Library was used to find three dimensional models of 
proteins to which the PK sequence had structural homology, as no 3D model of 
the PK was available on the PlasmoDB website. The Library is limited by the 
number of 3D models of crystal structures available in the database, so while 
other proteins may have better homology to the target, their 3D constructs may 
not yet have been created in the Swiss Model Template Library. The whole 
parasite PK sequence (2 485aa) had homology to template 1apmE (Figure 33). 
This template represents the crystal structure of the catalytic subunit of human 
cAMP-dependent protein kinase. This human enzyme is a serine/threonine protein 
kinase. The kinase domain shares sequence identity of only 26.4 percent with the 
template, indicating that errors in the sequence alignment algorithms may have 
occurred because the identity is less than 40 percent (Appendix, section 5.11; 
figure 73).  
 
1 
A B 
2 
Figure 33. Putative 3D model of PK kinase domain 
The putative model of the PK sequence (A) is based on template 1apmE (B), the 
catalytic subunit of human cAMP-dependent protein kinase. This template had 
most sequence identity to the PK sequence in the region of the kinase domain. The 
modeled residues are amino acids 2 117 to 2 353. The E-value is 2.80e-45. The 
areas designated 1 and 2 on model A indicate the bilobed structure of the kinase 
catalytic domain. The active site is found in the cleft between the two lobes 
(Hanks et al, 1998) 
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According to Hanks et al (1998) the 3D structure of eukaryotic PK catalytic 
domains is highly conserved, with the 300 amino acid residues constituting this 
area having a bilobal conformation. The active site is located in the cleft between 
the lobes, along with ATP and substrate binding sites (Hanks et al, 1998). This 
bilobed conformation can be seen in the putative model of the parasite PK 
sequence (Figure 33). The area of the PK that was modeled is indicated in figure 
34. 
 
A. 
 
B. 
EKDGYEEMNGGDKNEEMNGGDKNEEMNVGDKNGGINEEHKNEGINEEHKDELINKEHKNERINEEHKNERINEEHKN
EGINEEHKNEGINEEHKNERINEEHKNEGINKLTYHNMNKNNISNENNYNDDDSYDEDNLVSLKIINLKYLSKK
NSLKNILREVNFLKMCEHPNVVKYFESFFWPPCYLVIVCEYLSGGTLYDLYKNYGRISEDLLVYIL
DDVLNGLNYLHNECSSPLIHRDIKPTNIVLSKDGIAKIIDFGSCEELKNSDQSKELVGTIYYISPE
ILMRTNYDCSSDIWSLGITIYEIVLCTLPWKRNQSFENYIKTIINSSPKINITEGYSKHLCYFVEK
CLQKKPENRGNVKDLLNHKFLIKKRYIKKKPSSIYEIRDILKIYNGKGKTNIFRNFFKNLFFFNDKNKKKKPN
KMISSKSCDAEMFFEQLKRENFDFFEIKLKDDENSRSLNTFNINISKERDDISYSSLNLEKIKEHSLNMVASVVGTE
QSQK 
 
Figure 34. Sequence homology of PK to 3D template 
In A, the blue segment starting at amino acid 2 117 and ending at 2 353 indicates 
the section where the P. falciparum PK shares homology with template 1apmE. 
26.4 percent of the blue segment shares sequence identity with template 1apmE. 
The green segment represents the whole PK protein of 2 485 amino acids. 
In B, the amino acid sequence of the P. falciparum PK is represented. The red 
area indicates the kinase domain containing the enzyme active site which spans 
amino acids 2 079-2 354. The bold, larger red letters indicate the area of the 
parasite protein that shares homology with the 1apmE template, which falls 
within the kinase domain. 
 
The Jnet secondary structure prediction algorithm (Cuff and Barton, 2000) 
predicted a conformation of mainly alpha helices and some beta sheets for the PK 
kinase domain (Appendix, section 5.10, Figure 70) which seems to be consistent 
with the 3D model in figure 33. 
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3.5.10.2) Homology of P. falciparum PK with other proteins 
 
The entire P. falciparum PK protein sequence (2 485aa) was compared to the 
proteome of several organisms to determine sequence identity and positivity. 
Sequence identity refers to the two protein sequences having exactly the same 
amino acids in the same position; the sequence positivity value is the identity plus 
the number of amino acids of the same group residing in the same position. The 
first group that the sequence was compared to consisted of the following 
Plasmodium species: P knowlesi, P. vivax, P. yoelii, P. chabaudi and P. berghei.  
This search was performed to detect possible orthologues of the P. falciparum PK 
in the same genus. The results of the BLAST search are presented in table 14.  
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TABLE 14: Sequence identity of P. falciparum PK with other Plasmodium  
          proteins 
 
ORGANISM GENE AND 
PROTEIN 
SEQUENCE 
IDENTITY 
(percent) 
SEQUENCE 
POSITIVITY 
(percent) 
E-VALUE 
FOR 
KINASE 
DOMAIN 
W
ho
le
 p
ro
te
in
 
K
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as
e 
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n  
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K
in
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e 
do
m
ai
n 
P. vivax PVX003590; 
putative 
serine/threonine 
specific PK 
(6 378aa) 
11 49 14 66 6.3e-141 
P. knowlesi PKH041680; 
putative PK 
(6 390aa) 
10 57 13 74 3.0e-150 
P. yoelii PY00029; 
myosin light 
chain kinase 
(5 742aa) 
3 30 5 47 1.6e-24 
P. yoelii PY00403; 
kinase 
Akt/PKB-
related 
(2 178aa)  
4 26 7 46 1.5e-24 
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The kinase domain of the P. falciparum PK, containing the catalytic site, had 
most sequence identity with the Plasmodium sp proteins in table 14 (P.vivax PK 
BLAST, Appendix, section 5.9, Figure 65). The putative PKs of Plasmodium 
species infecting humans – namely P. vivax and P. knowlesi – had most sequence 
identity to the P. falciparum PK. No paralogues or in-genera orthologues for the 
P. falciparum PK are listed on the PlasmoDB website. This means that the 
proteins from the other Plasmodium sp. mentioned in table 14 are not derived 
from the same ancestral gene, nor do they have exactly the same function as the P. 
falciparum PK. 
 
The T. gondii proteome was searched using information from the ToxoDB 
website. This organism belongs to the same Apicomplexa phylum as P. 
falciparum. The results are shown in table 15. 
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TABLE 15: Sequence identity of P. falciparum PK with T. gondii proteins 
 
PRODUCT SEQUENCE 
IDENTITY 
(percent) 
SEQUENCE 
POSITIVITY 
(percent) 
E-VALUE 
FOR KINASE 
DOMAIN 
W
ho
le
 p
ro
te
in
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42.m03467; 
serine/threonine-
protein kinase-related 
(4 253aa) 
7 42 11 61 5.1e-40 
162.m00001; putative 
calcium-dependent 
protein kinase (583aa) 
3 37 5 60 5.7e-24 
641.m02549; 
serine/threonine-
protein kinase (296aa) 
3 29 5 47 2.2e-22 
541.m00134; putative 
calmodulin-domain 
protein kinase (538aa) 
3 32 6 51 6.4e-24 
 
The region of the P. falciparum protein where most sequence identity with 
T gondii proteins was shared was the kinase domain containing the catalytic site 
(42.m03467, Appendix, section 5.9, Figure 66). 
 
Finally, the human proteome was searched for molecules with homology to the P. 
falciparum PK protein sequence. This would determine the suitability of the 
parasite protein as a drug target; the fewer the hits and the lower the sequence 
identity between the human and parasite proteins, the more likely the utility as a 
drug target.  
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The whole P. falciparum PK protein has 3 percent identity and 5 percent 
positivity (E-value 2.0e-32) with H. sapiens serine/threonine protein kinase 24 
found on chromosome 13, which was the best match (Appendix, section 5.9, 
Figure 64). However, most sequence homology was shared in the kinase domain 
where the P. falciparum PK had 37 percent identity and 55 percent positivity with 
the human enzyme. H. sapiens serine/threonine protein kinase 24 is 304 amino 
acids in length and is part of a group of non-specific serine/threonine protein 
kinases that do not have an activating compound, or whose specificity has not 
been analysed to date (www.expasy.org). 
 
A BLASTP analysis on a non-redundant database encompassing all eukaryotes 
was carried out. The top thirty BLASTP hits (out of a total of 100) are shown in 
table 16 in descending order. The best hit occurred with a serine/ threonine-
protein kinase of Dictyostelium discoideum (soil-living amoeba). Ninety percent 
of the sequences producing high-scoring hits were serine/ threonine-protein 
kinases from a number of organisms, as seen in table 16. The number of hits with 
MAPK kinases was at a much lower ten percent (yellow highlighted sections), 
although interestingly, two out of these three hits occurred within the plant 
proteome of Arabidopsis thaliana (Mustard plant). 
 
TABLE 16: PK BLASTP analysis against eukaryotic proteomes 
 
 ORGANISM SWISSPROT 
CODE 
PROTEIN P VALUE 
1.  Dictyostelium 
discoideum (soil-
living amoeba) 
PAKF_DICDI 
Q869T7 
Serine/threonine-
protein kinase 
6.7e-33 
2.  Squalus acanthias 
(Dogfish) 
STK4_SQUAC 
Q802A6 
Serine/threonine-
protein kinase 
8.5e-31 
3.  Dictyostelium 
discoideum (soil-
living amoeba) 
SVKA_DICDI 
O61122 
Serine/threonine-
protein kinase 
9.8e-31 
4.  Homo sapiens STK24_HUMAN 
Q9Y6E0 
Serine/threonine-
protein kinase 24 
1.3e-30 
5.  Dictyostelium 
discoideum (soil-
living amoeba) 
PAKB_DICDI 
Q869N2 
Serine/threonine-
protein kinase 
1.3e-30 
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 ORGANISM SWISSPROT 
CODE 
PROTEIN P VALUE 
6.  Mus musculus STK24_MOUSE 
Q99KH8 
Serine/threonine-
protein kinase 24 
 
2.0e-30 
7.  Dictyostelium 
discoideum (soil-
living amoeba) 
DST1_DICDI 
Q86IX1 
Serine/threonine-
protein kinase 
3.9e-30 
8.  Schizosaccharomyces 
pombe (Yeast) 
PPK11_SCHPO 
O14047 
Serine/threonine-
protein kinase 
1.1e-29 
9.  Bos taurus STK25_BOVIN 
Q3SWY6 
Serine/threonine-
protein kinase 25 
1.1e-29 
10.  Homo sapiens STK25_HUMAN 
O00506 
Serine/threonine-
protein kinase 25 
1.1e-29 
11.  Xenopus laevis 
(Platana) 
STK4_XENLA 
Q6PA14 
Serine/threonine-
protein kinase 4 
2.3e-29 
12.  Arabidopsis thaliana 
(Mustard plant) 
M2K6_ARATH 
Q9FJV0 
Mitogen-activated 
protein kinase kinase 
2.3e-29 
13.  Mus musculus STK25_MOUSE 
Q9Z2W1 
Serine/threonine-
protein kinase 25 
 
2.3e-29 
14.  Cercopithecus 
aethiops (Vervet 
monkey) 
STK4_CERAE 
A4K2Y1 
Serine/threonine-
protein kinase 4 
5.4e-29 
15.  Macaca mulatta 
(Rhesus monkey) 
STK4_MACMU 
A4K2T0 
Serine/threonine-
protein kinase 4 
5.4e-29 
16.  Homo sapiens STK4_HUMAN 
Q13043 
Serine/threonine-
protein kinase 4 
5.4e-29 
17.  Mus musculus STK4_MOUSE 
Q9JI11 
Serine/threonine-
protein kinase 4 
5.4e-29 
18.  Papio anubis (Olive 
baboon) 
STK4_PAPAN 
A4K2M3 
Serine/threonine-
protein kinase 4 
5.4e-29 
19.  Oryza sativa 
(cultivated rice) 
M2K1_ORYSJ 
Q5QN75 
Serine/threonine-
protein kinase  
6.9e-29 
20.  Colobus guereza 
(Colobus monkey) 
STK4_COLGU 
A4K2P5 
Serine/threonine-
protein kinase 4 
7.1e-29 
21.  Dictyostelium 
discoideum (soil-
living amoeba) 
DST2_DICDI 
Q55GC2 
Mitogen-activated 
protein kinase kinase 
7.9e-29 
22.  Bos taurus STK4_BOVIN 
Q5E9L6 
Serine/threonine-
protein kinase 4 
9.3e-29 
23.  Danio rerio 
(Zebrafish) 
STK3_DANRE 
Q7ZUQ3 
Serine/threonine-
protein kinase 3 
1.0e-28 
24.  Lemur catta (Ring-
tailed lemur) 
STK4_LEMCA 
A4K2S1 
Serine/threonine-
protein kinase 3 
1.3e-28 
25.  Mus musculus STK3_MOUSE 
Q9JI10 
Serine/threonine-
protein kinase 3 
 
1.4e-28 
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 ORGANISM SWISSPROT 
CODE 
PROTEIN P VALUE 
26.  Rattus norvegicus STK3_RAT 
O54748 
Serine/threonine-
protein kinase 4 
1.6e-28 
27.  Otolemur garnettii 
(Garnett’s greater 
bushbaby) 
STK4_OTOGA 
A4K2Q5 
Serine/threonine-
protein kinase 4 
1.6e-28 
28.  Arabidopsis thaliana 
(Mustard plant) 
M2K1_ARATH 
Q94A06 
Mitogen-activated 
protein kinase kinase 
1.6e-28 
29.  Homo sapiens STK3_HUMAN 
Q13188 
Serine/threonine-
protein kinase 3 
2.9e-28 
30.  Xenopus laevis 
(Platana) 
STK3_XENLA 
Q6IP06 
Serine/threonine-
protein kinase 4 
6.2e-28 
 
Table 17 shows a summary of all 100 hits obtained from the BLASTP process. 
Six out of the nine matches with MAPK kinases were with plant proteins, 
specifically Arabidopsis thaliana (Mustard plant). However, the vast majority of 
hits (84%) occurred with serine/ threonine protein kinases. 
 
TABLE 17: Summary of BLASTP analysis 
 
PROTEIN  NUMBER OF HITS 
Serine/ threonine-protein kinase  84 
Mitogen-activated protein kinase 
kinase (MAPK kinase) 
9 
Myosin IIIA 2 
Cell division control protein 7 1 
Dual specificity protein kinase 1 
3-phosphoinositide-dependent protein 
kinase 
1 
Abscisic acid-inducible protein 
kinase 
1 
Protein kinase 1 
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3.6) Results for P. falciparum AP1 C-terminal 
 
3.6.1) Verification of AP1 C-terminal vector construct 
  
Plasmids ligated with theAP1 C-terminal insert were extracted from transformed 
DH5α colonies to ensure that the correct insert was present. Plasmids were 
digested with restriction endonucleases (not shown) and were amplified using 
insert specific primers. The PCR products were resolved on a 1% agarose gel 
(Figure 35). The AP1 C-terminal domain should be 723bp in size according to 
PlasmoDB, but migrated to between the 800bp and 900bp markers, as seen in 
figure 36. This aberrant migration occurred with all AP1 C-terminal-transformed 
colonies. 
 
                                1              2             3            4             5 
 
1 – MassRulerTM DNA ladder mix  
2 – Amplified P. falciparum DNA (control) 
3 – Amplified vector construct from colony 1 
4 – Amplified vector construct from colony 7  
5 – Amplified vector construct from colony 10 
 
 
 
 
Figure 35. Amplified AP1 C-terminal vector constructs from DH5α cells 
The presence of the AP1 C-terminal insert was verified in plasmids extracted from 
DH5α colonies 1, 7 and 10 which were resolved on a 1% agarose gel.  
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3.6.2) AP1 C-terminal vector construct sequence data  
 
The chromatogram for the AP1 C-terminal vector construct sequence showed 
well-delineated peaks with low background, indicating that the sequencing 
reaction was successful (Figure 36). 
 
 
Figure 36. Section of AP1 C-terminal vector construct chromatogram  
A vector construct from colony 1 was sequenced with a 5’ pGEX 4T-2 primer. The 
P. falciparum sequence begins at base pair 86, highlighted in blue, with the 
reverse primer 5’- CTG AGT TAC ACT TAA GGA AAA -3’.  
 
On aligning the subcloned region with the original sequence obtained from 
PlasmoDB it was found that the subcloned sequence contained an additional 
108bp DNA insert (Figure 37). On examination of the intron-exon structure of the 
gene, it was determined that intron retaining mode of alternative splicing had 
occurred between exon 5 and 6. This indicates the existence of an alternative 
isoform of the PFE1400c gene that has not been documented on PlasmoDB to 
date. Apart from this, the two sequences aligned perfectly.  
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1919 ACCATTCT---AAATC--ATCCAGT--------GATTCTTATAATAACTC   1955 
     |||||.||   |||||  |||..||        |||          .|:| 
  21 ACCATCCTCCAAAATCGGATCTGGTTCCGCGTGGAT----------CCYC     60 
 
1956 TTCGGATGAATTCAATAATGATATCGATGATGCAGATGATAGTAAAAAAT   2005 
     |||||||||||||||||||||||||||||||||||||||||||||||||| 
  61 TTCGGATGAATTCAATAATGATATCGATGATGCAGATGATAGTAAAAAAT    110 
 
2006 CTATGGACTTGATAGGATTAAATGATGATGAAAGCAAACCCCAAAAAACA   2055 
     |||||||||||||||||||||||||||||||||||||||||||||||||| 
 111 CTATGGACTTGATAGGATTAAATGATGATGAAAGCAAACCCCAAAAAACA    160 
 
2056 ATTCCACCGGTCAAAATGGTTCAGGTATTATCATCAGAGGATGCTGGTTT   2105 
     |||||||||||||||||||||||||||||||||||||||||||||||||| 
 161 ATTCCACCGGTCAAAATGGTTCAGGTATTATCATCAGAGGATGCTGGTTT    210 
 
2106 GAAGGGACAGACGGGTCTCTCCATTTTTGCCTCAATAAATCGTATTGACA   2155 
     |||||||||||||||||||||||||||||||||||||||||||||||||| 
 211 GAAGGGACAGACGGGTCTCTCCATTTTTGCCTCAATAAATCGTATTGACA    260 
 
2156 GAAAAATTCAACTCAAAATATCAGTAACAAATCAAACCCAGAACGAAATC   2205 
     |||||||||||||||||||||||||||||||||||||||||||||||||| 
 261 GAAAAATTCAACTCAAAATATCAGTAACAAATCAAACCCAGAACGAAATC    310 
 
2206 GTAGTATCAGGAGTTCAAATAAATAAAAATTCATTTGGATTATCGTCACC   2255 
     |||||||||||||||||||||||||||||||||||||||||||||||||| 
 311 GTAGTATCAGGAGTTCAAATAAATAAAAATTCATTTGGATTATCGTCACC    360 
 
2256 GAACAATTTGGATGTACAGAATATTGGCTTTGGAGAAACAAAAGAAATGC   2305 
     |||||||||||||||||||||||||||||||||||||||||||||||||| 
 361 GAACAATTTGGATGTACAGAATATTGGCTTTGGAGAAACAAAAGAAATGC    410 
 
2306 TCATATATTTAATTCCAAATACGTTAAATTCGAATACACCTCCAGCAACC   2355 
     |||||||||||||||||||||||||||||||||||||||||||||||||| 
 411 TCATATATTTAATTCCAAATACGTTAAATTCGAATACACCTCCAGCAACC    460 
 
2356 CCCTTATTTTTACAAGTTGCCATAAGAACAAATTTAGATATATTTTATTT   2405 
     |||||||||||||||||||||||||||||||||||||||||||||||||| 
 461 CCCTTATTTTTACAAGTTGCCATAAGAACAAATTTAGATATATTTTATTT    510 
 
2406 CAATGTACCGTACGACATTTTTGTCGTTTTTGTCGAAAATTTTCATATGG   2455 
     |||||||||||||||||||||||||||||||||||||||||||||||||| 
 511 CAATGTACCGTACGACATTTTTGTCGTTTTTGTCGAAAATTTTCATATGG    560 
 
2456 AAAAAGACATATTTAAAAAGAAATGGCAAATTATAGAAGAAGCAAAAGA-   2504 
     |||||||||||||||||||||||||||||||||||||||||||||||||  
 561 AAAAAGACATATTTAAAAAGAAATGGCAAATTATAGAAGAAGCAAAAGAG    610 
 
2505 --------------------------------------------------   2504 
                                                                        
 611 AGTATATTAATGGCTGTAAGCCCTATGGTTATAACATCAGACATGTTGAT    660 
 
2505 --------------------------------------------------   2504 
                                                                        
 661 AAAACGAATGAAAATTTTTAATATTTCTTTAATAGCTCGTAGAAATGTAA    710 
 
2505 -------GGAATTATATTATTTTGCTTGTATAACCACAAACAATCTAGTA   2547 
            ||||||||||||||||||||||||||||||||||||||||||| 
 711 ATAATATGGAATTATATTATTTTGCTTGTATAACCACAAACAATCTAGTA    760 
110 
 
2548 ATATTAAGTGAAGTCACAATTCAACCTGAGAAAAAGAACGTGAAATTGTG   2597 
     |||||||||||||||||||||||||||||||||||||||||||||||||| 
 761 ATATTAAGTGAAGTCACAATTCAACCTGAGAAAAAGAACGTGAAATTGTG    810 
 
2598 CATTCGTACAGATTCCTCATCTGTGATACCACTTTATAAGCTTTTATTTG   2647 
     |||||||||||||||||||||||||||||||||||||||||||||||||| 
 811 CATTCGTACAGATTCCTCATCTGTGATACCACTTTATAAGCTTTTATTTG    860 
 
2648 TTAAGGCATTTTCCTTAAGTGTAACTCAG   2676 
     ||||||||||||||||||||||||||||| 
 861 TTAAGGCATTTTCCTTAAGTGTAACTCAG    889 
 
Figure 37. Alignment of AP1 C-terminal DNA sequences from 5’ sequencing 
The sequence obtained from subcloning (red) was aligned with the original 
sequence obtained from the PlasmoDB database (blue). The double underlined 
section indicates the forward primer position, while the single underlined section 
indicates the reverse primer. The 108bp insert indicates the inclusion of the intron 
between exons 5 and 6. The codon demarcating the end of exon 5 is coloured 
green (blue line 2 456). The codon distinguishing the start of codon 6 is coloured 
purple (blue line 2 505). Key to ambiguous bases: Y = C and T overlap. A dot 
between base pairs indicates a non-alignment, while a dash indicates a missing 
base. 
 
The 108bp insert codes for the following 36 amino acids: 
SILMAVSPMVITSDMLIKRMKIFNISLIARRNVNNM. 
This increases the length of rGST AP1 C-terminal to 496 amino acids and the 
molecular weight to 56.8 kD. The theoretical pI changes to 5.81. 
 
3.6.3) Verification of AP1 C-terminal vector construct in Rosetta 2 cells  
 
AP1 C-terminal vector constructs were verified by PCR of Rosetta 2 (DE3) 
colonies with P. falciparum gene specific primers (Figure 38). The insert 
migrated closer to the 800bp marker, corroborating the sequencing data which 
indicated an actual size of 831bp. This can be seen in lanes 3, 4, 5 and 7 (Figure 
38), indicating that transformation was successful.  
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                         1         2         3          4        5        6         7     
 
1 – Mass-RulerTM DNA ladder mix  
2 – Amplified P. falciparum DNA (control) 
3-8 – Amplified vector constructs, colonies 1-6 
 
  
Figure 38. Amplified Rosetta vector constructs resolved on 1% agarose gel 
Four out of five Rosetta 2 (DE3) colonies were positive for the AP1 C-terminal 
insert (lanes 3-8).  
 
3.6.4) Laemmli SDS-PAGE of rGST AP1 C-terminal  
 
The estimated molecular weight of the rGST AP1 C-terminal was 53.2kD. 
However, with the extra 36 amino acids coded for by the 108bp insert, the 
molecular weight increases to 56.8kD. Soluble protein of the estimated molecular 
weight range was detected in the eluted fractions as seen in lanes 5-7 of figure 39.  
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                           1        2        3        4       5        6          7        8 
 
 
 
 
 
1 – RBC membrane marker                  6 – AP1 C-terminal 2nd elution 
2 – AP1 C-terminal total uninduced    7 – AP1 C-terminal stripped beads  
3 – AP1 C-terminal total induced         8 – AP1 C-terminal unbound fraction 
4 – AP1 C-terminal insoluble  
5 – AP1 C-terminal 1st elution 
Figure 39. Purification of rGST AP1 C-terminal protein  
The protein fractions obtained during extraction and purification from Rosetta 2 
(DE3) cells were resolved on a 12% SDS polyacrylamide gel. The RBC membrane 
marker (lane 1) consists of 3 indicated bands: Protein 4.2 – 72kD; Actin – 43kD; 
Glyceraldehyde 3-phosphate dehydrogenase (G3PD) – 35kD. 
 
  3.6.5) Western blot of rGST AP1 C-terminal  
 
Proteins were transferred from the SDS acrylamide gel (Figure 39) onto a 
nitrocellulose membrane (Figure 40). The membrane was immunoblotted with an 
anti-GST primary antibody and subsequently stained in amido black. Soluble AP1 
C-terminal protein of the estimated molecular weight range was confirmed in 
lanes 2-4. 
 
 
 
 
113 
 
                        1           2          3          4         5          6        7          8         9      
 
 1 – GST control                                       6 – AP1 C-terminal insoluble fraction 
2 – AP1 C-terminal stripped beads       7 – AP1 C-terminal total induced 
3 – AP1 C-terminal 2nd elution               8 – AP1 C-terminal total uninduced 
4 – AP1 C-terminal 1st elution                9 – AP1 C-terminal unbound fraction 
5 – RBC membrane marker
 
 
 
Figure 40. rGST AP1 C-terminal Western blot  
The Western blot was stained in amido black to visualise proteins. Bands of the 
expected size were obtained in the eluted and stripped fractions (lanes 2, 3 and 4), 
indicating that recombinant target protein was present in soluble form. Lane 1 
contained GST expressed from E. coli cells containing non-recombinant pGEX 
4T-2 plasmids. The RBC membrane marker (lane 5) has 3 bands labelled: Protein 
4.2 – 72kD; Actin – 43kD; Stomatin/tropomyosin – 29kD. An anti-GST primary 
antibody was used for immunoblotting. 
 
3.6.6) Immunoblot of rGST AP1 C-terminal 
 
The presence of soluble protein in the estimated molecular weight range for the 
rGST AP1 C-terminal was confirmed by an autoradiograph (Figure 41; lanes 2-
4). The chemiluminescent immunoblot – which had been probed with an HRP-
linked anti-GST primary antibody – was exposed to x-ray film.  
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1 – GST control                                        4 – AP1 C-terminal 1st elution     
2 – AP1 C-terminal stripped beads        5 – RBC membrane marker 
3 – AP1 C-terminal 2nd elution
Autoradiograph 
          1        2        3       4      5 
Western overlaid with autoradiograph 
              1        2        3        4       5 
 
 
 
Figure 41. Immunoblot of rGST AP1 C-terminal 
X-ray film was exposed to chemiluminescent immunoblots for 60 seconds to 
obtain autoradiographs. Lane 1 contained GST expressed from E. coli cells 
containing non-recombinant pGEX 4T-2 plasmids. The RBC membrane marker 
(lane 5) has 3 labelled bands: Protein 4.2 – 72kD; Actin – 43kD; Stomatin/tropo-
myosin – 29kD. 
 
The molecular weight of rGST AP1 C-terminal bands on the autoradiograph was 
determined via retardation factor (Rf) values of proteins making up the RBC 
membrane marker (Table 18). 
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TABLE 18: Data used to determine the Mr of rGST AP1 C-terminal 
 
PROTEIN Mr 
(kD) 
Log Mr MIGRATION 
DISTANCE (mm) 
Rf 
VALUE 
Band 3 93 1.9685 15 0.294 
Protein 4.1 78 1.8921 17.5 0.343 
Protein 4.2 72 1.8573 20 0.392 
Actin 43 1.6335 28 0.549 
G3PD 35 1.5441 33.5 0.657 
7 29 1.4624 37 0.725 
GST 25.5 1.4065 40 0.784 
AP1 C-terminal (band 
on autoradiograph) 
53.96 1.732 25 0.490 
Dye front   51  
 
The molecular weight of the AP1 C-terminal as determined by the ExPASy 
ProtParam tool – including the extra 36 amino acids due to alternate splicing – 
was 56.8kD. The molecular weight extrapolated from Graph 3 is 53.96kD. The 
discrepancy in molecular weight values could be due to the anomalous size 
migration of P. falciparum proteins as described in section 3.5.6. The R2 value 
indicates that the linear regression predicts the molecular weight with 
99.51 percent accuracy. 
 
 
Graph 3: rGST AP1 C-terminal - Plot of log Mr vs Rf 
values y = -1.147x + 2.2943
R2 = 0.9951
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3.6.7) Purity of rGST AP1 C-terminal 
 
Densitometric scans of the first and second elution fractions were obtained from 
the SDS acrylamide gel of rGST AP1 C-terminal protein (Figure 42). The peaks 
detected for the first elution fraction are shown in figure 43. The target protein is 
represented by peak 2, while peak 5 consists of a contaminating protein. 
 
 
Figure 42. Densitometric scan of first elution of rGST AP1 C-terminal 
Peak 2 consists of AP1 C-terminal protein with an estimated purity of 
63.9 percent. 
 
The first elution fraction had an approximate purity of 64 percent, as shown in 
table 19. 
 
TABLE 19: Densitometric data for first elution of rGST AP1 C-terminal 
 
PEAK AREA PERCENTAGE AREA 
2 2 600 63.9 
5 1 466 36.1 
TOTAL  4 066 100 
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The peaks detected for the second elution fraction are shown in figure 43. The 
target protein is represented by peak 4, which represents about 29 percent of the 
total protein (Table 20). 
 
 
Figure 43. Densitometric scan of second elution of rGST AP1 C-terminal 
The seven peak areas are represented by numbers 2, 4, 6, 7, 8, 9 and 10, and were 
determined to represent significant amounts of protein. The target protein is 
represented by peak 4. 
 
TABLE 20: Densitometric data for second elution of rGST AP1 C-terminal 
 
PEAK AREA PERCENTAGE AREA 
2 89 1.8 
4 1 441 28.7 
6 103 2 
7 58 1.2 
8 2 869 57.1 
9 169 3.4 
10 296 5.8 
TOTAL 5 025 100 
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The reduced purity of the second elution fraction is due to the increased levels of 
contaminating proteins, some of which may be E. coli proteins with GST-like 
sequences. These contaminants would compete with the target protein for binding 
to the glutathione-coated magnetic beads. 
 
3.6.8) Bioinformatic data for P. falciparum AP1 C-terminal 
3.6.8.1) Structure of P. falciparum AP1 C-terminal 
 
 The Swiss Model Template Library was used to find three dimensional models of 
proteins to which the AP-1 β subunit had structural homology, as no 3D model 
was available on the PlasmoDB website. The whole protein was compared to 
templates in the library and two hits resulted. Two separate templates were found 
that matched the C-terminal and the N-terminal of the whole protein, respectively. 
The AP1 C-terminal sequence had homology to template 1e42A (Figure 44). This 
template is human β2 appendage domain from clathrin adaptor AP-2. The target-
template pair shares sequence identity of 25 percent, indicating that errors in the 
sequence alignment algorithms may have occurred because the target-template 
pair has less than 40 percent identity (Appendix, section 5.11; figure 74).  
 
  
A B 
 Figure 44. Predicted 3D model of AP1 C-terminal 
The model (A) is based on template 1e42A (B), the human β2 appendage domain 
from clathrin adaptor AP-2, which had most sequence identity to the AP1 C-
terminal sequence. The residues modeled span amino acids 694-911. 
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The predicted 3D model of the parasite AP1 C-terminal consists mostly of beta 
sheets, with three alpha helices (Figure 44). However, no beta sheets can be seen 
in the Heldwein model (Figure 58). The fact that the template did not accurately 
predict the structure of the P. falciparum AP1 C-terminal, due to the low sequence 
identity between the target-template pair, could account for this discrepancy. 
 The area of the AP1 C-terminal that was modeled is indicated in figure 45. 
 
A. 
 
B. 
NNSSDEFNNDIDDADDSKKSMDLIGLNDDESKPQKTIPPVKMVQVLSSEDAGLKGQTGLSIFASINRIDRKI
QLKISVTNQTQNEIVVSGVQINKNSFGLSSPNNLDVQNIGFGETKEMLIYLIPNTLNSNTPPATPL
FLQVAIRTNLDIFYFNVPYDIFVVFVENFHMEKDIFKKKWQIIEEAKEELYYFACITTNNLVILSE
VTIQPEKKNVKLCIRTDSSSVIPLYKLLFVKAFSLSVTQT 
 
Figure 45. Homology of AP1 C-terminal to 3D template 
In A, the blue and red segment starting at amino acid 694 and ending at 911 
indicates the area where the AP1 C-terminal shares homology with template 
1e42A. 25 percent of this segment shares sequence identity with template 1e42A. 
The blue bar is the AP1 N-terminal. The green segment is the whole AP1 protein 
of 925 amino acids.  
In B, the AP1 C-terminal protein sequence is shown. The larger, bold type 
indicates the area with homology to template 1e42A. 
 
The secondary structure of the AP1 C-terminal, as predicted using the Jnet 
secondary structure prediction algorithm (Cuff and Barton, 2000), showed that the 
principal conformation was that of beta sheets, with a small percentage of alpha 
helices (Appendix, section 5.10, Figure 71). This is reflected in the 3D model 
(Figure 44), which consists overwhelmingly of beta sheets. 
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3.6.8.2) Homology of P. falciparum P. falciparum AP-1 β subunit to other proteins 
 
The whole putative AP-1 β subunit protein sequence (925aa) was compared to the 
proteomes of P. knowlesi, P. vivax, P. chabaudi, P. berghei and P. yoelii. Five 
proteins were found with high sequence identity to the P. falciparum sequence 
and these are listed as paralogues on the PlasmoDB website, indicating that the 
proteins are derived from the same ancestral gene. The results are presented in 
table 21.  
 
TABLE 21: Sequence identity of P. falciparum AP-1 β subunit with other  
          Plasmodium proteins 
 
ORGANISM PRODUCT SEQUENCE 
IDENTITY 
SEQUENCE 
POSITIVITY 
E-VALUE 
P. vivax  PVX079845; 
putative 
adapter-related 
protein complex 
1 β 1 subunit  
89 percent 95 percent 0 
P. knowlesi  PKH100410; 
putative β 
adaptin protein  
89 percent 95 percent 0 
P. chabaudi PC000299.01.0; 
putative β 
adaptin  
83 percent 91 percent 1.6e-283 
P. yoelii PY01282; 
putative β 
adaptin-like 
protein 
82 percent 91 percent 0 
P. berghei  PB000013.00.0; 
putative β 
adaptin  
81 percent 90 percent 0 
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 The BLAST data for the P. vivax protein is shown in the appendix (PVX079845, 
Appendix, section 5.10, Figure 67). 
 
No paralogues to the P. falciparum putative AP-1 β subunit were found in the 
T. gondii proteome, although several proteins showed sequence identity, as 
indicated in table 22. The protein that had the highest homology was T. gondii 
putative β adaptin protein, with an identity of 56 percent and positivity of 
74 percent over the whole protein (49.m00005, Appendix, section 5.9, Figure 68). 
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The other T. gondii proteins had most sequence identity in the N-terminal region 
of the P. falciparum AP-1 β1 subunit. 
 
TABLE 22: Sequence identity of P. falciparum AP-1 β subunit with T.gondii  
          proteins 
 
PRODUCT SEQUENCE 
IDENTITY 
(percent) 
SEQUENCE 
POSITIVITY 
(percent) 
E-VALUE 
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49.m00005; putative 
β adaptin protein 
(925aa)  
56 36 66 74 60 82 9.6e-274 
 
57.m01782; putative 
β adaptin-like 
protein (915aa) 
20 None 30 37 None 56 1.1e-82 
 
80.m02192; putative 
adapter-related 
protein complex 3 β 
2 subunit (1 187aa) 
7 None 26 13 None 51 6.4e-34 
 
57.m01829; putative 
β coat protein 
(1 104aa) 
13 26 21 26 45 45 1.2e-16 
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The P. falciparum putative AP-1 β1 subunit protein sequence was compared to 
the human proteome. The orthologous H. sapiens AP-1 β1 subunit, found on 
chromosome 22, was the best hit with 46 percent identity and 62 percent positivity 
to the whole protein; 63 percent identity and 81 percent positivity with the 
parasite N-terminal protein sequence and a much lower 28 percent identity and 
52 percent identity within the C-terminal region (E-value 2.0e-224) (Appendix, 
section 5.9, figure 69). The human protein is 949 amino acids in length compared 
to the 925 amino acid parasite protein sequence. The BLAST data indicate that the 
N-terminal of the AP-1 β subunit is more highly conserved than the C-terminal.  
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3.7) Results for P. falciparum AP1 N-terminal 
 
3.7.1) Verification of AP1 N-terminal vector construct 
 
The presence of PCR product (lanes 4, 5, 7 and 9; Figure 46) with the same 
length as the control – which contained amplified P. falciparum DNA – indicated 
that the AP1 N-terminal insert was present and that the transformation had been 
successful in DH5α colonies 2, 3, 5 and 7 (Figure 46). The expected size of the 
insert is 1 800bp, and the AP1 N-terminal band resolved between the 1 500bp and 
2 000bp DNA markers as expected. 
 
                               1        2        3        4        5       6        7       8        9                                      
 
1 – MassRulerTM DNA ladder mix                           
2 – Amplified P. falciparum genomic DNA             
3–9 Amplified vector constructs from colonies 1-
 
 
 
Figure 46. Digested AP1 N-terminal vector constructs from DH5α cells 
The AP1 N-terminal insert was excised by digestion with the same restriction 
endonucleases used for the plasmid preparation (section 3.4.2) and was resolved 
on a 1% agarose gel. 
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3.7.2) AP1 N-terminal vector construct sequence data  
 
Successful sequencing was carried out using the T7 terminator (Appendix) and 
promoter primers (Figure 47). The T7 promoter primer chromatogram for the 
AP1 N-terminal vector construct sequence demonstrated high amplitude peaks 
with minimal background, as seen in figure 47. 
 
 
Figure 47. Section of AP1 N-terminal vector construct chromatogram  
A vector construct from colony 5 was sequenced with a T7 promoter primer. The 
P. falciparum sequence begins at base pair 120, highlighted in blue, with the 
forward primer 5’- ATG TCT GAT TTA CGC TAC TTT -3’.  
 
To confirm that the subcloned sequence was identical to the sequence obtained 
from the PlasmoDB website, the two sequences were aligned (Figure 48). 
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1   ATGTCTGATTTACGCTACTTTCAAACGACTAAAAAAGGAGAAATCCATGA     50 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
120 ATGTCTGATTTACGCTACTTTCAAACGACTAAAAAAGGAGAAATCCATGA    169 
 
51  GCTTAAAGAAGAATTACATTCTTCTCATAAGGAAAAAAAAAAGGAAGCTA    100 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
170 GCTTAAAGAAGAATTACATTCTTCTCATAAGGAAAAAAAAAAGGAAGCTA    219 
 
101 TTAAAAAGATTATTGCTGCTATGACTGTTGGGAAAGATGTCTCGACATTA    150 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
220 TTAAAAAGATTATTGCTGCTATGACTGTTGGGAAAGATGTCTCGACATTA    269 
 
151 TTTTCTGATGTTGTGAATTGCATGCAAACATCGAATATAGAATTAAAGAA    200 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
270 TTTTCTGATGTTGTGAATTGCATGCAAACATCGAATATAGAATTAAAGAA    319 
 
201 GCTTGTTTATTTATACGTTATAAATTATGCTAAGGTACAACCTGAACTAG    250 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
320 GCTTGTTTATTTATACGTTATAAATTATGCTAAGGTACAACCTGAACTAG    369 
 
251 CTATTTTAGCTGTTAATACATTTCGAAAAGATTCCTCAGACCCAAATCCC    300 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
370 CTATTTTAGCTGTTAATACATTTCGAAAAGATTCCTCAGACCCAAATCCC    419 
 
301 CTTATAAGAGCTTTAGCTATTCGAACAATGGGATGTATACGACTAGAACA    350 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
420 CTTATAAGAGCTTTAGCTATTCGAACAATGGGATGTATACGACTAGAACA    469 
 
351 AATAACAGAATATTTAATCGAACCATTGAGGAGATGTTTAAAAGATGAAG    400 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
470 AATAACAGAATATTTAATCGAACCATTGAGGAGATGTTTAAAAGATGAAG    519 
 
401 ATCCATACGTAAGAAAAACAGCTGTTATATGTATAGCCAAATTATATGAT    450 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
520 ATCCATACGTAAGAAAAACAGCTGTTATATGTATAGCCAAATTATATGAT    569 
 
451 ATATCACCGAAATTAGTAGAAGAAGAAGGTTTTATAGATACGCTTTTAGA    500 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
570 ATATCACCGAAATTAGTAGAAGAAGAAGGTTTTATAGATACGCTTTTAGA    619 
 
501 TATATTAGATGATAATAATGCCATGGTTGTTGCTAATGCTGTTATATCGT    550 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
620 TATATTAGATGATAATAATGCCATGGTTGTTGCTAATGCTGTTATATCGT    669 
 
551 TAACGGATATTTGTGAGAATTCAAACAAGAGCATATTAAAAGATGTTATA    600 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
670 TAACGGATATTTGTGAGAATTCAAACAAGAGCATATTAAAAGATGTTATA    719 
 
601 AACAAAGATGAAAATAATGTGAATAAACTTTTAAATGCTATTAATGAATG    650 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
720 AACAAAGATGAAAATAATGTGAATAAACTTTTAAATGCTATTAATGAATG    769 
 
651 TGTAGAATGGGGACAAGTTTTTATTTTAGATGCATTAGTTTTATATGAAC    700 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
770 TGTAGAATGGGGACAAGTTTTTATTTTAGATGCATTAGTTTTATATGAAC    819 
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701 CTAAAACTAGTAAAGATGCTGAACGTGTTTTAGAAAGAATATTACCAAGA    750 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
820 CTAAAACTAGTAAAGATGCTGAACGTGTTTTAGAAAGAATATTACCAAGA    869 
 
751 TTATCACATGCTAATTCAGCAGTAGTTCTATCATCTATTAAAGTTATCTT    800 
    |||||||||||||||||||||||||||||||||||||||||||||||||| 
870 TTATCACATGCTAATTCAGCAGTAGTTCTATCATCTATTAAAGTTATCTT    919 
 
801 ATGCTTATTAGATAAAATCAATGATAAAGAATTTATTAAAAATGTACATA    850 
    ||||||||||||||||||||||||| ||||||||||| |||||||||||| 
920 ATGCTTATTAGATAAAATCAATGAT-AAGAATTTATT-AAAATGTACATA    967 
 
851  AGAAATTAAGCCCATCTTTAGTCACACTTTTATCTGCGGAACCAGAAATT    900 
     ||||||| ||||||||||||||||||||||||||||||  ||||| |||| 
968  AGAAATT-AGCCCATCTTTAGTCACACTTTTATCTGCG--ACCAG-AATT   1013 
 
901  CAATATATTGCATTAAGAAATATTAATTTAATAACACAGAAATTACCCAA    950 
     |||||||||||||||  .|||||| |||||  .||||||||  ||||| | 
1014 CAATATATTGCATTA--GAATATT-ATTTA--TACACAGAA--TACCC-A   1055 
951  CATGCTCTCTGATAAAATCAATATGTTTTTCTGTAAATATAATGAACCTG   1000 
     |||||||||||||  |||| |||||||||.:|||||| :|||||.| ||| 
1056 CATGCTCTCTGAT--AATC-ATATGTTTTCYTGTAAA-WTAATGGA-CTG   1100 
 
1001 CTTATGTAAAAATGGAAAAACTTGATATTATTATAAGACTTGTATCAGAT   1050 
     ||..|    |||||   |||| ||..|||||| |||||| ||.|||..|| 
1101 CTAGT----AAATG---AAAC-TGTAATTATT-TAAGAC-TGGATCGAAT   1140 
 
1051 AAAAATGTAGACCTTGTTCTAT-ATGAATTAAAAGAATATTCTAC   1094 
     |||           ||..||.| |||.|||  ||||||.|||||| 
1141 AAA-----------TGAACTGTCATGGATT--AAGAATTTTCTAC   1172 
 
Figure 48. Alignment of AP1 N-terminal DNA sequences from T7 promoter 
primer sequencing 
The sequence obtained from subcloning (red) was aligned with the original 
sequence obtained from the PlasmoDB database (blue). The underlined section 
indicates the P. falciparum forward primer position 5’ - ATG TCT GAT TTA CGC 
TAC TTT -3’. Key to ambiguous bases: W = T and A overlap in sequence; Y = C 
and T overlap. A dot between base pairs indicates a non-alignment, while a dash 
indicates a missing base. 
 
Discrepancies at the 3’ end of the sequence were resolved by sequencing the 
reverse strand using the T7 terminator primer, which confirmed that the sequences 
aligned with 100 percent identity ((Appendix, section 5.8 for T7 terminator primer 
sequence of AP1 N-terminal). 
 
128 
 
3.7.3) Verification of AP1 N-terminal vector construct in Rosetta 2 cells  
  
Successful transformations occurred in adaptin colonies 2, 3 and 4, as seen in 
lanes 4-6 of Figure 49, where two bands resolved on the gel after restriction 
endonuclease digestion of plasmids isolated from Rosetta 2 cells. The adaptin N-
terminal domain is 1 800bp in length, and resolved to a position between the 
1 500bp and 2 000bp standard markers. 
 
1         2         3          4         5         6   
 
1 – MassRulerTM DNA ladder mix 
2 – pET-15b whole recombinant plasmid  
3 – 6 Digested plasmids from colonies 1-4  
 
 
 
Figure 49. Digested Rosetta vector constructs resolved on 1% agarose gel 
Rosetta 2 (DE3) colonies 2-4 were positive for the AP1 N-terminal insert (lanes 4-
6). The restriction endonucleases used were the same as those used for digestion 
of plasmids (section 3.4.2). 
 
3.7.4) Laemmli SDS-PAGE of rHis AP1 N-terminal  
 
The rHis AP1 N-terminal protein has a predicted molecular weight of 72.2kD. 
Soluble protein of the correct molecular weight was not detected in the eluted 
fractions as seen in lanes 2-4 of figure 50. However, protein of the estimated 
correct molecular weight was observed in the unbound fraction (lane 6), soluble 
fraction (lane 7), insoluble fraction (lane 8) and the total induced protein fraction 
(lane 10).
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It is possible that the protein band could consist of E. coli proteins and not the 
target parasite protein.  
 
    1           2          3          4          5        6         7         8         9        10 
 
 
 
 
 
1 – His control      6 – AP1 N-terminal unbound fraction 
2 – AP1 N-terminal stripped beads    7 – AP1 N-terminal soluble fraction 
3 – AP1 N-terminal 2nd elution    8 – AP1 N-terminal insoluble fraction 
4 – AP1 N-terminal 1st elution     9 – AP1 N-terminal total uninduced 
5 – RBC membrane marker     10 – AP1 N-terminal total induced 
Figure 50. Purification of rHis AP1 N-terminal protein  
The protein fractions obtained during extraction and purification from Rosetta 2 
cells were resolved on a 12% SDS polyacrylamide gel. The RBC membrane 
marker (lane 5) consists of 5 indicated bands: Protein 4.1 – 78kD; Protein 4.2 – 
72kD; Actin – 43kD; Glyceraldehyde 3-phosphate dehydrogenase (G3PD) – 
35kD; Stomatin/tropo-myosin – 29kD. 
 
3.7.5) Western blot of rHis AP1 N-terminal 
 
Proteins were transferred from the SDS acrylamide gel (Figure 50) onto a 
nitrocellulose membrane (Figure 51). The membrane was immunoblotted with an 
anti-His primary antibody and subsequently stained in amido black. A faint 
protein band within the correct molecular weight range for the AP1 N-terminal 
was seen in the stripped bead fraction (Figure 51, lane 2). 
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                       1           2          3            4         5           6         7          8         9      10       
 
1 – His control                                     6 – AP1 N-terminal unbound fraction 
2 – AP1 N-terminal stripped beads   7 – AP1 N-terminal soluble fraction 
3 – AP1 N-terminal 2nd elution          8 – AP1 N-terminal insoluble fraction 
4 – AP1 N-terminal 1st elution           9 – AP1 N-terminal total uninduced 
5 – RBC membrane marker            10 – AP1 N-terminal total induced 
 
 
 
 
 Figure 51. rHis AP1 N-terminal Western blot  
The Western blot was stained in amido black to visualise proteins. Bands of the 
expected size were faintly observed in the stripped fraction (lane 2), and in the 
unbound, soluble, insoluble and total fractions (lanes 6, 7, 8 and 10). The RBC 
membrane marker (lane 5) has 2 bands labelled: Protein 4.2 – 72kD; Actin – 
43kD. An anti-His primary antibody was used for immunoblotting. 
 
3.7.6) Autoradiograph of rHis AP1 N-terminal 
 
The chemiluminescent immunoblot was exposed to x-ray film, resulting in an 
autoradiograph. No soluble protein in the correct molecular weight range for the 
rHis AP1 N-terminal was detected in the eluted fractions (not shown). However, 
the anti-His antibody bound to protein in the insoluble and total protein fractions 
(Figure 52, lanes 4 and 5) indicating that insoluble inclusion bodies had formed. 
The molecular weight of the bands obtained on the autoradiograph appears lower 
that 72kD. 
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  Autoradiograph Western overlaid with autoradiograph 
       1        2      3       4     5       6   1     2     3       4       5        6 
 
 
 
 
Figure 52. Immunoblot of rHis AP1 N-terminal 
X-ray film was exposed to chemiluminescent immunoblots for 60 seconds to 
obtain autoradiographs. Protein was detected in lanes 4 and 5, but was below the 
predicted molecular weight of 72.2kD. The RBC membrane marker (lane 2) has 2 
labelled bands: Protein 4.2 – 72kD; Actin – 43kD. 
 
Using retardation factor (Rf) values of proteins making up the RBC membrane 
marker, the molecular weight of rHis AP1 N-terminal bands on the 
autoradiograph was determined (Table 23). The extrapolated value is shown in 
bold type. 
 
TABLE 23: Data used to determine the Mr of rHis AP1 N-terminal 
 
PROTEIN Mr 
(kD) 
Log Mr 
 
MIGRATION 
DISTANCE (mm) 
Rf VALUE 
Band 3 93 1.9685 23 0.404 
Protein 4.1 78 1.8921 25.5 0.447 
Protein 4.2 72 1.8573 28 0.491 
Actin 43 1.6335 36.5 0.640 
G3PD 35 1.5441 42 0.737 
7 29 1.4624 46 0.807 
rHis AP1 N-
terminal (band on 
autoradiograph) 
63.566 1.8032 30 0.526 
Dye front   57  
1 – AP1 N-terminal unbound fraction      4 – AP1 N-terminal insoluble fraction 
2 – RBC membrane marker                      5 – AP1 N-terminal total induced 
3 – AP1 N-terminal soluble fraction         6 – AP1 N-terminal total uninduced 
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The molecular weight of adaptin that was extrapolated from Graph 4 is 63.6kD, 
which is much smaller that the estimated 72.2kD. With an R2 value of 
99.44 percent, the standard linear regression is accurate under conditions of 
normal protein size migration. However, due to the anomalous size migration of 
P. falciparum proteins, the value calculated for the parasite protein molecular 
weight is not exact, as described in section 3.5.6. 
 
Graph 4: rHis AP1 N-terminal - Plot of log Mr vs 
Rf values y = -1.253x + 2.4627
R2 = 0.9944
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3.7.6.1) Western blot of rHis AP1 N-terminal extracted from inclusion bodies  
 
Protein was extracted from inclusion bodies and refolded. The recovered protein 
was electrophoresed via SDS-PAGE (not shown) and then transferred onto a 
nitrocellulose membrane by means of Western blotting. The Western blot 
revealed protein bands in the estimated molecular weight range of 72.2kD in the 
soluble and insoluble fractions (not shown). 
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3.7.6.2) Autoradiograph of rHis AP1 N-terminal extracted from inclusion bodies 
  
His-tagged proteins were detected in the insoluble fraction and the total induced 
fraction as seen in lanes 8 and 9 (Figure 53). These proteins appeared in the 50 – 
75kD molecular weight range, according to the standard histidine ladder (Lane 1). 
This indicated that refolding of rHis AP1 N-terminal was not successful and the 
recombinant protein remained insoluble. 
  A. 
  
  B.   1      2       3      4       5       6       7      8       9  
 1 – 6x His ladder     6 – AP1 N-terminal unbound fraction 
2 – AP1 N-terminal stripped beads   7 – AP1 N-terminal soluble fraction 
3 – AP1 N-terminal 2nd elution   8 – AP1 N-terminal insoluble fraction 
4 – AP1 N-terminal1st elution    9 – AP1 N-terminal total induced  
5 – RBC membrane marker
 
 
 
Figure 53. Immunoblot of rHis AP1 N-terminal extracted from inclusion bodies 
A is the autoradiograph. B is the Western blot overlaid with the autoradiograph. 
X-ray film was exposed to chemiluminescent immunoblots for 60 seconds to 
obtain autoradiographs. Protein of the estimated molecular weight for the AP1 N-
terminal was detected in lanes 8 and 9. The 6X histidine ladder (lane 1) has 2 
labelled bands: band 2 – 75kD; band 3 – 50D. 
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The retardation factor (Rf) values of proteins making up the RBC membrane 
marker were determined. The molecular weight of the rHis AP1 N-terminal bands 
were then determined from these values (Table 24). The extrapolated value is 
shown in bold type. 
 
TABLE 24: Data used to determine the Mr of rHis AP1 N-terminal from   
          insoluble fraction 
 
6x HIS PROTEIN 
LADDER 
Mr 
(kD) 
Log Mr 
 
MIGRATION 
DISTANCE (mm) 
Rf VALUE 
1 100 2 24 0.453 
2 75 1.8750 27 0.509 
3 50 1.6989 34 0.642 
4 30 1.4771 42 0.792 
5 15 1.1760 49 0.925 
Adaptin inclusion 
bodies (x-ray 
film) 
64.401 1.8088 30 0.566 
Dye front   53  
 
The molecular weight of the rHis AP1 N-terminal that was extrapolated from 
Graph 5 is 64.4kD, which is much smaller that the predicted value of 72.2kD. 
This could be due to the same factors discussed in section 3.5.6. The R2 value 
indicates that the standard linear regression predicts the molecular weight with 
98.98 percent accuracy, under conditions of normal protein size migration.  
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Graph 5: rHis AP1 N-terminal from inclusion 
bodies - Plot of log Mr vs Rf values
y = -1.6658x + 2.7518
R2 = 0.9898
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3.7.7) Purity of rHis AP1 N-terminal 
 
As recombinant adaptin was not expressed in a soluble form, densitometric 
analysis was not carried out for this protein.  
 
 3.7.8) Bioinformatic data for P. falciparum AP1 N-terminal 
3.7.8.1) Structure of P. falciparum AP1 N-terminal 
  
The Swiss Model Template Library was used to find three dimensional models of 
proteins to which the AP-1 β subunit had structural homology (Section 3.6.8.1). 
The AP1 N-terminal sequence had homology to template 2vglB (Figure 54). This 
template is human AP2 clathrin adaptor core. The target-template pair shares 
sequence identity of 63 percent, indicating that the template closely predicts the 
3D structure of the parasite protein (Appendix, section 5.11; figure 75).This can 
be seen in figure 54, where the predicted model (A) has an almost identical 
structure to the template (B). 
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A B 
 
Figure 54. 3D model of AP1 N-terminal 
Template 2vglB (B) is human AP-2 clathrin adaptor core, which had most 
sequence homology to the AP1 N-terminal sequence as modeled (A). 
 
The putative model of the parasite protein (figure 54, A) consists mainly of alpha 
helices which is consistent with the crystal structure of AP-1 complexes as 
determined by Heldwein et al (2004) (Figure 58). The area of the AP1 N-terminal 
that shares sequence homology to the template is indicated in figure 55.  
 
 A. 
 
B.  
MSDLRYFQTTKKGEIHELKEELHSSHKEKKKEAIKKIIAAMTVGKDVSTLFSDVVNCMQTSNIELKK
LVYLYVINYAKVQPELAILAVNTFRKDSSDPNPLIRALAIRTMGCIRLEQITEYLIEPLRRCLKDE
DPYVRKTAVICIAKLYDISPKLVEEEGFIDTLLDILDDNNAMVVANAVISLTDICENSNKSILKDV
INKDENNVNKLLNAINECVEWGQVFILDALVLYEPKTSKDAERVLERILPRLSHANSAVVLSSIKV
ILCLLDKINDKEFIKNVHKKLSPSLVTLLSAEPEIQYIALRNINLITQKLPNMLSDKINMFFCKYN
EPAYVKMEKLDIIIRLVSDKNVDLVLYELKEYSTEVDVEFVKKSVRAIGSCAIKLPQSSEKCINIL
LDLIDTKINYVIQECIVVIKDIFRKYPNKYESIITILCENLESLDESNAKASLIWIIGEYVERIDN
ADELIDSFLENFSDEPYNVQLQILTASVKLFLKCSKNTKDIITKVLKLSTEESDNPDLRDRAYIYW
RLLSKNIDVAKKIVLADKPPIQEENKITDTKVLNKLIKNISMLSSVYHKLPETFISKKNSYSLNSDNN
NDHMQDDHYDDDDYDKDNHVL 
 
Figure 55. Sequence homology of AP1 N-terminal to 3D template 
In A, the blue and red segment starting at amino acid 12 and ending at 584 
indicates the area where the AP1 N-terminal shares homology with template 
2vglB. 63 percent of this segment has sequence identity to the template. The blue 
segment is the AP1 C-terminal. The green segment represents the whole AP-1 β 
subunit of 925 amino acids. In B, the protein sequence of the AP1 N-terminal is 
represented. The larger, bold black sequence represents the area sharing 
sequence homology with template 2vglB. 
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Using the Jnet secondary structure prediction algorithm (Cuff and Barton, 2000), 
the protein secondary structure of the AP1 N-terminal was predicted to consist 
mostly of alpha helices, with only one section of beta sheets (Appendix, section 
5.10, Figure 72). These data are supported by the 3D model (Figure 55) which is 
predominantly made up of alpha helical conformations. 
 
3.7.8.2) Homology of P. falciparum AP1 N-terminal to other proteins 
 
The data for the AP1 N-terminal are detailed in section 3.6.8.2, where the entire 
AP-1 β1 subunit was compared to the proteomes of P. knowlesi, P. vivax, P. 
chabaudi, P. berghei and P. yoelii, as well as T. gondii and H sapiens. 
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CHAPTER 4 
DISCUSSION 
 
4.1) PFB0150c – A P. falciparum PK 
 
The catalytic core of all PKs is conserved across eukaryotes, viruses and some bacteria 
and consists of about 260 amino acids (Hanks & Hunter, 1995). In higher eukaryotes, this 
catalytic domain contains an ATP-binding region at the N-terminal extremity which is 
made up of a glycine-rich region in the locale of a lysine residue. Conserved aspartic acid 
residues are situated in the carboxy terminus lobe and are significant for the catalytic 
activity of the enzyme. Higher eukaryotic PKs have twelve subdomains. The amino 
terminus lobe consists of subdomains I, II, III, IV and V. The carboxy terminus lobe is 
made up of subdomains VIA, VIB, VII, VIII, IX, X and XI (Figure 56) (Hanks, 2003).  
 
 
 
  
              
 
 
 
 
 
 
 
 
 
Figure 56A. Catalytic core of PKs 
The higher eukaryote PK catalytic domain. Invariant amino acids are underlined.  
 
I        II     III      IV      V      VIA   VIB      VII     VIII     IX      X      XI  
GxGxxG APE
K E 
DxxxN  
DFG RDxxxxG  
Amino terminus lobe 
(ATP binding) 
Carboxy terminus lobe 
(Peptide binding and phosphotransfer) 
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 In the case of PFB0150c, the catalytic core is 276 amino acids in length (Figure 57). The 
parasite kinase domain contains all the invariant residues that are present in eukaryotic 
PKs (Figure 56B). 
 
                 I                    II        III 
RINEEHKNEGINKLTYHNMNKNNISNENNYNDDDSYDEDNLVSLKIINLKYLSKKNSLKNILREVNFLKM 
                                  VIB 
CEHPNVVKYFESFFWPPCYLVIVCEYLSGGTLYDLYKNYGRISEDLLVYILDDVLNGLNYLHNECSSPLI 
                    VII                                        VIII                        IX 
HRDIKPTNIVLSKDGIAKIIDFGSCEELKNSDQSKELVGTIYYISPEILMRTNYDCSSDIWSLGITIYEI 
                                                  XI 
VLCTLPWKRNQSFENYIKTIINSSPKINITEGYSKHLCYFVEKCLQKKPENRGNVKDLLNHKFLIK 
 
Figure 56B. Catalytic core of P. falciparum PK  
The invariant residues found in the catalytic core of eukaryotic PKs are present in the 
catalytic core of the P. falciparum PK, spanning amino acids 2 079 – 2 354.  
 
3D templates available in the Swiss Model Template Library, determined from x-ray 
crystallography of proteins, did not closely predict the structure of the entire parasite PK, 
with the catalytic subunit of human cAMP-dependent protein kinase sharing the most 
sequence identity of only 26.4 percent in the kinase domain. This indicates that the 
predicted 3D model is not a reliable representation of the quaternary PK structure because 
the template does not share sequence identity of more than 40 percent (Arnold et al, 
2006; Schwede et al, 2003; Guex and Peitsch, 1997). However, the area of homology 
between the target-template pair occurred exclusively in the kinase domain, supporting 
the proposal of PK catalytic core conservancy across eukaryotes (Hanks & Hunter, 
1995).  
 
BLAST data indicated that the P. falciparum PK shares identity with other eukaryotic 
PKs in the region of the catalytic domain, while the protein as a whole has very low 
homology. This could be due to different sizes of the PKs among the different organisms 
– the P. falciparum enzyme is 2 485aa, the Plasmodium sp. PKs range from 2 178 to 
6 390aa, the human enzyme is 304aa and the T. gondii PKs are between 296 and 4 253aa 
in length. The P. vivax and P. knowlesi PKs had the most homology with the P. 
falciparum PK, more so than the P. yoelii PKs. 
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This is probably due to the fact that that the former three species infect humans, while the 
latter is a rodent malaria. Interestingly, the PKs with the best matches from the H. sapiens 
and T. gondii proteomes shared similar homology with the P. falciparum PK. Moreover, 
the number of conserved catalytic core residues in the human PK (Appendix, section 5.9, 
Figure 64) matched those in the P. falciparum PK better (T. gondii PK homology, 
appendix, section 5.9, Figure 66). This is unusual as one would expect more similarity 
between parasite proteins from the same phylum, rather than between the human and P. 
falciparum enzymes.  
 
4.1.1) PFB0150c protein and mRNA expression  
 
Mass spectrometry-based evidence indicates that the protein is expressed in notable 
quantities during the sporozoite, merozoite and gametocyte stages of the parasite life 
cycle, with no detectable expression during the trophozoite stage (Florens et al, 2002). 
Abundance of the PK is greatest during the gametocyte stage with 90 percent (percentage 
of the protein sequence covered by identified peptides) of whole protein being detected; 
this is followed by 70 percent abundance during the merozoite stage and 40 percent 
during the sporozoite stage (Florens et al, 2002). Photolithographic oligo array data for 
mRNA expression by Le Roch et al (2003) is represented in figure 57. From these data it 
can be deduced that the expression of the PFB0150c gene is greatest during the 
gametocyte stage, followed by the sporozoite, late schizont and then merozoite stage, 
respectively. Differences in the amount of protein and the expression of the gene may be 
attributed to the fact that not all mRNA transcripts are translated immediately into 
protein. Therefore, mRNA expression does not always mirror the amount of protein 
produced. 
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    Life stage 
Figure 57. Intraerythrocytic P. falciparum 3D7 photolithographic oligo array data for 
PFB0150c mRNA expression (Le Roch et al, 2003) 
x-axis: Plasmodium developmental stages* synchronised by sorbitol and temperature. 
Data for gametocyte sample corresponds to synchronisation by sorbitol only, and for 
sporozoite sample represents average of two replicates. 
y-axis: Absolute mRNA expression levels  
* Developmental stages: ER = Early Rings; LR = Late Rings; ET = Early Trophozoites; 
LT = Late Trophozoites; ES = Early Schizonts; LS = Late Schizonts; M = Merozoites; 
S = Sporozoites; G = Gametocytes 
 
4.1.2) Recombinant PFB0150c expression in E. coli 
 
Expression of the rGST PK insert was successful despite the predicted insolubility of 
63.2 percent, which was the highest prediction for all targeted domains. Presumably its pI 
of 5.88 predisposed the sequence to expression, as it fell within the ideal parameters of 
3.45 and 6.8, where most P. falciparum proteins are expressed in soluble form (Mehlin et 
al, 2006). The yield of purified rGST PK obtained, namely 180-210µg per litre of culture, 
was quite low. At least 2mg of protein is needed in order to carry out crystallisation 
(Vedadi et al, 2007), which would allow for further elucidation of its structure and 
biochemical function.  
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4.1.3) Classification of PFB0150c PK 
 
In 2005, Anamika et al carried out in silico studies and identified a 2 985 residue long 
putative kinase-like sequence (PKLS) annotated PFB0150c. The catalytic domain of this 
PKLS, one of 90 PKs with a conserved catalytic aspartic acid, was found to share 
30 percent identity with MAP kinase kinase (MAPK kinase) and p21-activated kinases. 
MAPK kinases are serine/threonine/tyrosine-specific protein kinases that are only 
activated once phosphorylated by a MAPK kinase kinase (MAP3K). The function of 
MAPK kinases is to activate MAPKs by phosphorylating threonine and tyrosine residues 
within a specific consensus sequence on their target molecule (Cobb, 1996). They 
postulated that the product of PFB0150c was a MAPK kinase involved in a cascade 
regulating various transcription factors. However, bioinformatic data collected in the 
current study indicate that PFB0150c codes for a serine/threonine PK. MAPK kinases did 
not feature among the top ten BLAST hits and 84 percent of the top 100 hits were with 
serine/threonine PKs (Table 16). However, it is interesting to note that out of the top 30 
hits, three were plant MAPK kinases which corroborates the postulated close 
evolutionary link between plant and parasite kinases (Anamika et al, 2005). The parasite 
PK also functioned without prior phosphorylation by a MAP3K, which is an essential 
characteristic of MAPK kinases. It is possible that PFB0150c is an atypical MAPK 
kinase variant, but the data from the current study strongly support the hypothesis that the 
parasite enzyme is a casein kinase. For example, the results of the kinase assay showed 
that the α casein 1 and 2 subunits of exogenous bovine casein were phosphorylated by the 
recombinant enzyme. However, the parasite PK does not have all the characteristics of 
higher eukaryotic isoforms of casein kinase 1 (CK1). While both the parasite PK and 
eukaryotic CK1’s contain the domains common to all serine/ threonine PKs, the CK1’s 
additionally have a Ser-Ile-Asn (SIN) motif in domain VIII (Gross & Anderson, 1998). In 
the parasite this motif has the sequence Ser-Pro-Glu (SPE) (Figure 57). Additionally, all 
CK1 isoforms contain a near-consensus SV40 T-antigen putative nuclear localisation 
sequence in the kinase catalytic domain which is made up of the following amino acids: 
TKKQKY (Gross & Anderson, 1998). This motif is not present in the parasite PK. 
Determining whether the parasite enzyme is inactivated by MAPK kinase inhibitors or 
casein kinase inhibitors would aid with further characterisation. 
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The hypothesis that PFB0150c is a PK that has protein 4.1 and/ or spectrin as its 
substrates would be futher substantiated by the presence of a PEXEL/ VTS export motif 
to facilitate trafficking of the parasite enzyme into the host RBC. This motif has the 
consensus sequence R/KxLxE/Q, where x is any amino acid, and it is present in the 
PFB0150c protein sequence (Appendix, figure 76).  
 
4.1.4) Probable function of PFB0150c PK 
 
A host-parasite PPI was found to exist between protein 4.1, as well as spectrin, and a PK 
encoded by the PFB0150c gene through the use of a P. falciparum phage display library 
(Lauterbach et al, 2003). The binding sequence spans amino acids 786-815 of the 
parasite enzyme, which is outside the kinase domain (2 079 – 2 354) (Lauterbach et al, 
2003). This implies that once the substrate has been bound, the folding conformation of 
the PK brings the phosphorylation target in proximity to the catalytic domain. Recent 
protein expression data using mass spectrometry ((Florens et al, 2002)) show that the 
enzyme is present with greatest abundance in gametocytes, followed by merozoites and 
then sporozoites. No enzyme expression was detected in the trophozoite stage. The kinase 
assay performed in the current study indicated that the PFB0150c product has casein 
kinase activity. The enzyme could therefore be involved in the phosphorylation of protein 
4.1 and/or spectrin – which weakens the host RBC membrane – and thereby aid rapid 
merozoite invasion of host RBCs. Research by Chishti et al (1994) determined that an 
enzyme that phosphorylated protein 4.1 in parasitised erythrocytes was a casein kinase of 
parasite origin, by showing that phosphorylation of the RBC membrane protein was 
prevented by casein kinase I and II inhibitors. Phosphorylated protein 4.1 was detected in 
pRBC at the trophozoite/schizont stage, but not at the ring stage. This phosphorylation 
was postulated to increase the flexibility of the host membrane and facilitate 
intraerythrocytic growth and exit of the parasite. Phosphorylation of protein 4.1 during 
invasion by merozoites was not documented by Chishti et al (1994). However, merozoite 
invasion is extremely rapid, due to the need to evade the host immune system, and it 
would thus be almost impossible to accurately obtain RBC membranes at this specific 
stage in order to capture these data. Therefore, further investigations are necessary to 
fully characterise the role of this enzyme, but it is tempting to speculate that the PK 
analysed in the current study is the enzyme first discovered by Chishti et al (1994).
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It is possible that the PK has other substrates in vivo, as it is also found in abundance in 
the gametocyte and sporozoite stages where its roles are unknown; but one can speculate 
that in sporozoites it could function in invasion of hepatocytes in the human host, while 
in gametocytes the PK could play a role in growth and survival of the parasite within the 
mosquito.  
 
The fact that the kinase domain makes up such a small part of the PK – 276 aa of a total 
2 485 – indicates that the enzyme may be multifunctional, although no additional roles 
have currently been attributed to it (www.plasmodb.org, 2008). 
 
4.1.5) Drug-target potential of PFB0150c  
 
Malarial PKs have long been investigated for their important roles in the replication and 
differentiation of the parasite (Doerig et al, 1995; Wiser, 1995; Kappes et al, 1995; 
Kappes et al, 1999; Harmse, 2006) and for the extensive changes they cause in the 
phosphorylation profile of the red blood cell membrane proteins to facilitate the invasion 
and development of P. falciparum (Rangachari et al, 1986; Jones & Edmundson, 1990; 
Chisti et al, 1994). P. falciparum PKs have recently been highlighted as targets for 
potential curative and transmission-blocking drugs (Syin et al, 2001; Doerig and Meijer, 
2007).  
 
Traditionally, one of the key criteria that a drug target should fulfill is that its protein 
sequence must be significantly different to host proteins. This prevents any non-selective 
inhibition of the host molecules. However, it has transpired that even in the case of host-
parasite orthologues sharing sequence identity of 40 to 60 percent, selectivity for the 
parasite protein can be achieved (Doerig and Meijer, 2007). An example of specific 
targeting of a drug to the protein of one species, even in the presence of an orthologue 
from another species, was demonstrated by Gray et al (1998). In the presence of human 
cyclin dependant kinase (CDK) 1and its orthologue in yeast, the CDK inhibitor 
purvalanol B demonstrated a 200-fold difference in IC50 values between the two (Gray et 
al, 1998).  
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Interestingly, P. falciparum casein kinase (CK) 1 is also a major target of purvalanol B, 
which has antiproliferative effects on the parasite (Harmse et al, 2001; Knockaert et al, 
2000). Further studies will show whether the same species-selective inhibition occurs in 
the presence of human CK1 (Doerig and Meijer, 2007). 
 
The data from this study indicated that the PK product of PFB0150c may represent a 
feasible drug target, since only the small stretch of amino acids making up the kinase 
domain (276aa) is relatively well conserved across eukaryotes. The rest of the protein 
could be targeted, where the binding of inhibitors could cause steric hindrance that 
interferes with the catalytic domain. Alternatively, the sequence that binds to protein 4.1 
and spectrin, which does not fall within the kinase domain spanning amino acids 2 079-
2 354, could be blocked so that the enzyme is prevented from docking with its 
phosphorylation target. Its probable function in invasion and growth of the erythrocytic 
stages of the parasite means that inhibiting this enzyme could prevent this stage from 
occurring and would thereby result in parasite death. Experiments with casein kinase 
inhibitors will determine whether there is parasite protein specificity of the drug, even in 
the presence of human orthologues. Gene knockout and/or knockdown experiments 
would also be required to validate this PK as a drug target. 
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4.2) PFE1400c – A putative AP-1 β subunit  
 
The function of the AP-1 β subunit – which forms a vital part of the AP-1 complex – has 
been well characterised in mammals (Ohno, 2006), where it induces the assembly of 
clathrin triskelions to form a latticed coat that supports the formation of vesicles for 
transporting proteins within cells (Brodsky et al, 2001). The putative function of the AP-1 
β subunit in malaria transport pathways is deemed to be the same as that for mammals, 
although it has not been proven (Cooke et al, 2004).  
 
Heldwein et al (2004) are the only group to have determined the crystal structure of AP-1 
complexes, specifically in Rattus norvegicus and Mus musculus, but due to the highly 
conserved nature of these proteins, the structure is probably similar in most eukaryotes. 
As a case in point, the AP-1 complex β subunit of R. norvegicus used by Heldwein et al 
(2004) has 61 percent identity and 78 percent positivity to the P. falciparum putative AP-
1 complex β subunit. All AP-1 complexes consist of four subunits – two large adaptin 
subunits designated γ-1 and β-1, a medium subunit termed μ-1 and a small subunit called 
σ-1 (Heldwein et al, 2004) (Figure 58).  
 
Figure 58. Structure of the AP-1 core. (Heldwein et al, 2004) 
(a) Ribbon representation. (b) Ribbon with molecular surface representation 
Colour coding: red - β-1 subunit; blue - γ-1 subunit; yellow/orange - μ-1C subunit; green 
- μ-1N subunit; magenta – σ-1 subunit. 
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This model indicates that the β subunit consists almost exclusively of alpha helices. This 
aligns with the putative 3D model obtained for the P. falciparum AP1 N-terminal (Figure 
54) and with its predicted secondary structure (Appendix, section 5.10, figure 72). 
However, no beta sheets can be seen in the Heldwein model (Figure 58), which is 
contrary to the putative 3D model (Figure 44) and secondary structure predictions 
(Appendix, section 5.10, figure 71) for the AP1 C-terminal of the β subunit. However, the 
3D model did not accurately predict the structure of the P. falciparum AP1 C-terminal 
due to the low sequence identity between the target-template pair, so a discrepancy is 
expected. Unfortunately, the Heldwein 3D model is not available in the Swiss Model 
Template Library, but one would assume that it would come up as the best match since it 
has higher sequence homology with the parasite transport protein than what the human 
AP-2 proteins have (sections 3.6.8.1 and 3.7.8.1).  
 
The P. falciparum AP1 C-terminal and the AP1 N-terminal domain that were subcloned 
in the current project constitute two important areas of the β subunit (Figure 58, red 
subunit). In eukaryotes, the AP1 C-terminal domain is found at the C-terminal end of the 
β subunit and recruits accessory proteins that modulate clathrin binding and 
polymerisation. The AP1 N-terminal domain is proposed to interact with a uniform area 
of the clathrin-coated vesicles. Together, the β subunit as a whole triggers the assembly 
of clathrin triskelions into an extensive latticed-coat which stabilises vesicles for the 
transport of cargo from the TGN to endosomes (Wang et al, 1995).  
 
The AP-1 heterotetramer is further grouped into a core and an appendage section. The 
core consists of the trunk (the N-terminals of the two large subunits, γ-1 and β-1) along 
with the μ-1 and σ-1 subunits. The appendages are the C-terminal regions of the two large 
subunits, which are attached to the core by a hinge segment (Heldwein et al, 2004) 
(Figure 59). 
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 Figure 59. Proposed AP-1 subunit organisation (Adapted from Heldwein et al, 2004) 
The proposed AP-1 subunit organisation is based on the structure of AP-2. AP-1 is a 
heterotetramer composed of 4 separate chains or subunits that assemble to form the 
functional AP complex. The trunk region consists of the N-terminals of the large γ-1 and 
β-1 subunits. The appendage region consists of the C-terminals of the large γ-1 and β-1 
subunits. The core consists of the trunk region and the μ-1 and σ-1 subunits. The 
appendage region is joined to the core by a hinge region.  
 
The trunk is composed almost entirely of 14 consecutive α-zigzags – known as HEAT 
elements – that are twisted to form a boomerang-like structure (Figure 58a, red domain). 
This is consistent with the secondary structure prediction for the N-terminal (Appendix, 
section 5.10, figure 72). This region acts as a point of contact for the small σ-1 and 
medium μ-1 subunits, thus stabilising the assembly of the four chains. According to 
Heldewein et al (2004), the heterotetramer will only be marginally stable if the trunk 
region is not able to interact with the other subunits, indicating that the N-terminal 
regions of the γ-1and β-1 subunits are vital for AP-1 complex stability. 
 
Paralogues of the P. falciparum β subunit were found in five other Plasmodium species, 
with P. vivax and P. knowlesi putative β subunits sharing the highest sequence homology. 
The T. gondii and H. sapiens β subunits also had high sequence homology to the P. 
falciparum protein, and interestingly shared similar levels of identity and positivity. This 
indicates extreme conservation of this protein among these eukaryotes. Overall, the P. 
falciparum AP1 N-terminal region had most homology with all proteins that were 
detected using the BLAST. This shows that the larger AP1 N-terminal region is highly 
conserved in eukaryotes, while the small C-terminal is less so. This difference in levels of 
conservation could be attributed to the function of each of the terminals.  
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The N-terminal interacts with a uniform area of clathrin-coated vesicles, which is 
probably common in most eukaryotes as clathrin is a ubiquitous structural protein. The C-
terminal, on the other hand, is proposed to interact with various accessory proteins that 
modulate AP complex function and these accessory proteins could be quite varied in type 
and structure in different species. 
 
4.2.1) PFE1400c protein and mRNA expression 
 
According to mass spectrometry-based evidence, the expression of PFE1400c protein is 
high during all life-cycle stages (Florens et al, 2002). This is supported by the photo-
lithographic oligo array data for PFE1400c mRNA expression (Figure 60) determined by 
Le Roch et al (2003). Marginally higher levels were detected during the early schizont 
(ES) stage, and lower expression occurred during the gametocyte (G) stage, but generally 
the expression levels remain similar and relatively high when compared to that of the PK 
(Section 4.1.1). This is expected, as trafficking of proteins occurs throughout the parasite 
life cycle and one trafficking molecule is physically needed to transport protein 
molecules. 
 
 
  Life stage 
Figure 60. Intraerythrocytic P. falciparum 3D7 photolithographic oligo array data for 
PFE1400c mRNA expression (Le Roch et al, 2003) 
x-axis: Plasmodium developmental stages* synchronized by sorbitol and temperature. 
Data for gametocyte sample corresponds to synchronization by sorbitol only, and for 
sporozoite sample represents average of two replicates. 
y-axis: Absolute mRNA expression levels  
Developmental stages: ER = Early Rings; LR = Late Rings; ET = Early Trophozoites; 
LT = Late Trophozoites; ES = Early Schizonts; LS = Late Schizonts; M = Merozoites; 
S = Sporozoites; G = Gametocytes 
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4.2.2) Recombinant PFE1400c expression in E. coli 
 
The AP1 C-terminal was expressed in soluble form despite the predicted insolubility of 
56.9 percent. The expression of 36 additional amino acids – due to the alternative splicing 
of the 108bp intron – increased the molecular weight from 53.2kD to 56.8kD, and the pI 
from 5.4 to 5.81. The change in the pI would probably not have affected the expression of 
the sequence as the new value still falls within the range of 3.45 to 6.8 which is 
associated with optimal expression of P. falciparum proteins (Mehlin et al, 2006). The 
inclusion of the 108bp making up the intron between exon 5 and 6 of gene PFE1400c is 
due to alternative splicing, which is a novel finding for this gene as PlasmoDB makes no 
mention of parasite AP-1 β-subunit isoforms. Alternative splicing is known to occur in P. 
falciparum pre-mRNA transcripts (Knapp et al, 1991; Singh et al, 2004). Consensus 
splice sites for P. falciparum have currently not been determined (PlasmoDB, 2008), and 
the consensus sequences for RNA splicing in higher eukaryotes (Alberts et al, 1994) were 
not found in the 108bp insert (Figure 61). 
 
AGAGAGTATATTAATGGCTGTAAGCCCTATGGTTATAACATCAGACATGTTGATAAAACGAATGAAAATTTT
TAATATTTCTTTAATAGCTCGTAGAAATGTAAATAATATG 
 
Figure 61. Exon/intron boundary sequences of PFE1400c intron 5  
The 108bp insert (red) comprising the intron between exons 5 and 6 in PFE1400c may 
have been retained in the final mRNA due to the mechanism of alternative splicing. In 
higher eukaryotes, the consensus sequence for the 5’ splice site, known as the donor site, 
is AAG or CAG on the 3’ end of the first exon and an invariant GT dinucleotide on the 
intron. These consensus sequences were not found in PFE1400c exon 5 (blue nucleotides) 
or the 5’ end of the intron (underlined). In higher eukaryotes the consensus sequence for 
the 3’ splice site, known as the acceptor site, begins with an invariant AG dinucleotide at 
the intron 3’ end, which was not found in the above insert (underlined) followed by an A 
or a G (green) at the 5’ end of the second exon, as seen in the above insert.    
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The exon/intron boundaries in the rest of the P. falciparum AP1 C-terminal are shown in 
table 25. 
 
TABLE 25: Donor and acceptor sites in non-alternatively spliced exon/intron boundaries  
         of P. falciparum AP1 C-terminal 
 
DONOR SITE ACCEPTOR SITE 
Exon 1, 3’ end 
ACA 
Intron 1, 5’ end 
GT 
Intron 1, 3’ end 
AG 
Exon 2, 5’ end 
G 
Exon 2, 3’ end 
TTC 
Intron 2, 5’ end 
GT 
Intron 2, 3’ end 
AG 
Exon 3, 5’ end 
A 
Exon 3, 3’ end 
AAG 
Intron 3, 5’ end 
GT 
Intron 3, 3’ end 
AG 
Exon 4, 5’ end 
A 
Exon 4, 3’ end 
CAA 
Intron 4, 5’ end 
GT 
Intron 4, 3’ end 
AG 
Exon 5, 5’ end 
G 
Exon 6, 3’ end 
GTG 
Intron 6, 5’ end 
GT 
Intron 6, 3’ end 
AG 
Exon 7, 5’ end 
A 
 
The exon donor sites are all different and do not conform to the eukaryotic consensus 
sequences. However, all the other sites contain the eukaryotic invariant residues or the 
A/G consensus nucleotides. The fact that intron 5 (Figure 61) does not contain the 
invariant donor and acceptor nucleotides indicates why the spliceosome did not recognise 
it and why the 108bp insert was retained in the mRNA. 
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There are a number of speculations as to why alternative splicing occurs in eukaryotes 
(Kriventseva et al, 2003). It has been proposed that a greater level of efficiency is attained 
because genetic information can be stored more economically. Multiple proteins are 
encoded by a single DNA sequence that could have only coded for a single protein. The 
mechanism of alternative splicing enables the evolution of new proteins without altering 
the original DNA sequence, which not only means faster evolution of proteins, but also 
prevents loss of integrity of established proteins (Kriventseva et al, 2003).  
 
The importance of this mechanism for P. falciparum is evident when the complex life 
cycle of the parasite is considered. The parasite is exposed to the immune systems of two 
organisms, the mosquito and the human, making the fast evolution of proteins in order to 
avoid detection an essential survival strategy. The parasite also needs to adapt quickly to 
new environmental factors –such as drugs, and the difference in mosquito and human 
cells – in order to survive.  
 
The AP1 N-terminal was predicted as the most soluble (49.6 percent) of the three 
domains analysed in this study, but despite this the protein was expressed in insoluble 
inclusion bodies. Interestingly, even though the pI of 6.3 was within the soluble 
expression range of 3.45 and 6.8 (Mehlin et al, 2006), the AP1 N-terminal protein was 
insoluble. It is possible that the size of the protein played a role in its insoluble status; the 
recombinant AP1 N-terminal protein contained the longest of all the expressed P. 
falciparum domains at 618 amino acids, compared to the AP1 C-terminal with 244 amino 
acids and the PK with 503 amino acids. However, the latter two had GST tags of an 
additional 220 amino acids, while the AP1 N-terminal had only a 6 amino acid His tag, 
along with a vector sequence of 9 amino acids. This resulted in the recombinant AP1 N-
terminal not being the largest protein in terms of molecular weight. However, while 
larger protein size has been correlated with decreased expression – with only 20 percent 
of proteins >60kD being expressed – no relationship was found between gene/protein size 
and solubility (Mehlin et al, 2006). The results obtained in the current study are therefore 
not consistent with the general conclusion of Mehlin et al (2006) as the AP1 N-terminal 
was expressed despite its size (72.2kD), but it was insoluble.  
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This highlights the fact that recombinant expression of each P. falciparum protein cannot 
be accurately predicted and remains a matter of trial and error. Numerous other factors 
could have influenced the solubility of the AP1 N-terminal. The presence of the GST tag 
could have influenced protein solubility, as the two proteins with this tag were soluble. 
However, estimations of solubility for the AP1 N-terminal were higher with the His tag 
when compared to the GST tag. This brings the accuracy of the recombinant protein 
solubility prediction tool into question, and indicates that it can only be used as a rough 
guide. Alternatively, more complex folding may have been required for the AP1 N-
terminal protein secondary structure, and the prokaryotic environment of E. coli does not 
contain the chaperones necessary for this process. The presence of eukaryotic protein 
chaperones could better facilitate the folding and subsequent soluble expression of the 
parasite protein (Sorenson and Mortenson, 2005).  
 
4.2.3) Drug-target potential of PFE1400c 
 
Molecules involved in protein trafficking within the parasite and pRBC offer novel 
targets for therapeutic intervention. By targeting these transport molecules, entire groups 
of cargo proteins could be prevented from reaching their destination and carrying out 
their function (Phelps et al, 2003). Because of the specificity of transport, therapies that 
interfere with the attachment of cargo to APs would have minimal cross-reactivity 
(Phelps et al, 2003). Based on the function of the AP1 C-terminal domain, it can be 
inferred that the knockout of this region would result in a cessation of clathrin binding 
and subsequent polymerisation to form a coat. CCVs would be incomplete, lacking the 
outer protein coat, and transport of associated cargo proteins would halt. If inhibition of 
this protein could be achieved in P. falciparum, the parasite would perish as vital proteins 
would be left stranded within the TGN, unable to reach their target destination and carry 
out their effector function.  
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The AP1 N-terminal domain that was subcloned and expressed in this project forms a 
significant part of the trunk region that stabilises the interaction of the subunits making 
up the AP-1 complex; therefore, if this region could be knocked out or blocked in some 
way, the AP-1 molecule would have decreased stability and may not be able to carry out 
its function in formation of clathrin-coated vesicles. This potential halt in the transport of 
proteins from the TGN to other endosomes would stop the development of erythrocytic–
stage P. falciparum. For example, the areas of the Golgi membrane containing RAMA 
would be prevented from budding and forming vesicles (Topolska et al, 2003). If this 
transport is inhibited, the biogenesis of the rhoptries may also be inhibited. A parasite 
lacking rhoptries would be unable to invade subsequent erythrocytes and would be 
sequestered by the host immune system. 
 
Studies involving double knockout mice lacking the μ-1subunit gene and γ-1 subunit 
gene have shown that the animals die early in their embryonic development, as the 
inability of the molecules to form a stable tetramer causes the degradation of the 
remaining subunits. The large γ-1 subunit was found to be particularly important, as no 
AP-1 subunits were found in the knockout mice at all, whereas the μ-1 knockout mice 
showed non-functional trimeric compounds consisting of the remaining subunits (Hinners 
& Tooze, 2003). It is inferred from these data that the other large subunit, namely the β 
subunit, is as critical to the AP-1 complex as the γ-1 subunit is. This provides 
confirmation that knocking-out or inactivating one of the vital large subunits could 
prevent the trafficking of key molecules within the parasite and lead to the eradication of 
infective erythrocytic-stage malaria parasites, making the AP-1 complex an attractive 
drug target.  
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Targeting P. falciparum invasion proteins is difficult because they are highly redundant. 
By inhibiting the protein trafficking complex, transport of invasion proteins to the 
micronemes and rhoptries would be blocked and they would be unable to reach their final 
destination and carry out their function. Thus invasion of host RBC by these defective 
merozoites would be prevented. A drawback is the high sequence identity of the human 
AP-1 β1 subunit (46 percent) with the parasite protein sequence, which could make it 
difficult to target the latter without harming the host. However, the C-terminal has much 
lower identity (28 percent) and could be exclusively targeted to prevent cross-reactivity. 
 
4.3) Future studies 
 
A number of experiments could be done to further characterise the structure and function 
of the P. falciparum proteins examined in the current study. Gene knockdown and/or 
knockout studies could be carried out to elucidate the function of the proteins and 
determine whether they are necessary for parasite survival. DNA microarrays could be 
used on knockout/knockdown parasites to see which genes are up- or downregulated and 
thereby infer which functional pathways they are involved in. Microarrays could also 
confirm the expression profile of the genes during each of the developmental stages, 
while protein arrays could indicate additional PPIs. Localisation studies using 
immunofluorescence and confocal microscopy may indicate the sites where the proteins 
reside within the parasite or pRBC, and co-localisation studies – for example with protein 
4.1, spectrin and the parasite PK; or with clathrin and the AP1 N- and C-terminals – 
could indicate which molecules the proteins interact with. The technique of two-hybrid 
screening could be utilised to determine which proteins associate with the AP1 N- and C-
terminal domains. The AP1 sequences could be used as the bait proteins to identify 
binding partners from a parasite lysate of prey proteins (Fields & Song, 1989). Kinetic 
studies would specify the optimum pH and temperature for PK activity, while doing a 
kinase assay with purified protein 4.1 and spectrin would determine whether they are 
phosphorylation targets for the PK in vitro. 
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Measuring the effect of the casein kinase inhibitors used in the Chishti et al study (1994) 
on the PK would provide some evidence on whether the enzyme is the same as that 
described by these authors, as hypothesised in the present study. To determine whether 
the enzyme functions as a MAPK kinase, inhibition by PD 98059 and U0126 -  which 
prevent activation of classical MAPK kinases - could be carried out and measured 
(Dudley et al, 1995; Favata et al, 1998). Additionally, including further negative controls 
in the kinase assay would ensure that the observed enzyme activity was not carried out by 
a co-purified E. coli protein. A negative control could be generated via site-directed 
mutagenesis to eradicate the enzyme activity. 
 
To further elucidate the 3D and secondary structure of the molecules, protein 
crystallisation could be performed. For some of these studies – especially the protein 
array, protein crystallisation and kinetic experiments – increased yields and solubility of 
the proteins are needed. 
 
A number of methods could be utilised to improve the expression of soluble recombinant 
P. falciparum proteins in future studies (Birkholtz et al, 2008). A method for preventing 
the formation of insoluble inclusion bodies – which are loosely aggregated folding 
intermediates of the recombinant protein – is the co-expression of protein chaperones 
(Sorenson and Mortenson, 2005). While the expression of these plasmid-encoded 
chaperones may not guarantee improved folding and solubility of the recombinant 
protein, they may minimise the level of protein aggregation, making it easier for native 
protein to be prepared from inclusion bodies (Sorenson and Mortenson, 2005). This 
process may prove effective for the AP1 N-terminal, as solubilisation and refolding of the 
recombinant protein – using guanidine hydrochloride and dialysis against a native buffer 
– was not successful. This result may have been due to the high initial concentration of 
guanidine hydrochloride. 
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According to Singh and Panda (2005), the use of extremely high initial concentrations of 
chaotropic agents – like urea and guanidine hydrochloride – increases the rate of protein 
aggregation. These agents cause areas of hydrophobic amino acids to be exposed on the 
protein through the production of random coil structures. The intermolecular interactions 
between the hydrophobic regions on protein molecules compete with intramolecular 
bonds and cause aggregation of the molecules. To prevent the exposure of hydrophobic 
patches and subsequent protein aggregation, lower initial concentrations of chaotropic 
agents can be coupled with a pH shock during refolding (Singh & Panda, 2005). 
 
Singh and Panda (2005) found that the use of 2M urea, with a refolding buffer pH that 
was more alkaline than the pI of the protein, destabilised unwanted intermolecular 
interactions. In the case of the AP1 N-terminal, the pH of the refolding buffer was 8, 
whereas the pI of the recombinant protein is 6.3, which seems to be a viable combination. 
However, an initial concentration of 6M guanidine hydrochloride was used for refolding 
which could have prevented the recovery of bioactive recombinant protein.  
 
Another factor that could have affected the expression of the recombinant PFE1400c 
AP1 N-terminal is codon bias (Baneyx, 1999). Due to the different codon usage of the 
parasite to that of the E. coli host, recombinant protein expression could have been 
stalled. Rare codons cause mRNA and plasmid instability via ribosome stalling which 
results in slow, error-prone translation and can completely inhibit protein synthesis and 
host cell growth (Zahn, 1996). An additional setback to expression is that the levels of 
tRNAs to their associated rare codons remain very low in E. coli cells (Baneyx, 1999).  
 
There are two strategies for preventing the unwanted effects of codon bias. The first is to 
use a plasmid that encodes rare tRNAs that are lacking in the usual E. coli tRNA pool. 
This approach was used in the current study, but did not facilitate the expression of the 
AP1 N-terminal. This finding is supported by several studies that have shown 
inconsistent results when employing this method (Hannig & Makrides, 1998).  
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The other strategy involves codon optimisation (Zhou et al, 2004). This process involves 
the production of a synthetic gene by changing the native codons to those most 
commonly used by E. coli cells, without changing the amino acid composition of the 
translated product. In a study on recombinant malaria candidate vaccine proteins by Zhou 
et al (2004), the use of a codon optimised gene was found to increase the expression level 
threefold, as well as promoting better host cell growth. While this method has been 
successful for the expression of several P. falciparum proteins – namely dihydrofolate 
reductase, merozoite surface protein-1 and serine repeat antigen – the production of the 
synthetic gene tends to be a costly process and is not always successful (Zhou et al, 
2004).  
 
Alternatively, the process of codon harmonisation can be utilised to increase the 
heterologous P. falciparum protein expression in E. coli (Angov et al, 2008). The method 
involves determining the codon usage frequencies of both P. falciparum and E.coli using 
a bioinformatic algorithm and then substituting the native codons with synonymous ones 
having analogous usage frequencies in the host (Angov et al, 2008). Genes that were 
recoded in this manner had expression levels 4 to 1 000 times greater than the original 
genes (Angov et al, 2008).  
 
The use of more advanced, eukaryotic expression systems would also increase the 
probability of successful recombinant P. falciparum protein expression. The use of yeast 
cells, or a baculovirus system utilising insect cells, could result in improved solubility due 
to the greater similarity in the microenvironment between the eukaryotic organisms 
(Possee, 1997). Different tags, like maltose binding protein (MBP) (New England 
Biolabs, www.neb.com) or NusA (Novagen, www.emdbiosciences.com), could also be 
incorporated and may result in improved solubility of the recombinant proteins.  
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4.4) Conclusion 
 
To conclude, the three proteins analysed in this study present varying promise as drug 
targets. The PK has high sequence similarity with a human enzyme in the catalytic kinase 
domain, but areas in the proximity of the active site could be targeted to interfere with its 
function, for example, by steric hindrance or by blocking the binding of ATP. The human 
kinase is also only 304aa in length compared to the large 2 485aa parasite PK, so it is 
hypothesised that the domains not present in the former could be inhibited in the latter 
with no toxic side effects for the host. However, further elucidation of the function of 
these domains is needed in order to substantiate this claim. 
 
In the case of the P. falciparum AP-1 β subunit, the N-terminal is very well conserved in 
eukaryotic organisms and high homology to its human counterpart renders it unsuitable 
as a drug target. However, the smaller C-terminal shows promise, as it shares minimal 
identity with the human trafficking protein.  
  
For future studies with these P. falciparum proteins, the expression of soluble 
recombinant AP1 N-terminal and increased yield of AP1 C-terminal and PK could be 
most economically achieved through the use of a eukaryotic expression system. If 
inclusion bodies are still present in the case of the AP1 N-terminal, mild solubilisation 
during the refolding stage could aid in recovery of active protein. Codon harmonisation 
and optimisation are more involved and more expensive processes, which could be 
utilised at a later stage if the eukaryotic expression system fails. The increased recovery 
of soluble protein will facilitate future functional studies and attempts at crystallisation.  
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CHAPTER 5 
APPENDIX 
 
All sterile solutions were filtered using a Millipore syringe-driven filter unit (0.22µm), 
unless stated otherwise. 
 
5.1) Malaria culturing techniques 
  
 Sterile incomplete medium 
 1x GIBCO™ RPMI Medium 1640 (Invitrogen, USA) with L-Glutamine and 
25mM HEPES 
 4g glucose 
 0.044g hypoxanthine 
 0.05g gentamycin 
 1L autoclaved Milli-Q water 
 Store in sterile Schott bottles at 4°C 
 
 Sterile complete medium 
 10% heat-inactivated AB plasma 
 5g NaHCO3 
 Make up to 100ml with incomplete medium 
 Store at 4°C and use within 5 days  
 
 Sterile 5% NaHCO3 
 2.5g NaHCO3 
 50ml autoclaved Milli-Q water 
 Store at 4°C 
 
 Sterile PBS (pH 7.2 – 7.4)  
8g NaCl 
0.2g KCl 
1.78g Na2HPO4.2H2O 
0.2g KH2PO4  
Make up to 1L using Milli-Q water 
Store at room temperature  
 
Sterile 12% NaCl  
12g NaCl 
100ml Milli-Q water 
Store at 4°C 
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Sterile 1.6% NaCl  
1.6g NaCl 
100ml Milli-Q water 
Store at 4°C 
 
Sterile 0.9% NaCl / 0.2% Glucose  
0.9g NaCl  
0.2g glucose 
100ml Milli-Q water 
Store at 4°C 
  
 PBS for freezing 
7.2g NaCl 
14.8g Na2HPO4.2H2O  
4.4g KH2PO4 
Make up to 1L with Milli-Q water 
Store at 4°C 
 
Sterile 60 % Glycerol solution 
40ml PBS for freezing 
60ml glycerol 
Decant into sterile tubes and store at -20°C until needed 
 
5.2) Reagents for DNA and RNA experiments 
 
PBS ( pH 7.2 - 7.4) 
8g NaCl 
0.2g KCl 
1.78g Na2HPO4.2H2O 
0.2g KH2PO4  
Make up to 1L using Milli-Q water 
 
5% Saponin in PBS 
0.05g saponin (USB Corporation, USA) 
1ml PBS 
 
Lysis Buffer 
Make up lysis buffer from stock solutions of 1M Tris-HCl and 0.5M EDTA: 
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1M Tris-HCl (pH 8.0) 
12.11g Tris 
Add 90ml Milli-Q water 
pH to 8.0 using HCl 
Make up to 100ml with Milli-Q water 
 
0.5M EDTA (pH 8.0) 
18.61g EDTA 
Add 90ml Milli-Q water 
pH to 8.0 using NaOH  
Make up to 100ml with Milli-Q water 
 
Making up 100ml lysis buffer from stock solutions: 
4ml of 1M Tris-HCl (final concentration 40mM) 
16ml of 0.5M EDTA (final concentration 80mM) 
2g SDS (final concentration 2%) 
Add 90ml Milli-Q water and check pH 8.0 
Adjust pH if necessary 
Make up to 100ml with Milli-Q water 
NB: Add 0.1mg/ml Proteinase-K just before use 
 
3M Sodium Acetate ( pH 5.2) 
24.61g sodium acetate 
Add 90ml Milli-Q water 
pH to 5.2 using HCl 
Make up to 100ml with Milli-Q water 
 
TE Buffer 
0.12g Tris 
0.037g EDTA 
Add 90ml Milli-Q water 
pH to 8.0 using HCl  
Make up to 100ml with Milli-Q water 
OR 
1ml of 1M Tris-HCl (pH 8.0) (final concentration 10mM) 
200µl of 0.5M EDTA (final concentration 1mM) 
Add 90ml Milli-Q water and check pH 8.0 
Adjust pH with HCl if necessary 
Make up to 100ml with Milli-Q water 
 
0.8% Agarose gel for DNA 
0.32g agarose 
40ml 1X TAE buffer 
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Dissolve in microwave 
Cool to about 60°C 
Add 3ul of 10ug/µl ethidium bromide 
Mix and pour 
Allow gel to set for 20-30 minutes at room temperature 
For RNA prepare 1% Agarose gel with 0.4g of agarose 
 
50x TAE buffer 
24.2g Tris 
10ml 0.5M EDTA 
5.71ml acetic acid 
Make up to 100ml with Milli-Q water 
 
1x TAE buffer 
20ml 50x TAE buffer 
Make up to 1L with Milli-Q water 
 
5.3) Reagents for sub-cloning experiments 
 
 Luria broth 
 10g BactoTM Tryptone (Becton Dickinson Biosciences, USA) 
 5g yeast extract (Oxoid, UK) 
 10g NaCl 
 10ml 1M Tris-HCl (pH 7.5) 
 Make up to 1L with Milli-Q water 
 Autoclave solution and cool 
  
Sterile 100mg/ml ampicillin 
1g ampicillin 
10ml Milli-Q water 
Store in 500ul aliquots at -20°C and use within 6 months 
 
Sterile 50mg/ml chloramphenicol 
0.5g chloramphenicol 
10ml Milli-Q water 
Store in 500ul aliquots at -20°C and use within 6 months 
 
Agar plates 
15g agar 
1L Luria broth 
Autoclave the solution and allow it to cool 
For DH5α cell cultures (Invitrogen, USA), add 100mg/ml ampicillin to a final 
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concentration of 100ug/ml. 
For Rossetta 2 (DE3) cell cultures (Novagen, USA), add 100mg/ml ampicillin to a 
final concentration of 100ug/ml and 50mg/ml chloramphenicol to a final 
concentration of 50ug/ml. 
 
Bacterial cell lysis buffer 
0.9g glucose 
0.37g EDTA 
2.5ml 1M Tris-HCl (pH 8.0) 
Make up to 100ml with autoclaved Milli-Q water 
Store at 4°C 
 
0.4M NaOH 
1.6g NaOH 
100ml autoclaved Milli-Q water 
Store at room temperature 
 
10% SDS 
1g SDS 
10ml autoclaved Milli-Q water 
Store at room temperature 
 
Fresh 0.2M NaOH/2% SDS solution 
5ml 0.4M NaOH 
200ul 10% SDS 
4.8ml Milli-Q water 
 
5M Potassium acetate 
49.075g potassium acetate 
100ml autoclaved Milli-Q water 
Store at 4°C 
 
5M Acetic acid 
29ml 17.4M acetic acid 
71ml autoclaved Milli-Q water 
Store at 4°C 
 
Fresh Potassium acetate (pH 4.8) 
2ml 5M potassium acetate 
4ml 5M acetic acid 
Mix by inversion 
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TE Buffer 
See section 5.2 
 
5.4) Reagents for protein experiments 
 
 5.4.1) Reagents for recombinant protein purification 
 
MagneGSTTM binding/wash buffer (pH 8.5) 
0.075g Na2HPO4.2H2O (4.2mM) 
0.035g KH2PO4 (2mM) 
2.92g NaCl (500mM) 
0.0745g KCl (10mM) 
Add 100ml Milli-Q water and check the pH 
 
1M Glutathione stock (pH 7.0-8.0) 
3.07g glutathione 
Add 9ml Milli-Q water and check the pH 
Adjust pH with HCl 
Make up to 10ml with Milli-Q water 
 
MagneGSTTM elution buffer 
1ml 1M Glutathione stock (pH 7.0-8.0) (final concentration 100mM) 
500ul 1M Tris-HCl (pH 8.0) (final concentration 50mM) 
8.5ml Milli-Q water 
Store at -20°C in 500µl aliquots 
 
0.5M sodium phosphate (pH 8.0) 
7.8g NaH2PO4.2H2O 
100ml Milli-Q water 
 
HIS-SelectTM equilibration/wash buffer 
10ml 0.5M sodium phosphate (final concentration 50mM) 
1.75g NaCl (0.3M) 
0.068g imidazole (10mM) 
90ml Milli-Q water 
 
HIS-SelectTM elution buffer 
10ml 0.5M sodium phosphate (final concentration 50mM) 
1.75g NaCl (0.3M) 
1.7g imidazole (250mM) 
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90ml Milli-Q water 
 
5.4.2) Reagents for SDS PAGE analysis of recombinant protein  
 
5x Suspension solution  
0.303g Tris (50mM) 
0.093g EDTA (5mM) 
2.5g SDS (5%) 
12.5g sucrose (25%) 
Add 40ml Milli-Q water. 
Adjust pH to 8.0 with HCl 
Make up volume to 50ml with Milli-Q water 
Store at room temperature 
 
Bromophenol blue solution 
0.25g sucrose 
0.05g Bromophenol blue 
Make up to 10ml with Milli-Q water and store at 4°C 
 
30% Acrylamide w/v 
30g acrylamide (Promega, USA) 
Make up to 100ml with Milli-Q water 
Store at 4°C in a dark bottle 
 
1% Bisacrylamide w/v 
1g bisacrylamide (Promega, USA) 
Make up to 100ml with Milli-Q water 
Store at 4°C in a dark bottle 
 
4x Stacking gel buffer (pH 6.8) 
12.12g Tris (0.5M) 
Add 180ml Milli-Q water and pH with HCl 
Make up to 200ml with Milli-Q water 
Store at 4°C 
 
4x Separating gel buffer (pH 8.8) 
18.17g Tris (1.5M) 
Make up to 90ml with Milli-Q water and pH with HCl 
Adjust volume to 100ml with Milli-Q water 
Store at 4°C 
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10% SDS 
1g SDS 
10ml Milli-Q water 
 
10% APS (Make fresh each time) 
0.1g APS 
1ml Milli-Q water 
 
Electrophoresis buffer 
3.03g Tris (0.125M) 
14.4g glycine (0.096mM) 
1g SDS (0.1%) 
Make up to 1L with Milli-Q water 
 
12% Separating gel for SDS-PAGE 
6ml 30% acrylamide 
1.6ml 1% bisacrylamide 
3.75ml 4x running gel buffer 
80µl 10% SDS 
3.5ml Milli-Q water 
100µl 10% APS 
7.5µl TEMED 
 
4% Stacking gel for SDS-PAGE 
1.3ml 30% acrylamide 
1ml 1% bisacrylamide 
2.5ml 4x stacking gel buffer 
20µl 10% SDS 
4.9ml Milli-Q water 
200µl 10% APS 
7.5µl TEMED 
 
0.05% Coomassie blue stain 
1g Coomassie blue R-250 (Merck, Germany) 
500ml Isopropanol 
200ml Acetic acid 
Make up to 2L with Milli-Q water 
 
1st Destain 
10% Acetic acid 
10% Methanol 
Add 200ml of acetic acid and 200ml of methanol to 1.6L of Milli-Q water 
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2nd Destain 
10% Acetic acid 
Add 200ml of acetic acid to 1.8L of Milli-Q water 
 
5.4.3) Reagents for immunoblot analysis of recombinant protein  
 
Transblot buffer 
6.06g Tris (25mM) 
28.8g glycine (192mM) 
Dissolve the reagents in 1.5L Milli-Q water 
Add 400ml methanol (20%) and adjust the final volume to 2L with Milli-Q water 
 
Ponceau S (Nitrocellulose membrane stain) 
700µl acetic acid 
9.3ml Milli-Q water 
0.1g Ponceau S (Sigma-Aldrich Inc, USA) 
 
TBS buffer (pH 7.5) 
6.06g Tris (25mM) 
9g NaCl (150mM) 
Add 900ml Milli-Q water 
Adjust to pH 7.5 with HCl 
Adjust to 1L with Milli-Q water 
 
0.5% Tween-TBS 
0.5ml Tween-20 (Sigma-Aldrich Inc, USA) 
1L TBS buffer (pH 7.5) 
 
3% BSA – Anti-GST  HRP conjugated blocking buffer 
0.75g BSA 
25ml TBS buffer (pH 7.5) 
 
Anti-GST HRP-conjugated antibody 
(1:100 000) 
0.5g BSA in 50ml TBS buffer (pH 7.5) 
0.5µl anti-GST HRP-conjugated antibody (Amersham Biosciences, UK) 
 
Anti-His HRP-conjugated blocking buffer (Qiagen, UK) 
0.1g Blocking Reagent  
20ml 1x Blocking Reagent Buffer (0.5% w/v) 
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Heat mixture to 70°C until dissolved 
Add 20µl Tween-20 (0.1% v/v) 
Allow to cool to room temperature before use 
 
Anti-His HRP-conjugated antibody 
(1:2 000) 
12.5µl anti-His HRP-conjugated antibody (Qiagen, UK) 
25ml anti-His HRP-conjugated blocking buffer 
 
Amido black stain 
1% amido black (AppliChem, Germany) 
10% methanol 
2% acetic acid 
88ml Milli-Q water 
Store at room temperature 
 
Amido black destain 
50% methanol 
7% acetic acid 
43ml Milli-Q water 
Store at room temperature 
 
5.4.4) Reagents for inclusion body experiments 
 
6M Guanidine HCl buffer 
14.32g guanidine HCl (6M) 
1.25ml 1M Tris pH 8.0 (final concentration 50mM) 
0.15g NaCl (100mM) 
0.093g EDTA (10mM) 
0.039g DTT (10mM) 
Make up to 25ml with Milli-Q water 
 
Refolding buffer stock 
100ml 1M Tris-HCl pH 8.0 (final concentration 200mM) 
0.93g EDTA (10mM) 
43.55g L-Arginine (1M) (Merck, Germany) 
Make up to 500ml with Milli-Q water 
Store at room temperature 
 
To make complete refolding buffer, add the following reagents fresh each time: 
0.00044g PMSF (0.1mM)  
0.0154g reduced glutathione (2mM) (Sigma-Aldrich Inc, USA) 
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0.0031g oxidised glutathione (0.2mM) (Sigma-Aldrich Inc, USA) 
Make up to 25ml with refolding buffer base 
Note: PMSF is soluble in aqueous solution to a concentration of 2mM; for 
concentrations >2mM, dissolve in an organic solvent (Price & Stevens, 2002). 
 
10mM DTT 
0.00154g DTT (Sigma-Aldrich Inc, USA) 
Make up to 1ml with Milli-Q water 
Make up fresh each time 
 
5.5) Reagents for PK assay  
  
 Kinase reaction mix 
 6µl 0.1M Tris-HCl pH 7.4 (final concentration 20mM) 
 6µl 0.1M MgCl2 (final concentration 20mM) 
0.6µl 0.1M MnCl2 (final concentration 2mM) 
3µl 0.1M β-glycerophosphate (final concentration 10mM)  
3µl 0.1M NaF (final concentration 10mM) (Calbiochem, Germany) 
3µl 0.1mM ATP (final concentration 10µM) (Novagen, USA) 
0.5µl 250µCi γ-[32P] ATP (final concentration 2.5µCi) (PerkinElmer, USA) 
0.5µl 4µg/µl casein (Merck, Germany) 
0.5µl 10µg/µl myelin basic protein (Sigma-Aldrich Inc, USA) 
1µl 10µg/µl histone protein 1 (Merck, Germany) 
Add 5.9µl of recombinant protein to result in a total volume of 30µl 
 
0.1M Tris-HCl stock (pH 7.4)  
0.1211g Tris 
9ml Milli-Q water 
pH to 7.4 with HCl 
Make up to 10ml with Milli-Q water 
Store at 4°C 
 
0.1M MgCl2.6H2O stock 
0.2033g MgCl2.6H2O  
10ml Milli-Q water 
Store at 4°C 
 
0.1M MnCl2.2H2O stock 
0.1618g MnCl2.2H2O  
10ml Milli-Q water 
Store at 4°C 
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0.1M NaF stock  
0.042g NaF 
10ml Milli-Q water 
Store at 4°C 
 
0.1M β-glycerophosphate stock 
0.3061g β-glycerophosphate (Calbiochem, Germany) 
10ml Milli-Q water 
Store at 4°C 
 
Gel drying solution 
4% glycerol 
20% ethanol 
76ml Milli-Q water 
 
5.6) Data for graphs  
 
TABLE 26: BSA standard curve data from Coomassie assay  
 
SAMPLE VOLUME 
(µl) 
AMOUNT 
(µg) 
A595 AVERAGE 
A595 
BSA Standard 1 1 2 0.033 0.0365 
Duplicate 1 1 2 0.04 
BSA Standard 2 2 4 0.085 0.0915 
Duplicate 2 2 4 0.098 
BSA Standard 3 4 8 0.205 0.207 
Duplicate 3 4 8 0.209 
BSA Standard 4 6 12 0.295 0.299 
Duplicate 4 6 12 0.303 
BSA Standard 5 8 16 0.386 0.4015 
Duplicate 5 8 16 0.417 
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5.7) Vector maps 
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5.8) Sequencing data 
 
   
         1 TCATTTCTGGGATTGTTCAGTCCCGACAACAGATGCTACCATATTGAGAC     50 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       102 TCATTTCTGGGATTGTTCAGTCCCGACAACAGATGCTACCATATTGAGAC    151 
 
        51 TGTGTTCTTTGATTTTTTCCAAATTTAAAGAAGAATATGATATGTCGTCT    100 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       152 TGTGTTCTTTGATTTTTTCCAAATTTAAAGAAGAATATGATATGTCGTCT    201 
 
       101 CTTTCTTTAGATATATTTATATTAAACGTATTCAAGGATCTACTATTTTC    150 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       202 CTTTCTTTAGATATATTTATATTAAACGTATTCAAGGATCTACTATTTTC    251 
 
       151 ATCATCTTTTAATTTAATTTCAAAAAAATCAAAATTTTCCCTTTTTAACT    200 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       252 ATCATCTTTTAATTTAATTTCAAAAAAATCAAAATTTTCCCTTTTTAACT    301 
 
       201 GTTCAAAGAACATTTCTGCATCACAGGATTTGGAACTGATCATTTTATTT    250 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       302 GTTCAAAGAACATTTCTGCATCACAGGATTTGGAACTGATCATTTTATTT    351 
 
       251 GGTTTTTTTTTTTTATTCTTATCATTGAAGAAAAAAAGGTTCTTAAAAAA    300 
           || ||||||||||||||||||||||||||.|||||||||||||.|||||| 
       352 GG-TTTTTTTTTTTATTCTTATCATTGAARAAAAAAAGGTTCTWAAAAAA    400 
 
       301 ATTTCGGAAGATATTTGTTTTACCTTTACCATTATATATTTTTAATATAT    350 
           ||||||.||.||.||||||||.|||||.||||||||||||||.||.|||| 
       401 ATTTCGRAARATWTTTGTTTTMCCTTTMCCATTATATATTTTWAAWATAT    450 
 
       351 CTCTTATTTCATATATAGAACTAGGTTTCTTTTTAATATACCTCTTTTTA    400 
           |.||.||||||.|.|||.||||.||||||||||.||||..|||||||||| 
       451 CYCTWATTTCAWAWATARAACTRGGTTTCTTTTWAATAWMCCTCTTTTTA    500 
 
       401 ATCAAAAATTTATGATTTAATAAATCTTTCACATTTCCTCTGTTCTCAGG    450 
           |.||||||||||.|||||||||||.|||.||||||||||||||||||||| 
       501 AYCAAAAATTTAKGATTTAATAAAYCTTYCACATTTCCTCTGTTCTCAGG    550 
 
       451 TTTCTTTTGTAAACACTTCTCAACAAAATAACATAAGTGTTTACTATATC    500 
           ||||||||||||||.||||||||||||||||||||||.||||||||||.| 
       551 TTTCTTTTGTAAACMCTTCTCAACAAAATAACATAAGKGTTTACTATAYC    600 
 
       501 CTTCTGTTATGTTAATTTTTGGTGATGAATTAATTATGGTTTTTATATAA    550 
           |||||||||||||||||||.||.|||.||||||||||||||||||||||| 
       601 CTTCTGTTATGTTAATTTTKGGRGATRAATTAATTATGGTTTTTATATAA    650 
 
       551 TTTTCAAATGATTGATTTCTTTTCCATGGTAAGGTACATAAAACAATTTC    600 
           |||||||||||||||||||||||||||||.|||||||||||||||||||| 
       651 TTTTCAAATGATTGATTTCTTTTCCATGGGAAGGTACATAAAACAATTTC    700 
 
       601 ATATATTGTAATACCCAATGACCATATATCAGATGAACAATCATAATTAG    650 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       701 ATATATTGTAATACCCAATGACCATATATCAGATGAACAATCATAATTAG    750 
 
       651 TTCTCATCAA-TATTTCAGGTGATATATAATATATAGTACCCACTAATTC    699 
           |||||||||| ..|||||||.|||||||||||||||||.||||||||||| 
       751 TTCTCATCAAWWWTTTCAGGKGATATATAATATATAGTMCCCACTAATTC    800 
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       700 TTTAGACTGATCACTATTTTTCAATTCTTCACAAGAACCAAAATCAATTA    749 
           |||||||||||||||||||||||||||||||||||||||||||||||||. 
       801 TTTAGACTGATCACTATTTTTCAATTCTTCACAAGAACCAAAATCAATTW    850 
 
       750 TCTTAGCTATACCATCTTTGGAAAGAACGATATTTGTTGGTTTTATATCT    799 
           ||||||||||||||||||||||||||||.||||||| ||||||||. ||| 
       851 TCTTAGCTATACCATCTTTGGAAAGAACRATATTTG-TGGTTTTAW-TCT    898 
 
       800 CTATGTATAAGTGGTGAACTACATTCATTATGTAAATAATTTAAACCATT    849 
           ||.||||| ||.||||||||||| ||||||||| |||||||||||||||| 
       899 CTWTGTAT-AGKGGTGAACTACA-TCATTATGT-AATAATTTAAACCATT    945 
 
       850 TAATACATCATCTAAGATATATA-CTAAAAGATCTTCTGATATTCTACCA    898 
           .|.   .||||||||||.   || |||||||| ||||||| ||||.||   
       946 AAT---MTCATCTAAGAW---TAWCTAAAAGA-CTTCTGA-ATTCWAC--    985 
 
       899 TAATTTTTATATAAATCATATAATGTTCCTCCTGATAAATATTCACACAC    948 
              .|.||.|||||||||.   ||||  |||    |.||.|||||||||  
       986 ---ATATTTTATAAATCAW---ATGT--CTC----TGAAAATTCACACA-   1022 
       949 AATAACTAAATAACAAGGAGGCCAAAAAAAAGATTCGAAATATTTTACTA    998 
              .||||   .|||.|  .||     |||||||.||||     ||.||| 
      1023 ---TACTA---TACATG--AGC-----AAAAGATCCGAA-----TTTCTA   1054 
 
       999 CATTTGGATGTTCACACATTTTTAAAAAATTTACTTCTCTCAAAATGTTT   1048 
           |||..|     ||   .|||..||              |||..|.|     
      1055 CATGAG-----TC---MATTAATA--------------CTCYGAGT----   1078 
 
      1049 TTTAAACTATTCTTTTTACTTAAATAT   1075 
               ||||.|.||.||..  ||||..| 
      1079 ----AACTCTACTATTAG--TAAACCT   1099 
 
Figure 62. Alignment of PFB0150c DNA sequences from 3’ sequencing 
The sequence obtained from subcloning (red) was aligned with the original 
sequence obtained from the PlasmoDB database (blue). The underlined sections 
indicate the reverse primer position 5’-TCA TTT CTG GGA TTG TTC AGT -3’. 
Key to ambiguous bases: W = T and A overlap in sequence; M = multiple overlap 
of peaks in sequence; R = A and G overlap; Y = C and T overlap. A dot between 
base pairs indicates a non-alignment, while a dash indicates a missing base. 
 
 
       627 ACTTTTAAATGCTATTAATGAATGTGTAGAATGGGGACAAGTTTTTATTT    676 
           |||||  ||||||||| ||||   |||..||||..|.|.          | 
         1 ACTTT--AATGCTATT-ATGA---TGTGAAATGCAGTCC----------T     34 
 
       677 TAGATGCATTAGTTTTATATGAACCTAAAACTAGTAAAGATGCTGAACGT    726 
           |||||||| ||||    |||||.|   .||||||| ||||||||| |||  
        35 TAGATGCA-TAGT----TATGATC---TAACTAGT-AAGATGCTG-ACG-     73 
 
       727 GTTTTAGAAAGAATATTACCAAGATTATCACATGCTAATTCAGCAGTAGT    776 
              ||||||||||||     .||| ||||||||||| ||||  ||||||| 
        74 ---TTAGAAAGAATA-----CAGA-TATCACATGCT-ATTC--CAGTAGT    111 
 
       777 TCTATCATCTATTAAAGTTATCTTATGCTTATTAGATAAAATCAATGATA    826 
           ||||||||||| ||||| |||||||||||  .||||||||||| |||||| 
       112 TCTATCATCTA-TAAAG-TATCTTATGCT--ATAGATAAAATC-ATGATA    156 
 
176 
 
       827 AAGAATTTATTAAAAATGTACATAAGAAATTAAGCCCATCTTTAGTCACA    876 
           ||||||   |..|||||||||||||| ||||||||||||| ||||||||| 
       157 AAGAAT---TATAAAATGTACATAAG-AATTAAGCCCATC-TTAGTCACA    201 
 
       877 CTTTTATCTGCGGAACCAGAAATTCAATATATTGCATTAAGAAATATTAA    926 
           ||||..  ||||||||||||||||||||||| |||||||||||||||||| 
       202 CTTTAT--TGCGGAACCAGAAATTCAATATA-TGCATTAAGAAATATTAA    248 
 
       927 TTTAATAACACAGAAATTACCCAACATGCTCTCTGATAAAATCAATATGT    976 
           |||||||||||||||||||||||||||||||||||||||||||||||||  
       249 TTTAATAACACAGAAATTACCCAACATGCTCTCTGATAAAATCAATATG-    297 
 
       977 TTTTCTGTAAATATAATGAACCTGCTTATGTAAAAATGGAAAAACTTGAT   1026 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       298 TTTTCTGTAAATATAATGAACCTGCTTATGTAAAAATGGAAAAACTTGAT    347 
 
      1027 ATTATTATAAGACTTGTATCAGATAAAAATGTAGACCTTGTTCTATATGA   1076 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       348 ATTATTATAAGACTTGTATCAGATAAAAATGTAGACCTTGTTCTATATGA    397 
 
      1077 ATTAAAAGAATATTCTACAGAAGTAGATGTCGAATTTGTTAAAAAAAGTG   1126 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       398 ATTAAAAGAATATTCTACAGAAGTAGATGTCGAATTTGTTAAAAAAAGTG    447 
 
      1127 TAAGAGCTATAGGTAGCTGTGCAATAAAATTACCACAATCAAGTGAAAAA   1176 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       448 TAAGAGCTATAGGTAGCTGTGCAATAAAATTACCACAATCAAGTGAAAAA    497 
 
      1177 TGTATTAATATATTATTAGATTTAATAGATACCAAAATTAATTATGTTAT   1226 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       498 TGTATTAATATATTATTAGATTTAATAGATACCAAAATTAATTATGTTAT    547 
 
      1227 ACAAGAATGTATAGTTGTAATTAAAGATATTTTTAGAAAATATCCAAATA   1276 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       548 ACAAGAATGTATAGTTGTAATTAAAGATATTTTTAGAAAATATCCAAATA    597 
 
      1277 AATATGAAAGTATAATAACCATTCTATGTGAAAATCTAGAATCTTTAGAT   1326 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       598 AATATGAAAGTATAATAACCATTCTATGTGAAAATCTAGAATCTTTAGAT    647 
 
      1327 GAATCAAATGCAAAAGCATCCTTAATATGGATAATAGGAGAATATGTAGA   1376 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       648 GAATCAAATGCAAAAGCATCCTTAATATGGATAATAGGAGAATATGTAGA    697 
 
      1377 ACGTATTGATAATGCTGATGAATTAATAGATTCCTTTTTAGAAAATTTTA   1426 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       698 ACGTATTGATAATGCTGATGAATTAATAGATTCCTTTTTAGAAAATTTTA    747 
 
      1427 GTGATGAACCATATAATGTTCAATTACAAATTCTAACGGCTAGCGTCAAA   1476 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       748 GTGATGAACCATATAATGTTCAATTACAAATTCTAACGGCTAGCGTCAAA    797 
 
      1477 TTATTTTTAAAATGTTCAAAAAACACAAAAGATATTATAACCAAAGTCTT   1526 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       798 TTATTTTTAAAATGTTCAAAAAACACAAAAGATATTATAACCAAAGTCTT    847 
 
      1527 AAAATTATCCACAGAAGAAAGTGATAATCCTGATTTAAGAGATAGGGCTT   1576 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       848 AAAATTATCCACAGAAGAAAGTGATAATCCTGATTTAAGAGATAGGGCTT    897 
177 
 
      1577 ATATTTATTGGAGATTGTTATCTAAAAATATTGATGTTGCCAAAAAAATT   1626 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       898 ATATTTATTGGAGATTGTTATCTAAAAATATTGATGTTGCCAAAAAAATT    947 
 
      1627 GTACTTGCCGATAAACCCCCAATACAAGAAGAGAATAAAATTACTGATAC   1676 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       948 GTACTTGCCGATAAACCCCCAATACAAGAAGAGAATAAAATTACTGATAC    997 
       
      1677 CAAAGTATTAAATAAATTAATTAAAAATATATCCATGTTATCATCTGTAT   1726 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
       998 CAAAGTATTAAATAAATTAATTAAAAATATATCCATGTTATCATCTGTAT   1047 
 
      1727 ATCATAAATTACCAGAAACTTTTATATCAAAAAAAAATTCCTATTCCTTA   1776 
           |||||||||||||||||||||||||||||||||||||||||||||||||| 
      1048 ATCATAAATTACCAGAAACTTTTATATCAAAAAAAAATTCCTATTCCTTA   1097 
 
      1777 AATTCTGATAATAATAATGATCAT--ATGCAAGATGATCACTATGATGAT   1824 
           ||||||||||||||||||||||||  || |..|.||.|.||.|.|.     
      1098 AATTCTGATAATAATAATGATCATGGAT-CCGGCTGCTAACAAAGC----   1142 
 
      1825 GACGATTATGATAAAGAT   1842 
            .|||     |..|||.| 
      1143 -CCGA-----AAGAAGTT   1154 
 
Figure 63. Alignment of AP1 N-terminal domain DNA sequences from T7 
terminal primer sequencing 
The sequence obtained from subcloning (red) was aligned with the original 
sequence obtained from the PlasmoDB database (blue). The underlined sections 
indicate the reverse primer position 5’-TTC TGA TAA TAA TAA TGA TCA T-3’. 
Key to ambiguous bases: W = T and A overlap in sequence; M = multiple overlap 
of peaks in sequence; R = A and G overlap; Y = C and T overlap. A dot between 
base pairs indicates a non-alignment, while a dash indicates a missing base. 
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5.9) BLAST data 
Note: For a given score, the E-value is the number of hits in a database search that we 
expect to see by chance with this score or better. The lower the E-value, the more 
significant the score. 
 
3ckx_A mol: protein length: 304 Serine/threonine-protein kinase 24 
Organism: Homo sapiens Length 304 
 
Score = 355 (130.0 bits), Expect = 2.0e-32, P = 2.0e-32 
Identities = 87/2485 (3%), Positives = 127/2485 (5%) 
Identities = 87/230 (37%), Positives = 127/230 (55%) 
 
Hs:    59 LSQCDSPYVTKYYGSYL-KDTKLWIIMEYLGGGSALDLLEP-GPLDETQIATILREILKG 116 
          L  C+ P V KY+ S+      L I+ EYL GG+  DL +  G + E  +  IL ++L G 
Pf:  2146 LKMCEHPNVVKYFESFFWPPCYLVIVCEYLSGGTLYDLYKNYGRISEDLLVYILDDVLNG 2205 
 
Hs:   117 LDYLHSEKK---IHRDIKAANVLLSEHGEVKLADFGVAGQLTDTQIKRNXFVGTPFWMAP 173 
          L+YLH+E     IHRDIK  N++LS+ G  K+ DFG   +L ++   +   VGT ++++P 
Pf:  2206 LNYLHNECSSPLIHRDIKPTNIVLSKDGIAKIIDFGSCEELKNSDQSKE-LVGTIYYISP 2265 
 
Hs:   174 EVIKQSAYDSKADIWSLGITAIELARGEPPHSELHPMKVLFLIPKNNPPTL---EGNYSK 230 
          E++ ++ YD  +DIWSLGIT  E+     P       +       N+ P +   EG YSK 
Pf:  2266 EILMRTNYDCSSDIWSLGITIYEIVLCTLPWKRNQSFENYIKTIINSSPKINITEG-YSK 2325 
 
Hs:   231 PLKEFVEACLNKEPSFRPTAKELLKHKFILRNA---KKTSYLTELIDRYK 277 
           L  FVE CL K+P  R   K+LL HKF+++     KK S + E+ D  K 
Pf:  2326 HLCYFVEKCLQKKPENRGNVKDLLNHKFLIKKRYIKKKPSSIYEIRDILK 2375 
 
Figure 64. BLAST data for P. falciparum PK with Homo sapiens protein 
The parasite PK insert shares most homology with human serine/threonine protein kinase 
24 within the kinase domain which spans amino acids 2 079-2 354. The sequence 
homology begins at parasite PK amino acid 2 146 and ends at 2 375. Conserved residues 
found in the catalytic core of higher eukaryotes are highlighted. The invariant residues 
are underlined. A dash indicates no amino acid match. A plus sign indicates sequence 
positivity, while a matching letter shows areas of sequence identity. Pf indicates the 
parasite protein sequence and Hs the amino acid sequence of the human protein kinase. 
 
>gb|PVX_003590 | organism=Plasmodium_vivax_SaI-1 | 
product=serine/threonine-specific protein kinase, putative | 
location=CM000445:748722-755099(+) | length=2125  
        Length = 2125 
 
 Score = 1291 (459.5 bits), Expect = 6.3e-141, Sum P(5) = 6.3e-141 
Identities = 265/2485 (11%), Positives = 354/2485 (14%) 
 Identities = 265/533 (49%), Positives = 354/533 (66%) 
 
Query:  1932 ENLNLENKKKGYIDETN-VNENYESDNE-YDSDEDDTESDNDDEQNKENERGDEKDGYEE 1989 
             E  NL+ +K      +N + EN+E   E  +   DDT           N  G  K   EE 
Sbjct:  1532 EEHNLKRQKSDSTRSSNEMLENFERIAERINFILDDTVEFFKKNLYVHNGYGSVKVSKEE 1591 
 
Query:  1990 MNGGDKNE--EMNGGDKNEEMNVGDKNGGINEEHKNEGINEEHKDELINKE--HKNERIN 2045 
                  +N   E +   K  ++     +G +    + E   ++ ++E    E  H  ++ N 
Sbjct:  1592 TGWLGENTLGEWSHVYKINKVVCKGAHGVVFSAWRGEDSAKQCEEEAERGEAGHSTDQGN 1651 
 
Query:  2046 EEHKNERINEEHKNEGINEEH-KNEGINEEHKNERINEEHKNEGINKLTYH-NMNKNNIS 2103 
              E   E         G  EE+ K +  +    N + N +  + G ++     N+ +N+   
Sbjct:  1652 AEGSGEG-GGGGSGGGSGEENGKGKDQDNAQGNAQGNAQGNDRGNDQENVEENVEENDQG 1710 
179 
 
Query:  2104 NENNYNDDDSYDEDNLVSLKIINLKYLSKKNSLKNILREVNFLKMCEHPNVVKYFESFFW 2163 
             N+ +  D +SYDE+ LV+LKI+NL+YLSKKNSL+ I++EV+FL++C+HPN+VKY ESFFW 
Sbjct:  1711 NDRD-GDQESYDEEKLVTLKIVNLRYLSKKNSLRRIMKEVHFLQICDHPNIVKYHESFFW 1769 
 
Query:  2164 PPCYLVIVCEYLSGGTLYDLYKNYGRISEDLLVYILDDVLNGLNYLHNECSSPLIHRDIK 2223 
             PPCYLVIVCE+LSGGTL+DLYK  GRI+ED+LV+ILDDVL  L YLHNEC+S L+HRDIK 
Sbjct:  1770 PPCYLVIVCEFLSGGTLFDLYKKCGRITEDVLVHILDDVLKALQYLHNECTSCLVHRDIK 1829 
 
Query:  2224 PTNIVLSKDGIAKIIDFGSCEELKNSDQSKELVGTIYYISPEILMRTNYDCSSDIWSLGI 2283 
             PTNIV SK G+AKI+DFGSCE +++  +  E+VGT+YYISPEIL R  YDCS+DIWSLGI 
Sbjct:  1830 PTNIVFSKSGVAKIVDFGSCERVEDL-KMHEVVGTLYYISPEILKREKYDCSADIWSLGI 1888 
 
Query:  2284 TIYEIVLCTLPWKRNQSFENYIKTIINSSPKINITEGYSKHLCYFVEKCLQKKPENRGNV 2343 
             TIYE+V+C LPWK  +  E  IK I+ SSPKIN+  G++K  C+FVE CLQ  P  R N  
Sbjct:  1889 TIYEVVMCALPWKGKKHIEESIKQIVGSSPKINLCSGFTKQFCFFVESCLQNDPGKRANA 1948 
 
Query:  2344 KDLLNHKFLIKKRYIKKKPSSIYEIRDILKIYNGKGKTNIFRNFFKNLFFFNDKNKKKKP 2403 
               LL HKFL KKR +++KPSSI+EIRDILK+ NGKGK NIFRNFFKNLFF NDKNK+++  
Sbjct:  1949 AHLLGHKFLTKKRLLRRKPSSIFEIRDILKVNNGKGKNNIFRNFFKNLFFLNDKNKRRR- 2007 
 
Query:  2404 NKMISSKSCDAEMFFEQLKRENFDFFEIKLKDDENSRSLNTFNINISKERDDI 2456 
             NK + SKSC+ EMF+ +LKRENFDFFEI+L+D  +SRSL   ++   K  +++ 
Sbjct:  2008 NKALGSKSCEPEMFYRKLKRENFDFFEIRLRDG-SSRSLGHLHVGEGKREEEV 2059 
 
Figure 65. BLAST data for P. falciparum PK with P. vivax protein  
The P. falciparum PK shares homology with P. vivax putative serine/threonine specific 
protein kinase within the kinase domain which spans amino acids 2 079-2 354 of the 
entire protein sequence. The sequence homology begins at P. falciparum PK amino acid 
2 119 and ends at 2 456. Conserved residues found in the catalytic core of higher 
eukaryotes are highlighted. The invariant residues are underlined. A dash indicates no 
amino acid match. A plus sign indicates sequence positivity, while a matching letter 
shows areas of sequence identity. Query indicates the P. falciparum protein sequence and 
Sbjct the amino acid sequence of the P. vivax protein kinase. 
 
Toxoplasma_gondii|X|42.m03467|Annotation|Toxoplasma_gondii_TIGR|(protein 
coding) serine/threonine-protein kinase-related / mediator complex 
subunit SOH1-related  
        Length = 4253 
 
Score = 286 (105.7 bits), Expect = 5.1e-40, Sum P(5) = 5.1e-40 
Identities = 181/2485 (7%), Positives = 276/2485 (11%) 
Identities = 128/305 (42%), Positives = 185/305 (61%) 
 
Query:  2263 SPEILMRTNYDCSSDIWSLGITIYEIVLCTLPWKRNQSFENYIKTIINSSP-KINITEGY 2321 
             SP       YD   D+W+LGIT YE+ + +LPW R    E+ + TI+  SP +IN+ EGY 
Sbjct:  1870 SPGFGASEGYDFRVDLWALGITAYEVAVGSLPWPRRMRLEDLLGTILEGSPPRINLNEGY 1929 
 
Query:  2322 SKHLCYFVEKCLQKKPENRGNVKDLLNHKFLIKK-RYIKKKPSSIYEIRDILKIYNGKGK 2380 
              K  C+FVE+CL+K  E RG   +LL H F  K     + +P+S  E+R+ +++ NGK K 
Sbjct:  1930 EKTFCFFVERCLRKNSEERGTATELLQHPFFKKFCASSRSRPASHQELREAIEVANGKRK 1989 
 
Query:  2381 TNIFRNFFKNLFFFNDK---NKKKK 2402 
              N+  N  K + FF      N +KK 
Sbjct:  1990 ANVLSNLLKFIPFFRKPQPTNGRKK 2014 
 
Query:  2111 DDSYDEDNLVSLKIINLKYL----------SKKNSLKNILREVNFLKMCEHPNVVKYFES 2160 
             ++  +ED  V+LKII+L             ++ N L  ++REV+ LK C H  +VK +E+ 
Sbjct:  1633 EEDVEEDE-VALKIIDLDGALQLQGATDKEARVNYLNQVMREVDVLKQCNHEGIVKMYEA 1691 
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Query:  2161 FFWPPCYLVIVCEYLSGGTLYDLYKNYGRISEDLLVYILDDVLNGLNYLHN 2211 
             F WPPCYLV   E L GG+L DLY + G + E L+  +L DVL  L YLHN 
Sbjct:  1692 FQWPPCYLVFSMELLPGGSLRDLYASAGPLPEPLIAALLQDVLKALKYLHN 1742 
 
 
Query:  1897 SCIYKINKIVRKGAHGVVFSAWRSENV--------DFFNHSFFENLNLENKKKGYIDETN 1948 
             S +Y + ++V KGAHG VF   R              F  +F + ++   +KK   +ET  
Sbjct:  1554 SAVYVVEELVGKGAHGAVFKCTRYRKAARPEEKTGGSFLGAFGKKVSEAREKKA--EETR 1611 
 
Query:  1949 VN-ENYESDNEY-DSDEDDTESDNDDEQNKENERGDEKDGYEEMNGG-DKNEEMN 2000 
                E  E   +  D DE D  ++ D E+++   +  + DG  ++ G  DK   +N 
Sbjct:  1612 PGVERPEGARQVSDGDERDG-AEEDVEEDEVALKIIDLDGALQLQGATDKEARVN 1665 
 
 
Query:   686 PKENNIIYTSGKS 698 
             P+EN ++ +SGKS 
Sbjct:    21 PEENALLGSSGKS 33 
 
Figure 66. BLAST data for P. falciparum PK with T. gondii proteins 
The P. falciparum PK shares most homology with the T. gondii serine/threonine protein 
kinase-related complex within the kinase domain which spans amino acids 2 079-2 354 of 
the entire protein sequence. The sequence homology occurs at many different areas 
throughout the T. gondii protein, with large gaps of no homology in between. Conserved 
residues found in the catalytic core of higher eukaryotes are highlighted. The invariant 
residues are underlined. A dash indicates no amino acid match. A plus sign indicates 
sequence positivity, while a matching letter shows areas of sequence identity. Query 
indicates the P. falciparum protein sequence and Sbjct the T. gondii protein kinase. 
 
gb|PVX_079845 | organism=Plasmodium_vivax_SaI-1 | product=adapter-
related protein complex 1 beta 1 subunit, putative | 
location=CM000451:144521-148411(+) | length=930  
        Length = 930 
 
 Score = 4205 (1485.3 bits), Expect = 0., P = 0. 
 Identities = 837/925 (89%), Positives = 893/925 (95%) 
 
Query:     1 MSDLRYFQTTKKGEIHELKEELHSSHKEKKKEAIKKIIAAMTVGKDVSTLFSDVVNCMQT 60 
             MSDLRYFQTTKKGEIHELKEELHSSHKEKKKEAIKKIIAAMTVGKDVSTLFSDVVNCMQT 
Sbjct:     1 MSDLRYFQTTKKGEIHELKEELHSSHKEKKKEAIKKIIAAMTVGKDVSTLFSDVVNCMQT 60 
 
Query:    61 SNIELKKLVYLYVINYAKVQPELAILAVNTFRKDSSDPNPLIRALAIRTMGCIRLEQITE 120 
             SNIELKKLVYLYVINYAKVQPELAILAVNTFRKDSSDPNPLIRALAIRTMGCIRLEQITE 
Sbjct:    61 SNIELKKLVYLYVINYAKVQPELAILAVNTFRKDSSDPNPLIRALAIRTMGCIRLEQITE 120 
 
Query:   121 YLIEPLRRCLKDEDPYVRKTAVICIAKLYDISPKLVEEEGFIDTLLDILDDNNAMVVANA 180 
             YLIEPLRRCLKDEDPYVRKTAVICIAKLYDISPKLVEEEGFI+TLL+ILDDNNAMVVANA 
Sbjct:   121 YLIEPLRRCLKDEDPYVRKTAVICIAKLYDISPKLVEEEGFIETLLNILDDNNAMVVANA 180 
 
Query:   181 VISLTDICENSNKSILKDVINKDENNVNKLLNAINECVEWGQVFILDALVLYEPKTSKDA 240 
             +ISLTDICENSNKSILKDVINKDENNVNKLLNAINECVEWGQVFILDALVLYEPKTSKDA 
Sbjct:   181 IISLTDICENSNKSILKDVINKDENNVNKLLNAINECVEWGQVFILDALVLYEPKTSKDA 240 
 
Query:   241 ERVLERILPRLSHANSAVVLSSIKVILCLLDKINDKEFIKNVHKKLSPSLVTLLSAEPEI 300 
             ERVLERILPRLSHANSAVVLSSIKVIL LLDKINDKEFIKNVHKKLSPSLVTLLSAEPEI 
Sbjct:   241 ERVLERILPRLSHANSAVVLSSIKVILSLLDKINDKEFIKNVHKKLSPSLVTLLSAEPEI 300 
 
Query:   301 QYIALRNINLITQKLPNMLSDKINMFFCKYNEPAYVKMEKLDIIIRLVSDKNVDLVLYEL 360 
             QYIALRNINLITQKLP+ML+DKINMFFCKYNEPAYVKMEKLDIIIRLVSDKNVDLVLYEL 
Sbjct:   301 QYIALRNINLITQKLPHMLADKINMFFCKYNEPAYVKMEKLDIIIRLVSDKNVDLVLYEL 360 
181 
 
 
Query:   361 KEYSTEVDVEFVKKSVRAIGSCAIKLPQSSEKCINILLDLIDTKINYVIQECIVVIKDIF 420 
             KEYSTEVDVEFVKKSVRAIGSCAIKLPQSSEKCINILLDLIDTKINYVIQECIVVIKDIF 
Sbjct:   361 KEYSTEVDVEFVKKSVRAIGSCAIKLPQSSEKCINILLDLIDTKINYVIQECIVVIKDIF 420 
 
Query:   421 RKYPNKYESIITILCENLESLDESNAKASLIWIIGEYVERIDNADELIDSFLENFSDEPY 480 
             RKYPNKYESIITILCENLESLDESNAKASLIWIIGEYVERI+NADELIDSFLENF+DEPY 
Sbjct:   421 RKYPNKYESIITILCENLESLDESNAKASLIWIIGEYVERIENADELIDSFLENFTDEPY 480 
 
Query:   481 NVQLQILTASVKLFLKCSKNTKDIITKVLKLSTEESDNPDLRDRAYIYWRLLSKNIDVAK 540 
             NVQLQILTASVKLFLKCSKNTKDIITKVLKLSTEESDNPDLRDRA+IYWRLLSKNI++AK 
Sbjct:   481 NVQLQILTASVKLFLKCSKNTKDIITKVLKLSTEESDNPDLRDRAFIYWRLLSKNIEIAK 540 
 
Query:   541 KIVLADKPPIQEENKITDTKVLNKLIKNISMLSSVYHKLPETFISKKNSYSLNSDNNNDH 600 
             KIVLA+KPPIQE+NKITDTKVLNKLIKNISMLSSVYHKLPETFISKK +Y  ++D ++D  
Sbjct:   541 KIVLAEKPPIQEDNKITDTKVLNKLIKNISMLSSVYHKLPETFISKKANYVFHNDKDDD- 599 
 
Query:   601 MQDDHYDD-DDYDKDNHVLKIKKQMDKQKYDSYSSDNKKSNHSKSSSDSYNNSSDEFNND 659 
              +D+  D+ DDY+    V K KKQM++QKYDSYSS+++KSN S+SSS+S NNSSD+ N+D 
Sbjct:   600 -EDNRIDNMDDYN----VSKFKKQMERQKYDSYSSESRKSNRSRSSSESSNNSSDDANDD 654 
 
Query:   660 IDD---ADDSKKSMDLIGLNDDES---KPQKTIPPVKMVQVLSSEDAGLKGQTGLSIFAS 713 
              DD   ADDSKKSMDLIGLNDDE+   KP+++ PPVK+VQVLS ED GLKGQTGLSI +S 
Sbjct:   655 KDDDEDADDSKKSMDLIGLNDDEASNAKPRRSAPPVKLVQVLSPEDTGLKGQTGLSILSS 714 
 
Query:   714 INRIDRKIQLKISVTNQTQNEIVVSGVQINKNSFGLSSPNNLDVQNIGFGETKEMLIYLI 773 
             INRI+ KIQLKI+VTNQT N +V+SGVQINKNSFGLSSPNNLD+QN+ FGETKE+LI L+ 
Sbjct:   715 INRIEGKIQLKIAVTNQTPNPVVISGVQINKNSFGLSSPNNLDIQNVSFGETKEILILLV 774 
 
Query:   774 PNTLNSNTPPATPLFLQVAIRTNLDIFYFNVPYDIFVVFVENFHMEKDIFKKKWQIIEEA 833 
             PN LNSNTPP+TPLFLQVAIRT++DIFYFNVPYDIF+VFVENF+MEKDIFKKKWQ+IE++ 
Sbjct:   775 PNLLNSNTPPSTPLFLQVAIRTSIDIFYFNVPYDIFIVFVENFNMEKDIFKKKWQLIEDS 834 
 
Query:   834 KESILMAVSPMVITSDMLIKRMKIFNISLIARRN----ELYYFACITTNNLVILSEVTIQ 889 
             KESILMA SPMVITSD+LIKRMKIFNISLIARRN    ELYYFAC+TTNNLVILSEV IQ 
Sbjct:   835 KESILMASSPMVITSDILIKRMKIFNISLIARRNVNNMELYYFACLTTNNLVILSEVAIQ 894 
 
Query:   890 PEKKNVKLCIRTDSSSVIPLYKLLFVKAFSLSVTQT 925 
             PEKK VKLC+RTDS+SVIPLYKLLFVKAFSLSVTQT 
Sbjct:   895 PEKKVVKLCVRTDSTSVIPLYKLLFVKAFSLSVTQT 930 
 
Figure 67. BLAST data for P. falciparum AP-1 β1 subunit with P. vivax protein  
The P. falciparum AP-1 β1 subunit shares homology with P. vivax putative adaptor 
related complex 1 β1subunit across the entire protein sequence of 925 amino acids. The 
sequence homology begins at P. falciparum amino acid 1 and ends at 925. The N-
terminal is coloured red and spans amino acids 1 to 618, while the C-terminal is shown 
in blue and spans amino acids 650 to 925. A dash indicates no amino acid match. A plus 
sign indicates sequence positivity, while a matching letter shows areas of sequence 
identity. Query indicates the P. falciparum protein sequence and Sbjct the amino acid 
sequence of the P. vivax protein. 
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>Toxoplasma_gondii|VI|49.m00005|Annotation|Toxoplasma_gondii_TIGR|(prote
in coding) beta adaptin protein, putative  
        Length = 925 
 
 Score = 2616 (925.9 bits), Expect = 9.6e-274, P = 9.6e-274 
 Identities = 519/925 (56%), Positives = 689/925 (74%) 
 
Query:     1 MSDLRYFQTTKKGEIHELKEELHSSHKEKKKEAIKKIIAAMTVGKDVSTLFSDVVNCMQT 60 
             M+D  YFQ  K+GE+HELKEELHSS+KEKKKEA+KK+IAAMTVGKDVS+LF DVVNCMQT 
Sbjct:     1 MTDGNYFQPAKRGELHELKEELHSSNKEKKKEAVKKVIAAMTVGKDVSSLFPDVVNCMQT 60 
 
Query:    61 SNIELKKLVYLYVINYAKVQPELAILAVNTFRKDSSDPNPLIRALAIRTMGCIRLEQITE 120 
             +N+ELKKLVYLYVINYAK QPELAILA+NTFRKDS DPNPLIRALA+RTMGCIRLE+ITE 
Sbjct:    61 TNMELKKLVYLYVINYAKAQPELAILAINTFRKDSLDPNPLIRALAVRTMGCIRLEEITE 120 
 
Query:   121 YLIEPLRRCLKDEDPYVRKTAVICIAKLYDISPKLVEEEGFIDTLLDILDDNNAMVVANA 180 
             YL+EPLRR  KD DPYVRKTA IC+AKL+ I P +V EEGFI+ L  +L D+N +VVANA 
Sbjct:   121 YLVEPLRRSCKDPDPYVRKTAAICVAKLFSIRPDMVGEEGFIEELTTMLSDSNPVVVANA 180 
 
Query:   181 VISLTDICENSNKSILKDVINKDENNVNKLLNAINECVEWGQVFILDALVLYEPKTSKDA 240 
             V +L++I ENS ++ +K+++N  E+NVNKLL A+NEC EWGQVFILDAL  +EP+T + A 
Sbjct:   181 VAALSEISENSGRNYMKNILNAKESNVNKLLAALNECTEWGQVFILDALAQFEPETPRAA 240 
 
Query:   241 ERVLERILPRLSHANSAVVLSSIKVILCLLDKINDKEFIKNVHKKLSPSLVTLLSAEPEI 300 
             E VL+R+  RLSHANSAVVLS+IKV++ LLDK+ + + ++ VH+KL P LVTLLSAEPEI 
Sbjct:   241 ESVLDRVTARLSHANSAVVLSAIKVVMKLLDKVTNPDVVRAVHRKLCPPLVTLLSAEPEI 300 
 
Query:   301 QYIALRNINLITQKLPNMLSDKINMFFCKYNEPAYVKMEKLDIIIRLVSDKNVDLVLYEL 360 
             QY+ALRNI LI QK P++L+ ++ MFFCKYN+P YVK+EKLDI++RLVS+KNVD VL EL 
Sbjct:   301 QYVALRNIELIVQKRPSILASEVKMFFCKYNDPVYVKIEKLDILVRLVSEKNVDQVLSEL 360 
 
Query:   361 KEYSTEVDVEFVKKSVRAIGSCAIKLPQSSEKCINILLDLIDTKINYVIQECIVVIKDIF 420 
             KEY+TEVDV+FV+K+VR IG CAIKL  ++E+C+ +LLDLI TK+NYV+QE IV IKDIF 
Sbjct:   361 KEYATEVDVDFVRKAVRCIGRCAIKLDCAAERCVAVLLDLIQTKVNYVVQEAIVAIKDIF 420 
 
Query:   421 RKYPNKYESIITILCENLESLDESNAKASLIWIIGEYVERIDNADELIDSFLENFSDEPY 480 
             RKYPN+YES+I+ LCENLE+LDE  AKAS++WI+GEYV+RIDNADEL+++FLE F DEP  
Sbjct:   421 RKYPNQYESMISTLCENLETLDEPAAKASMVWIVGEYVDRIDNADELLETFLETFHDEPS 480 
 
Query:   481 NVQLQILTASVKLFLKCSKNTKDIITKVLKLSTEESDNPDLRDRAYIYWRLLSKNIDVAK 540 
              VQLQ+LTA+VKLFLK   +T+D++TKVLK++TEE+ NPDLRDRAYIYWR+L++N + AK 
Sbjct:   481 IVQLQLLTATVKLFLKKPAHTQDLVTKVLKMATEETYNPDLRDRAYIYWRMLARNPEAAK 540 
 
Query:   541 KIVLADKPPIQEENKITDTKVLNKLIKNISMLSSVYHKLPETFISKKNSYSLNSDNNNDH 600 
             K+V A KPPI E+    D   L++LI NIS+LSSVYHK PETF+++    S          
Sbjct:   541 KVVFAPKPPINEDADALDYNTLDRLIGNISLLSSVYHKAPETFVARAMPPSAALPK---- 596 
 
Query:   601 MQDDHYDDDDYDKDNHVLKIKKQMDKQKYDSYSSDNKKSNHSKSSSDSYNNSSDEFNNDI 660 
              +      D    D  V + K+ M KQ Y S   + + S  S   SDS ++   +      
Sbjct:   597 -EVGSCSSDGESTDARVEQAKQSMQKQHYSSDEKEEESSPTSSEDSDSDSDGPTDLLGLS 655 
 
Query:   661 DDADDSKKSMDLIGLND--DESKPQKTIPPVKMVQVLSSEDAGLKGQTGLSIFASINRID 718 
             D+A   K+S      +D  D S P +    V    VL+++  G +G+TGL + A++ R   
Sbjct:   656 DEATPRKRSSKESS-DDLFDLSSPPEDPRGVGKTLVLAADRPGNQGRTGLQVSAALTRAH 714 
 
Query:   719 RKIQLKISVTNQTQNEIVVSGVQINKNSFGLSSPNNLDVQNIGFGETKEMLIYLIPNTLN 778 
              +IQL +++ N++   +    +Q N+NSFGL+   NL V ++  G++ E  + ++P  L  
Sbjct:   715 GRIQLHLTLANKSSMTLNGWAIQFNRNSFGLAPAANLQVADLLSGQSAETTVPVVPGQLM 774 
 
Query:   779 SNTPPATPLFLQVAIRTNLDIFYFNVPYDIFVVFVENFHMEKDIFKKKWQIIEEAKESIL 838 
             SN  P  PL LQVA++TNLDIF F VP+D+ VV  EN   +KD+F+++WQ I EA++S L 
Sbjct:   775 SNAAPEQPLSLQVAVKTNLDIFCFTVPFDLSVVLQENSSADKDVFRQRWQNIGEARQSSL 834 
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Query:   839 MAVSPMVITSDMLIKRMKIFNISLIARRN----ELYYFACITTNNLVILSEVTIQPEKKN 894 
             MA +P   +   + K+M+  NISL+A+R+    +  YF+  TTNNLV+L+EV++Q      
Sbjct:   835 MASAPSSQSPQAVTKQMQAANISLVAQRSADTFDALYFSATTTNNLVVLAEVSLQRNGNA 894 
 
Query:   895 VKLCIRTDSSSVIPLYKLLFVKAFSLS 921 
             VKL  R+++++++PL+      A  L+ 
Sbjct:   895 VKLVTRSEAAALLPLFTSTVCAALRLT 921 
 
Figure 68. BLAST data for P. falciparum AP-1 β1 subunit with T. gondii protein  
The P. falciparum AP-1 β1 subunit shares homology with T. gondii putative β adaptin 
protein across the entire protein sequence of 925 amino acids. The N-terminal is 
coloured red and spans amino acids 1 to 618, while the C-terminal is shown in blue and 
spans amino acids 650 to 921. A dash indicates no amino acid match. A plus sign 
indicates sequence positivity, while a matching letter shows areas of sequence identity. 
Query indicates the P. falciparum protein sequence and Sbjct the amino acid sequence of 
the T. gondii protein. 
 
Q10567| organism=Human | product= AP-1 complex subunit beta-1 
length=949  
 
Score = 1971 (698.9 bits), Expect = 2.0e-224, Sum P(2) = 2.0e-224 
Identities = 428/925 (46%), Positives = 577/925 (62%) 
Identities = 374/585 (63%), Positives = 478/585 (81%) 
 
Query:     1 MTDSKYFTTTKKGEIFELKAELNSDKKEKKKEAVKKVIASMTVGKDVSALFPDVVNCMQT 60 
             M+D +YF TTKKGEI ELK EL+S  KEKKKEA+KK+IA+MTVGKDVS LF DVVNCMQT 
Sbjct:     1 MSDLRYFQTTKKGEIHELKEELHSSHKEKKKEAIKKIIAAMTVGKDVSTLFSDVVNCMQT 60 
 
Query:    61 DNLELKKLVYLYLMNYAKSQPDMAIMAVNTFVKDCEDPNPLIRALAVRTMGCIRVDKITE 120 
              N+ELKKLVYLY++NYAK QP++AI+AVNTF KD  DPNPLIRALA+RTMGCIR+++ITE 
Sbjct:    61 SNIELKKLVYLYVINYAKVQPELAILAVNTFRKDSSDPNPLIRALAIRTMGCIRLEQITE 120 
 
Query:   121 YLCEPLRKCLKDEDPYVRKTAAVCVAKLHDINAQLVEDQGFLDTLKDLISDSNPMVVANA 180 
             YL EPLR+CLKDEDPYVRKTA +C+AKL+DI+ +LVE++GF+DTL D++ D+N MVVANA 
Sbjct:   121 YLIEPLRRCLKDEDPYVRKTAVICIAKLYDISPKLVEEEGFIDTLLDILDDNNAMVVANA 180 
 
Query:   181 VAALSEIAESHPSSNLLDL---NPQSINKLLTALNECTEWGQIFILDCLANYMPKDDREA 237 
             V +L++I E+   S L D+   +  ++NKLL A+NEC EWGQ+FILD L  Y PK  ++A 
Sbjct:   181 VISLTDICENSNKSILKDVINKDENNVNKLLNAINECVEWGQVFILDALVLYEPKTSKDA 240 
 
Query:   238 QSICERVTPRLSHANSAVVLSAVKVLMKFMEMLSKDLDYYGTLLKKLAPPLVTLLSAEPE 297 
             + + ER+ PRLSHANSAVVLS++KV++  ++ ++ D ++   + KKL+P LVTLLSAEPE 
Sbjct:   241 ERVLERILPRLSHANSAVVLSSIKVILCLLDKIN-DKEFIKNVHKKLSPSLVTLLSAEPE 299 
 
Query:   298 LQYVALRNINLIVQKRPEILKHEMKVFFVKYNDPIYVKLEKLDIMIRLASQANIAQVLAE 357 
             +QY+ALRNINLI QK P +L  ++ +FF KYN+P YVK+EKLDI+IRL S  N+  VL E 
Sbjct:   300 IQYIALRNINLITQKLPNMLSDKINMFFCKYNEPAYVKMEKLDIIIRLVSDKNVDLVLYE 359 
 
Query:   358 LKEYATEVDVDFVRKAVRAIGRCAIKVEQSAERCVSTLLDLIQTKVNYVVQEAIVVIKDI 417 
             LKEY+TEVDV+FV+K+VRAIG CAIK+ QS+E+C++ LLDLI TK+NYV+QE IVVIKDI 
Sbjct:   360 LKEYSTEVDVEFVKKSVRAIGSCAIKLPQSSEKCINILLDLIDTKINYVIQECIVVIKDI 419 
 
Query:   418 FRKYPNKYESVIATLCENLDSLDEPEARAAMIWIVGEYAERIDNADELLESFLEGFHDES 477 
             FRKYPNKYES+I  LCENL+SLDE  A+A++IWI+GEY ERIDNADEL++SFLE F DE  
Sbjct:   420 FRKYPNKYESIITILCENLESLDESNAKASLIWIIGEYVERIDNADELIDSFLENFSDEP 479 
 
Query:   478 TQVQLQLLTAIVKLFLKKPTETQELVQQVLSLATQDSDNPDLRDRGYIYWRLLSTDPVAA 537 
               VQLQ+LTA VKLFLK    T++++ +VL L+T++SDNPDLRDR YIYWRLLS +   A 
Sbjct:   480 YNVQLQILTASVKLFLKCSKNTKDIITKVLKLSTEESDNPDLRDRAYIYWRLLSKNIDVA 539 
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Query:   538 KEVVLAEKPLISEETDLIEPTLLDELICYIGTLASVYHKPPSAFV 582 
             K++VLA+KP I EE  + +  +L++LI  I  L+SVYHK P  F+ 
Sbjct:   540 KKIVLADKPPIQEENKITDTKVLNKLIKNISMLSSVYHKLPETFI 584 
 
 Score = 201 (75.8 bits), Expect = 2.0e-224, Sum P(2) = 2.0e-224 
 Identities = 54/190 (28%), Positives = 99/190 (52%) 
 
Query:   731 GLEISGTFTRQVGSISMDLQLTNKALQVMTDFAIQFNRNSFGLAPAAPLQVHAPLSPNQT 790 
             GL I  +  R    I + + +TN+    +    +Q N+NSFGL+    L V   +   +T 
Sbjct:   707 GLSIFASINRIDRKIQLKISVTNQTQNEIVVSGVQINKNSFGLSSPNNLDVQN-IGFGET 765 
 
Query:   791 VEISLPL--STVGS-VMKMEPLNNLQVAVKNNIDVFYFSTLYPLHILFVEDGKMDRQMFL 847 
              E+ + L  +T+ S      PL  LQVA++ N+D+FYF+  Y + ++FVE+  M++ +F  
Sbjct:   766 KEMLIYLIPNTLNSNTPPATPLF-LQVAIRTNLDIFYFNVPYDIFVVFVENFHMEKDIFK 824 
 
Query:   848 ATWKDIPNENEAQFQ-IRDCPLNAEAASSKLQSSNIFTVAKRNVEGQDMLYQSLKLTNGI 906 
               W+ I    E+    +    + ++    +++  NI  +A+RN    ++ Y +   TN + 
Sbjct:   825 KKWQIIEEAKESILMAVSPMVITSDMLIKRMKIFNISLIARRN----ELYYFACITTNNL 880 
 
Query:   907 WVLAELRIQP 916 
              +L+E+ IQP 
Sbjct:   881 VILSEVTIQP 890 
 
Figure 69. BLAST data for P. falciparum AP-1 β1 subunit with H. sapiens protein  
The P. falciparum AP-1 β1 subunit shares 46 percent identity and 62 percent positivity 
with H. sapiens AP-1 complex subunit β1. The sequence homology begins at P. 
falciparum amino acid 1 and ends at 584 which is part of the AP1 N-terminal (red). This 
area shares 63 percent identity and 81 percent positivity with the H. sapiens protein. Part 
of the AP1 C-terminal, from amino acid 707 to 890 (blue), shares only 28 percent identity 
and 52 percent positivity with the H. sapiens protein. A dash indicates no amino acid 
match. A plus sign indicates sequence positivity, while a matching letter shows areas of 
sequence identity. Sbjct indicates the P. falciparum protein sequence and Query the 
amino acid sequence of the H. sapiens protein. 
5.10) Secondary structure data 
 
1---------11--------21--------31--------41--------51--------61--------71--------81--------91--------101-------111 
EKDGYEEMNGGDKNEEMNGGDKNEEMNVGDKNGGINEEHKNEGINEEHKDELINKEHKNERINEEHKNERINEEHKNEGINEEHKNEGINEEHKNERINEEHKNEGINKLTYH 
------------------------------------------------------HHHHHHHHHHHHHHHHHHH--------------------------------------EE 
 
-------121-------131-------141-------151-------161-------171-------181-------191-------201-------211-------221 
NMNKNNISNENNYNDDDSYDEDNLVSLKIINLKYLSKKNSLKNILREVNFLKMCEHPNVVKYFESFFWPPCYLVIVCEYLSGGTLYDLYKNYGRISEDLLVYILDDVLNG 
EEEEEE----EEEEEEEE-----EEEEEEE-------HHHHHHHHHHHHHHHH------EEEEEEE-----EEEEEEEE-----HHHHHH------HHHHHHHHHHHHHH 
 
-------231-------241-------251-------261-------271-------281-------291-------301-------311-------321-------331 
LNYLHNECSSPLIHRDIKPTNIVLSKDGIAKIIDFGSCEELKNSDQSKELVGTIYYISPEILMRTNYDCSSDIWSLGITIYEIVLCTLPWKRNQSFENYIKTIINSSPKI 
HHHHHH-----------------------EEEEE-----------------------------------HHHHHHHHHHHHHHHH---------HHHHHHHHH------- 
 
-------341-------351-------361-------371-------381-------391-------401-------411-------421-------431-------441 
NITEGYSKHLCYFVEKCLQKKPENRGNVKDLLNHKFLIKKRYIKKKPSSIYEIRDILKIYNGKGKTNIFRNFFKNLFFFNDKNKKKKPNKMISSKSCDAEMFFEQLKREN 
-------HHHHHHHHHHHH--------HHHHHHH---------------------------------------------------------------------------- 
 
-------451-------461-------471-------481-------491-------501 
FDFFEIKLKDDENSRSLNTFNINISKERDDISYSSLNLEKIKEHSLNMVASVVGTEQSQK 
----EEE----------------------------------------------------- 
 
Figure 70. Secondary structure prediction of PK  
The P. falciparum PK sequence from amino acid 1 982-2 485 (the sequence expressed in E. coli) has a predicted secondary structure 
consisting mainly of alpha helices (H) and beta sheets (E). The areas with a ‘-’ indicate that no secondary structure conformations were 
predicted by Jnet. 
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1---------11--------21--------31--------41--------51--------61--------71--------81--------91--------101-------111 
NNSSDEFNNDIDDADDSKKSMDLIGLNDDESKPQKTIPPVKMVQVLSSEDAGLKGQTGLSIFASINRIDRKIQLKISVTNQTQNEIVVSGVQINKNSFGLSSPNNLDVQNIGF 
------------HH---------------------------EEEEE------------EEEEEEEE----EEEEEEEEE--------EEEEEE---EEEEEE----------- 
 
-------121-------131-------141-------151-------161-------171-------181-------191-------201-------211-------221 
GETKEMLIYLIPNTLNSNTPPATPLFLQVAIRTNLDIFYFNVPYDIFVVFVENFHMEKDIFKKKWQIIEEAKEELYYFACITTNNLVILSEVTIQPEKKNVKLCIRTDSS 
---EEEEEEE-----------------EEEE-----EEEEEE---EEEEE-------HHHHHHHHHH------EEEEEE-------EEEEEEEEE----EEEEEEE---- 
 
-------231-------241- 
SVIPLYKLLFVKAFSLSVTQT 
HHHHHHHHHHHHH--HE---- 
 
Figure 71. Secondary structure prediction of AP1 C-terminal  
The P. falciparum AP1 C-terminal spanning amino acids 650-925 has a predicted secondary structure consisting mainly of beta sheets (E) 
with a few alpha helices (H), according to Jnet. The areas with a ‘-’ indicate that no secondary structure conformations were predicted. 
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1---------11--------21--------31--------41--------51--------61--------71--------81--------91--------101-------111 
MSDLRYFQTTKKGEIHELKEELHSSHKEKKKEAIKKIIAAMTVGKDVSTLFSDVVNCMQTSNIELKKLVYLYVINYAKVQPELAILAVNTFRKDSSDPNPLIRALAIRTMGCI 
-----------HHHHHHHHHHH----HHHHHHHHHHHHHHHH------HHHHHHHHH------HHHHHHHHHHHH------HHHHHHHHHHHHH-----HHHHHHHHHHHH—- 
 
-------121-------131-------141-------151-------161-------171-------181-------191-------201-------211-------221 
RLEQITEYLIEPLRRCLKDEDPYVRKTAVICIAKLYDISPKLVEEEGFIDTLLDILDDNNAMVVANAVISLTDICENSNKSILKDVINKDENNVNKLLNAINECVEWGQV 
-----HHHHHHHHHHHH----HHHHHHHHHHHHHHHH----------HHHHHHHHH------HHHHHHHHHHHHHH--------------HHHHHHHHHH------HHHH 
 
-------231-------241-------251-------261-------271-------281-------291-------301-------311-------321-------331 
FILDALVLYEPKTSKDAERVLERILPRLSHANSAVVLSSIKVILCLLDKINDKEFIKNVHKKLSPSLVTLLSAEPEIQYIALRNINLITQKLPNMLSDKINMFFCKYNEP 
HHHHHHHH------HHHHHHHHHHHHHH-----HHHHHHHHHHHHH------HHHHHHHHHHHHHHHHHH-----HHHHHHHHHHHHHHHH-HHHHH---EEEEE----- 
 
-------341-------351-------361-------371-------381-------391-------401-------411-------421-------431-------441 
AYVKMEKLDIIIRLVSDKNVDLVLYELKEYSTEVDVEFVKKSVRAIGSCAIKLPQSSEKCINILLDLIDTKINYVIQECIVVIKDIFRKYPNKYESIITILCENLESLDE 
HHHHHHHHHHHHH-----HHHHHHHHHHHHH----HHHHHHHHHHHHHHHH-----HHHHHHHHHHHHH------HHHHHHHHHHHHH---HHHHHHHHHHHHHHH---- 
 
-------451-------461-------471-------481-------491-------501-------511-------521-------531-------541-------551 
SNAKASLIWIIGEYVERIDNADELIDSFLENFSDEPYNVQLQILTASVKLFLKCSKNTKDIITKVLKLSTEESDNPDLRDRAYIYWRLLSKNIDVAKKIVLADKPPIQEE 
-HHHHHHHHHHH--------HHHHHHHHHHH-----HHHHHHHHHHHHHHHHH-----HHHHHHHHHHHHH------HHHHHHHHHHHH---HHHHHHHH---------- 
 
-------561-------571-------581-------591-------601-------611----- 
NKITDTKVLNKLIKNISMLSSVYHKLPETFISKKNSYSLNSDNNNDHAANKARKEAELAAATAEQ 
-----HHHHHHHHHH-------------------------------------------------- 
 
Figure 72. Secondary structure prediction of AP1 N-terminal  
The P. falciparum AP1 N-terminal spanning amino acids1-618 has a predicted secondary structure consisting mainly of alpha helices (H) 
with one section of beta sheets (E), according to Jnet. The areas with a ‘-’ indicate that no secondary structure conformations were predicted. 
 
 
5.11) Target-template pair alignments 
 
TARGET    2117          DN LVSLKIINLK YLSKKNSLKN ILREVNFLKM CEHPNVVKYF 
1apmE     60    vkhkes--gn hyamkildkq kvvklkqieh tlnekrilqa vnfpflvkle 
 
TARGET    2159  ESFFWPPCYL VIVCEYLSGG TLYDLYKNYG RISEDLLVYI LDDVLNGLNY 
1apmE     108   fsfkdn-snl ymvmeyvagg emfshlrrig rfaepharfy aaqivltfey 
 
TARGET    2209  LHNECSSPLI HRDIKPTNIV LSKDGIAKII DFGSCEELKN SDQSKELVGT 
1apmE     157   lhs---ldli yrdlkpenll idqqgyiqvt dfgfakrvkg --rtwtlcgt 
 
TARGET    2259  IYYISPEILM RTNYDCSSDI WSLGITIYEI VLCTLPWKRN QSFENYIKTI 
1apmE     202   peylapeiil skgynkavdw walgvliyem aagyppffad qpiq-iyeki 
 
TARGET    2309  INSSPKINIT EGYSKHLCYF VEKCLQKKPE NRGN-----V KDLLNHKFLI 
1apmE     251   vsgkv--rfp shfssdlkdl lrnllqvdlt krfgnlkngv ndiknhkwfa 
 
Figure 73. Target-template pair alignment for PK kinase domain 3D model  
The target template pair shared homology in the kinase domain of the PK, from amino 
acids 2 117-2 353. Target – PK protein sequence; 1apmE - catalytic subunit of human 
cAMP-dependent protein kinase protein sequence. 
 
TARGET    694              VLSSEDAGLK GQTGLSIFAS INRIDRKIQL KISVTNQTQN 
1e42A     705   ggyvapka-- vwlpa---vk ak-gleisgt fthrqghiym emnftnkalq 
 
TARGET    734   EIVVSGVQIN KNSFGLSSPN NLDVQNI-GF GETKEMLIYL IPNTLNSNTP 
1e42A     749   hmtdfaiqfn knsfgvipst plaihtplmp nqsidvslpl ntlgpvmkme 
 
TARGET    783   PATPLFLQVA IRTNLDIFYF NVPYDIFVVF VENFHMEKDI FKKKWQIIEE 
1e42A     799   p--lnnlqva vknnidvfyf scliplnvlf vedgkmerqv flatwkdipn 
 
TARGET    833   AKESILMAVS PMVITSDMLI KRMKIFNISL IARRN----E LYYFACITTN 
1e42A     847   ene-lqfqik echlnadtvs sklqnnnvyt iakrnvegqd mlyqslkltn 
 
TARGET    879   NLVILSEVTI QPEKKNVKLC IRTDSSSVIP LYK ------ --         
1e42A     896   giwilaelri qpgnpnytls lkcrapevsq yiyqvydsil kn         
 
Figure 74. Target-template pair alignment for AP1 C-terminal 3D model  
The target template pair shared homology from amino acids 694-911. Target – PK 
protein sequence; 1e42A – human β2 appendage domain from clathrin adaptor AP-2. 
 
TARGET    12      KGEIHELK EELHSSHKEK KKEAIKKIIA AMTVGKDVST LFSDVVNCMQ 
2vglB     12      kgeifelk aelnnekkek rkeavkkvia amtvgkdvss lfpdvvncmq 
 
TARGET    60    TSNIELKKLV YLYVINYAKV QPELAILAVN TFRKDSSDPN PLIRALAIRT 
2vglB     60    tdnlelkklv ylylmnyaks qpdmaimavn sfvkdcedpn pliralavrt 
 
TARGET    110   MGCIRLEQIT EYLIEPLRRC LKDEDPYVRK TAVICIAKLY DISPKLVEEE 
2vglB     110   mgcirvdkit eylceplrkc lkdedpyvrk taavcvaklh dinaqmvedq 
 
TARGET    160   GFIDTLLDIL DDNNAMVVAN AVISLTDICE NSNKSILKDV INKDENNVNK 
2vglB     160   gfldslrdli adsnpmvvan avaalseise shpnsnlldl ---npqnink 
 
189 
 
TARGET    210   LLNAINECVE WGQVFILDAL VLYEPKTSKD AERVLERILP RLSHANSAVV 
2vglB     207   lltalnecte wgqifildcl snynpkddre aqsicervtp rlshansavv 
 
TARGET    260   LSSIKVILCL LDKI-NDKEF IKNVHKKLSP SLVTLLSAEP EIQYIALRNI 
2vglB     257   lsavkvlmkf lellpkdsdy ynmllkklap plvtllsgep evqyvalrni 
 
TARGET    309   NLITQKLPNM LSDKINMFFC KYNEPAYVKM EKLDIIIRLV SDKNVDLVLY 
2vglB     307   nlivqkrpei lkqeikvffv kyndpiyvkl ekldimirla sqaniaqvla 
 
TARGET    359   ELKEYSTEVD VEFVKKSVRA IGSCAIKLPQ SSEKCINILL DLIDTKINYV 
2vglB     357   elkeyatevd vdfvrkavra igrcaikveq saercvstll dliqtkvnyv 
 
TARGET    409   IQECIVVIKD IFRKYPNKYE SIITILCENL ESLDESNAKA SLIWIIGEYV 
2vglB     407   vqeaivvird ifrkypnkye siiatlcenl dsldepdara amiwivgeya 
 
TARGET    459   ERIDNADELI DSFLENFSDE PYNVQLQILT ASVKLFLKCS KNTKDIITKV 
2vglB     457   eridnadell esflegfhde stqvqltllt aivklflkkp setqelvqqv 
 
TARGET    509   LKLSTEESDN PDLRDRAYIY WRLLSKNIDV AKKIVLADKP PIQEENKITD 
2vglB     507   lslatqdsdn pdlrdrgyiy wrllstdpvt akevvlsekp liseetdlie 
 
TARGET    559   TKVLNKLIKN ISMLSSVYHK LPETFI                           
2vglB     557   ptlldelich igslasvyhk ppnafv-                          
 
Figure 75. Target-template pair alignment for AP1 N-terminal 3D model  
The target template pair shared homology from amino acids 12-584. Target – PK protein 
sequence; 2vglB – human AP-2 clathrin adaptor core 
 
MKTTKENDNNNIVHYVDWINQIFKKNSLQCDLYFLDDNKEKDVSKKRKAQLKDEYDNISR 
SKENINNSKKIKNELSIKDNMHDYIYDDRIYNNDKEKNVIKSDNKNVIKSDNKNVIKSDN 
KNVIKSDNKNVIKSDNKNVIKSDNKNVIKSDYKSDDRNACDIYKSNKKNVPDNCHIYDDN 
SSVENLDGKNKLNNIRNIHNDNSSSCDISDIKSEDEYIEPYEKKNEENINEYKNKKNIAN 
ENIKEGKSSIYNDEHNYNSLLYNSCNGEISKINKISSHNNIDNNMDNYNTFANVNNFIIY 
SSDDEDNISNYYNGKDVLNDEIMFPIKFNFEKLKKNIYVIEHIDKIYYDTFLNKNPSEKS 
VFMNDESTGYLKNDVNDKCVVDNINVINPSSVNTLSNISNIRNEKIENNNKNEKLIKSYP 
TQSKNVMSTFSFWNIEKETFITKPLYAQNLRKKQFSLLDESEEMIRNYSSNQYSIKFVPR 
HLLYVMSQVASRSFFDPLYRKQLFFLELENRSGYKKRKKKKWNNKSTGQDKFTNKDIISE 
EKEEGLDIECGHNILGDVQYDGTYNINEQVKKNSLFYFKCKEEINLKDGNIILDDKNRKV 
DDINITGDDKNIKVDDKNIKVDDKNITGEDKNITGEDKNITGDDKNIIFDVDEILIHQHN 
TSNSNIYINCNDNNNDIRNSSNVQHYYNDKIKENINKQNKKYVLINDYINNKYILSKNKT 
CKINKGKKLIKKKKVNNISRRRNHILYKCRNKLYNGNVFSDDIIKSEVNVCNSLTVLHKN 
YNINMDNYLDDNIHTNNSNIYDINYTNENVINSTCRYYPIGNNNTLSKDEVTKSSSKINS 
LSYFDDIINVNKNDIPILHDKENINIISNKESCHKDEKEEEKYIMYNSNLVEEKKQKKMI 
WNSLNVLPIDILLKNGHDEINKEICKKKKKSFFSQNDIKSKMLYNNKSYSKSEKVLYTNN 
KNSNTFIPIFFLNKVGDKFKNSENIYDMYNNKKNVYIHDKKIYTNMYSNKLKQKHYYSTS 
NINLLYNNIGKVLDNGLHLSNNMYCRLNSNPPYKSISLINNNVFFYKKRKSNSNNNNNNN 
NISSS
KDLFE
SSSSSKKNHVIINKKISSYNIHYKERKDSFKENFLFFKEKILPSKKDTCVFNERQ 
KSNEHIKCVSSFNNTSDDISSHSSVNKKEPFFALKNNSIRHIPKENNIIYTSGKS 
FNHVQDKEKTVLLKKKKEINDKNTFSSCLINHNITTYTLQNGVNKNLNMLGIRDSIYKID 
EKNNMLKECYNGNNDSNNKKKKKKKKLSFSCDIINDNITPYESDKEKNNSNNIKSMDIFN 
YVKRKSNLYNNLSSNRDSTVDMHNKYNSEEYINIQRTNKIYELSNKRIRNYKLYSMDEIF 
KVSLKEKKYIDNISNNMERVTYKNEMINEKISKMDDILYPCDKNKSLNMSCPVIIENNIS 
REENEKNSSVILNKKKNENMFNCVGRLHCHMGKMNNQDNIYDQGNIKKNEEEITKHDEYI 
SREEKNKYNSKCIRNFDDYKYEQVLSYHTLDEDKKKNDMNNLIDMNNEAIIETVNGVINN 
IILDRKDNNSRKDMEKEMEKEMEKKMEKEMEKVMEKEMEKVMEKEVEKELKNEMNNRMNN 
RMNNEMKNEINIYKNNEIYVDNDKELEIVNEEKKLIYPFNYESDVHKNMNMSININNCKD 
DYNNILKEYVDNSCLAQKEENIFRPLFNLNKKDKVWKRFNIKNNIKTIIHNEEMKRIYQT 
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INKNVFPIYNFNRYENFLINHLTYNFPKNDLFKLSYKVSMNNIRNLYIANKHINNNYDYM 
NKLYNQNIYTLKYQVANIDNDHHICKKGGGLDYINMNISKECKNRKDKTYLNKIFHYKKK 
KDARFFINDEIGSNDYMYDIKKKYSNDENNYKLNEKMNISMSNDEDMIPTLNSEHGNNFP 
SCQPNLLEKKSTYIDLNLYDSNSMDDFTEEKYNFVNNENDLFNTKRWKFNFSKGKNLFNN 
KFFNVSNEDGVFSFFKNMNLFRELNKSNNSLKLESVKNSNNNCSNNKGDDNIGNMENMNT 
TNVTIASDEHISTKGDIHDESFSRDDNDCILLKIEGRSKKYSDITLYNEDKSNLENDNET 
INEYENVCSNIDVNEWEDKVNGTCNSVGDKETEKNNEKNNEKNNEKNNEKNNEKNNEKNN 
EKNNEKNNEENNEGNNEENNEENNEENNEENNDIEKNDIKDNNSGQVKENIIVMNNTNNM 
DVDNDDNNNNYNNVSTDEGIDIIKNIKSEMNDYIYNDNIMIKINNKSIDLMNIKNQKNEP 
FLNYTNEKDIHMKSNSSYNVNDKMNLFNNNEKTEKNNTSLNDLLYKRKEELDDEKISEYK 
DTNLTNNTFEHIAKRINLILNDTIEFFQKHTYLHNGYGNVQVCKKNKRKLEKKKLKKWSC 
IYKINKIVRKGAHGVVFSAWRSENVDFFNHSFFENLNLENKKKGYIDETNVNENYESDNE 
YDSDEDDTESDNDDEQNKENERGDEKDGYEEMNGGDKNEEMNGGDKNEEMNVGDKNGGIN 
EEHKNEGINEEHKDELINKEHKNERINEEHKNERINEEHKNEGINEEHKNEGINEEHKNE 
RINEEHKNEGINKLTYHNMNKNNISNENNYNDDDSYDEDNLVSLKIINLKYLSKKNSLKN 
ILREVNFLKMCEHPNVVKYFESFFWPPCYLVIVCEYLSGGTLYDLYKNYGRISEDLLVYI 
LDDVLNGLNYLHNECSSPLIHRDIKPTNIVLSKDGIAKIIDFGSCEELKNSDQSKELVGT 
IYYISPEILMRTNYDCSSDIWSLGITIYEIVLCTLPWKRNQSFENYIKTIINSSPKINIT 
EGYSKHLCYFVEKCLQKKPENRGNVKDLLNHKFLIKKRYIKKKPSSIYEIRDILKIYNGK 
GKTNIFRNFFKNLFFFNDKNKKKKPNKMISSKSCDAEMFFEQLKRENFDFFEIKLKDDEN 
SRSLNTFNINISKERDDISYSSLNLEKIKEHSLNMVASVVGTEQSQK 
 
Figure 76. Protein sequence of PFB0150c  
The PEXEL/ VTS motif consensus sequence (R/KxLxE/Q) is present in the PFB0150c 
protein sequence as shown in red. This indicates that the parasite protein is exported into 
the host erythrocyte. The bold underlined section indicates the catalytic kinase domain. 
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